U.S. patent application number 10/613684 was filed with the patent office on 2004-05-20 for amide, carbamate, and urea derivatives.
Invention is credited to Arnold, MacKlin Brian, Bender, David Michael, Bleisch, Thomas John, Jones, Winton Dennis, Ornstein, Paul Leslie, Zarrinmayeh, Hamid H., Zimmerman, Dennis Michael.
Application Number | 20040097499 10/613684 |
Document ID | / |
Family ID | 27791192 |
Filed Date | 2004-05-20 |
United States Patent
Application |
20040097499 |
Kind Code |
A1 |
Arnold, MacKlin Brian ; et
al. |
May 20, 2004 |
Amide, carbamate, and urea derivatives
Abstract
The present invention provides certain amide, carbamate and urea
derivatives useful for potentiating glutamate receptor function in
a mammal and therefore, useful for treating a wide variety of
conditions, such as psychiatric and neurological disorders.
Inventors: |
Arnold, MacKlin Brian;
(Morgant wn, IN) ; Bender, David Michael;
(Indianapolis, IN) ; Bleisch, Thomas John;
(Noblesville, IN) ; Jones, Winton Dennis; (Carmel,
IN) ; Ornstein, Paul Leslie; (Carmel, IN) ;
Zarrinmayeh, Hamid H.; (Carmel, IN) ; Zimmerman,
Dennis Michael; (Zionsville, IN) |
Correspondence
Address: |
ELI LILLY AND COMPANY
PATENT DIVISION
P.O. BOX 6288
INDIANAPOLIS
IN
46206-6288
US
|
Family ID: |
27791192 |
Appl. No.: |
10/613684 |
Filed: |
July 3, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10613684 |
Jul 3, 2003 |
|
|
|
09744412 |
Jan 23, 2001 |
|
|
|
6617351 |
|
|
|
|
09744412 |
Jan 23, 2001 |
|
|
|
PCT/US99/17126 |
Jul 28, 1999 |
|
|
|
60094997 |
Jul 31, 1998 |
|
|
|
Current U.S.
Class: |
514/235.5 ;
514/210.2; 514/235.8; 514/252.03; 514/252.12; 514/253.01; 514/256;
514/326; 514/340; 514/365; 514/372; 514/374; 514/438; 514/459;
514/471; 544/124; 544/238; 544/333; 544/360; 546/193; 546/270.4;
546/271.1; 546/272.1 |
Current CPC
Class: |
C07C 233/18 20130101;
C07C 271/20 20130101; C07C 233/13 20130101; C07C 255/60 20130101;
C07C 275/28 20130101; C07C 275/24 20130101; C07C 255/58 20130101;
C07C 311/05 20130101; C07D 333/20 20130101; C07D 333/24 20130101;
C07C 271/14 20130101 |
Class at
Publication: |
514/235.5 ;
514/235.8; 514/210.2; 514/253.01; 514/252.12; 514/252.03; 514/256;
514/365; 514/374; 514/340; 514/326; 514/372; 514/459; 514/471;
514/438; 544/124; 544/238; 544/333; 544/360; 546/193; 546/270.4;
546/271.1; 546/272.1 |
International
Class: |
C07D 417/02; C07D
413/02; C07D 49/02; C07D 43/02; C07D 45/02; A61K 031/5377; A61K
031/506; A61K 031/501; A61K 031/496; A61K 031/4439 |
Claims
We claim:
1. A compound of the formula: 148wherein B is CONR.sup.a,
NR.sup.aCO, NR.sup.aCO.sub.2 or NR.sup.aCONR.sup.a; R.sup.a
represents hydrogen or (1-6C) alkyl, q is zero or 1; R.sup.1
represents a naphthyl group or a phenyl, furyl, thienyl or pyridyl
group which is unsubstituted or substituted by one or two
substituents selected independently from halogen; nitro; cyano;
hydroxyimino; (1-10C)alkyl; (2-10C)alkenyl; (2-10C)alkynyl;
(3-8C)cycloalkyl; hydroxy(3-8C)cycloalkyl; oxo(3-8C)cycloalkyl;
halo(1-10C)alkyl; (CH.sub.2).sub.yX.sup.1R.sup.9 in which y is 0 or
an integer of from 1 to 4, X.sup.1 represents O, S, NR.sup.10, CO,
COO, OCO, CONR.sup.11, NR.sup.12CO, NR.sup.12COCOO or OCONR.sup.13,
R.sup.9 represents hydrogen, (1-10C)alkyl, (3-10C)alkenyl,
(3-10C)alkynyl, pyrrolidinyl, tetrahydrofuryl, morpholino or
(3-8C)cycloalkyl and R.sup.10, R.sup.11, R.sup.12 and R.sup.13 each
independently represents hydrogen or (1-10C)alkyl, or R.sup.9 and
R.sup.10, R.sup.11, R.sup.12 or R.sup.13 together with the nitrogen
atom to which they are attached form an azetidinyl, pyrrolidinyl,
piperidinyl or morpholino group; N-(1-4C)alkylpiperazinyl;
N-phenyl(1-4C)alkylpiperaz- inyl; thienyl; furyl; oxazolyl;
isoxazolyl; pyrazolyl; imidazolyl; thiazolyl; pyridyl; pyridazinyl;
pyrimidinyl; dihydro-thienyl; dihydrofuryl; dihydrothiopyranyl;
dihydropyranyl; dihydrothiazolyl;
(1-4C)alkoxycarbonyldihydrothiazolyl;
(1-4C)alkoxycarbonyldimethyldihydro- thiazolyl; tetrahydro-thienyl;
tetrahydrofuryl; tetrahydrothiopyranyl; tetrahydropyranyl; indolyl;
benzofuryl; benzothienyl; benzimidazolyl; and a group of formula
R.sup.14-(L.sup.a).sub.n--X.sup.2-(L.sup.b).sub.m in which X.sup.2
represents a bond, O, NH, S, SO, SO.sub.2, CO, CH(OH), CONH, NHCO,
NHCONH, NHCOO, COCONH, OCH.sub.2CONH or CH.dbd.CH, L.sup.a and
L.sup.b each represent (1-4C)alkylene, one of n and m is 0 or 1 and
the other is 0, and R.sup.14 represents a phenyl or heteroaromatic
group which is unsubstituted or substituted by one or two of
halogen, nitro, cyano, hydroxyimino, (1-10C) alkyl, (2-10C)alkenyl,
(2-10C)alkynyl, (3-8C)-cycloalkyl,
4-(1,1-dioxotetrahydro-1,2-thiazinyl), halo(1-10C)alkyl,
cyano(2-10C)alkenyl, phenyl, and (CH.sub.2).sub.zX.sup.3R.sup.15 in
which z is 0 or an integer of from 1 to 4, X.sup.3 represents O, S,
NR.sup.16, CO, CH(OH), COO, OCO, CONR.sup.17, NR.sup.18CO,
NHSO.sub.2, NHSO.sub.2NR.sup.17, NHCONH, OCONR.sup.19 or
NR.sup.19COO, R.sup.15 represents hydrogen, (1-10C)alkyl,
phenyl(1-4C)alkyl, halo(1-10C)alkyl,
(1-4C)alkoxycarbonyl(1-4C)alkyl,
(1-4C)alkylsulfonylamino(1-4C)alkyl,
(N-(1-4C)alkoxycarbonyl)(1-4C)alkyls- ulfonylamino-(1-4C)alkyl,
(3-10C)alkenyl, (3-10C)alkynyl, (3-8C)-cycloalkyl, camphoryl or an
aromatic or heteroaromatic group which is unsubstituted or
substituted by one or two of halogen, (1-4C)alkyl, halo(1-4C)alkyl,
di(1-4C)alkylamino and (1-4C)alkoxy and R.sup.16, R.sup.17,
R.sup.18 and R.sup.19 each independently represents hydrogen or
(1-10C)alkyl, or R.sup.15 and R.sup.16 R.sup.17, R.sup.18 or
R.sup.19 together with the nitrogen atom to which they are attached
form an azetidinyl, pyrrolidinyl, piperidinyl or morpholino group;
R.sup.2 represents hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl,
fluoro(1-6C)alkyl, chloro(1-6C)alkyl, (2-6C)alkenyl,
(1-4C)alkoxy(1-4C)alkyl, (1-4C)alkylCO.sub.2(1-4C)alkyl,
phenyl(1-6C)alkyl, heteroaromatic, phenyl which is unsubstituted or
substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group of
formula R.sup.3R.sup.4N in which R.sup.3 and R.sup.4 each
independently represents (1-4C)alkyl or, together with the nitrogen
atom to which they are attached form an azetidinyl, pyrrolidinyl,
piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or
octahydroazocinyl group; and R.sup.5, R.sup.6, R.sup.7 and R.sup.8
are each independently selected from the group consisting of
hydrogen, (1-6C)alkyl; aryl(1-6C)alkyl; (2-6C)alkenyl;
aryl(2-6C)alkenyl and aryl; or two of R.sup.5, R.sup.6, R.sup.7 and
R.sup.8 together with the carbon atom or carbon atoms to which they
are attached form a (3-8C) carbocyclic ring; and the remainder of
R.sup.5, R.sup.6, R.sup.7 and R.sup.8 represent hydrogen; or a
pharmaceutically acceptable salt thereof; with the proviso that
when R.sup.2 represents R.sup.3R.sup.4N, then B is other than
NR.sup.aCONR.sup.a or CONR.sup.a.
2. A compound according to claim 1 wherein B is CONR.sup.a.
3. A compound according to claim 1 wherein B is NR.sup.aCO.
4. A compound according to claim 1 wherein B is
NR.sup.aCO.sub.2.
5. A compound according to claim 1 wherein B is
NR.sup.aCONR.sup.a.
6. A compound as claimed in any one of claims 1 to 5 wherein q is
1.
7. A compound as claimed in any one of claims 1 to 5 wherein
R.sup.a is hydrogen.
8. A compound as claimed in any one of claims 1-5 wherein R.sup.2
represents hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl,
fluoro(1-6C)alkyl, chloro(1-6C)alkyl, (2-6C)alkenyl
1-4C)alkoxy(1-4C)alkyl, heteroaromatic, or phenyl which is
unsubstituted or substituted by halogen, (1-4C)alkyl or
(1-4C)alkoxy.
9. A compound according to claim 8 wherein R.sup.2 represents
hydrogen, (1-4C)alkyl; (3-6C)cycloalkyl or heteroaromatic, or
phenyl which is unsubstituted or substituted by halogen,
(1-4C)alkyl or (1-4C)alkoxy.
10. A compound according to claim 9 wherein R.sup.2 represents
methyl, ethyl, isopropyl, t-butyl, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, isovaleryl, phenyl, benzyl, 2-furyl,
2-thienyl, 5-oxazoyl, 2-pyridyl, 3-pyridyl, 4-pryidyl
11. A compound as claimed in any one of claims 1-5 wherein q is 1
and R.sup.6 and R.sup.7 represent hydrogen.
12. A compound according to claim 11 wherein R.sup.5 and R.sup.8
are each independently hydrogen or (1-4C)alkyl, or together with
the carbon atom to which they are attached form a (3-8C)
carbocyclic ring.
13. A compound as claimed in any one of claims 1-12 wherein R.sup.8
represents methyl and R.sup.5 represents hydrogen.
14. A compound as claimed in claim 1, which is selected from:
5 a 149 b 150 c 151 d 152 e 153 f 154 g 155 h 156 i 157 j 158 k 159
m 160 n 161 o 162 p 163 q 164 r 165 s 166 t 167 u 168 v 169 w 170 x
171 y 172 z 173 aa 174 bb 175 cc 176 dd 177 ee 178 ff 179 gg 180 hh
181 ii 182 jj 183 kk 184 mm 185 nn 186 oo 187 pp 188 qq 189 rr 190
tt 191 uu 192 vv 193 xx 194 yy 195 zz 196 aaa 197 bbb 198
pharmaceutically acceptable salts thereof.
15. A pharmaceutical composition, which comprises a compound as
claimed in claim 1 and a pharmaceutically acceptable diluent or
carrier.
16. A method of potentiating glutamate receptor function in a
mammal requiring such treatment, which comprises administering an
effective amount of a compound of formula: 199wherein B is
CONR.sup.a, NR.sup.aCO, NR.sup.aCO.sub.2 or NR.sup.aCONR.sup.a;
R.sup.a represents hydrogen or (1-6C) alkyl, q is zero or 1;
R.sup.1 represents an unsubstituted or substituted aromatic or
heteroaromatic group; R.sup.2 represents hydrogen, (1-6C)alkyl,
(3-6C)cycloalkyl, fluoro(1-6C)alkyl, chloro(1-6C)alkyl,
(2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl,
(1-4C)alkylCO.sub.2(1-4C)alkyl, phenyl(1-6C)alkyl, heteroaromatic,
phenyl which is unsubstituted or substituted by halogen,
(1-4C)alkyl or (1-4C)alkoxy, or a group of formula R.sup.3R.sup.4N
in which R.sup.3 and R.sup.4 each independently represents
(1-4C)alkyl or, together with the nitrogen atom to which they are
attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino,
piperazinyl, hexahydroazepinyl or octahydroazocinyl group; and
R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each independently
selected from the group consisting of hydrogen, (1-6C)alkyl;
aryl(1-6C)alkyl; (2-6C)alkenyl; aryl(2-6C)alkenyl and aryl; or two
of R.sup.5, R.sup.6, R.sup.7 and R.sup.8 together with the carbon
atom or carbon atoms to which they are attached form a (3-8C)
carbocyclic ring; and the remainder of R.sup.5, R.sup.6, R.sup.7
and R.sup.8 represent hydrogen; or a pharmaceutically acceptable
salt thereof; with the proviso that when R.sup.2 represents
R.sup.3R.sup.4N, then B is other than NR.sup.aCONR.sup.a or
CONR.sup.a.
17. A method of potentiating glutamate receptor function in a
mammal requiring such treatment, which comprises administering an
effective amount of a compound of claim 1.
18. A method of treating a cognitive disorder, a neuro-degenerative
disorder; age-related dementia; age-induced memory impairment;
movement disorder; reversal of a drug-induced state; depression;
attention deficit disorder; attention deficit hyperactivity
disorder; psychosis; cognitive deficits associated with psychosis;
or drug-induced psychosis in a patient, which comprises
administering to a patient in need thereof an effective amount of a
compound of formula: 200wherein B is CONR.sup.a, NR.sup.aCO,
NR.sup.aCO.sub.2 or NR.sup.aCONR.sup.a; R.sup.a represents hydrogen
or (1-6C) alkyl, q is zero or 1; R.sup.1 represents an
unsubstituted or substituted aromatic or heteroaromatic group;
R.sup.2 represents hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl,
fluoro(1-6C)alkyl, chloro(1-6C)alkyl, (2-6C)alkenyl,
(1-4C)alkoxy(1-4C)alkyl, (1-4C)alkylCO.sub.2(1-4C)alkyl,
phenyl(1-6C)alkyl, heteroaromatic, phenyl which is unsubstituted or
substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group of
formula R.sup.3R.sup.4N in which R.sup.3 and R.sup.4 each
independently represents (1-4C)alkyl or, together with the nitrogen
atom to which they are attached form an azetidinyl, pyrrolidinyl,
piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or
octahydroazocinyl group; and R.sup.5, R.sup.6, R.sup.7 and R.sup.8
are each independently selected from the group consisting of
hydrogen, (1-6C)alkyl; aryl(1-6C)alkyl; (2-6C)alkenyl;
aryl(2-6C)alkenyl and aryl; or two of R.sup.5, R.sup.6, R.sup.7 and
R.sup.8 together with the carbon atom or carbon atoms to which they
are attached form a (3-8C) carbocyclic ring; and the remainder of
R.sup.5, R.sup.6, R.sup.7 and R.sup.8 represent hydrogen; or a
pharmaceutically acceptable salt thereof; with the proviso that
when R.sup.2 represents R.sup.3R.sup.4N, then B is other than
NR.sup.aCONR.sup.a or CONR.sup.a.
19. A method of treating a cognitive disorder; a neuro-degenerative
disorder; age-related dementia; age-induced memory impairment;
movement disorder; reversal of a drug-induced state; depression;
attention deficit disorder; attention deficit hyperactivity
disorder; psychosis; cognitive deficits associated with psychosis;
or drug-induced psychosis in a patient, which comprises
administering to a patient in need thereof an effective amount of a
compound according to claim 1.
20. A method for improving memory or learning ability in a patient,
which comprises administering to a patient in need thereof an
effective amount of a compound of formula: 201wherein B is
CONR.sup.a, NR.sup.aCO, NR.sup.aCO.sub.2 or NR.sup.aCONR.sup.a,
R.sup.a represents hydrogen or (1-6C) alkyl, q is zero or 1;
R.sup.1 represents an unsubstituted or substituted aromatic or
heteroaromatic group; R.sup.2 represents hydrogen, (1-6C)alkyl,
(3-6C)cycloalkyl, fluoro(1-6C)alkyl, chloro(1-6C)alkyl,
(2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl,
(1-4C)alkylCO.sub.2(1-4C)alkyl, phenyl(1-6C)alkyl, heteroaromatic,
phenyl which is unsubstituted or substituted by halogen,
(1-4C)alkyl or (1-4C)alkoxy, or a group of formula R.sup.3R.sup.4N
in which R.sup.3 and R.sup.4 each independently represents
(1-4C)alkyl or, together with the nitrogen atom to which they are
attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino,
piperazinyl, hexahydroazepinyl or octahydroazocinyl group; and
R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each independently
selected from the group consisting of hydrogen, (1-6C)alkyl;
aryl(1-6C)alkyl; (2-6C)alkenyl; aryl(2-6C)alkenyl and aryl; or two
of R.sup.5, R.sup.6, R.sup.7 and R.sup.8 together with the carbon
atom or carbon atoms to which they are attached form a (3-8C)
carbocyclic ring; and the remainder of R.sup.5, R.sup.6, R.sup.7
and R.sup.8 represent hydrogen; or a pharmaceutically acceptable
salt thereof; with the proviso that when R.sup.2 represents
R.sup.3R.sup.4N, then B is other than NR.sup.aCONR.sup.a or
CONR.sup.a.
21. A method for improving memory or learning ability in a patient,
which comprises administering to a patient in need thereof an
effective amount of a compound according to claim 1.
Description
[0001] The present invention relates to the potentiation of
glutamate receptor function using certain amide, carbamate and urea
derivatives. It also relates to novel amide, carbamate and urea
derivatives, to processes for their preparation and to
pharmaceutical compositions containing them.
[0002] In the mammalian central nervous system (CNS), the
transmission of nerve impulses is controlled by the interaction
between a neurotransmitter, that is released by a sending neuron,
and a surface receptor on a receiving neuron, which causes
excitation of this receiving neuron. L-Glutamate, which is the most
abundant neurotransmitter in the CNS, mediates the major excitatory
pathway in mammals, and is referred to as an excitatory amino acid
(EAA). The receptors that respond to glutamate are called
excitatory amino acid receptors (EAA receptors). See Watkins &
Evans, Ann. Rev. Pharmacol. Toxicol., 21, 165 (1981); Monaghan,
Bridges, and Cotman, Ann. Rev. Pharmacol. Toxicol., 29, 365 (1989);
Watkins, Krogsgaard-Larsen, and Honore, Trans. Pharm. Sci., 11, 25
(1990). The excitatory amino acids are of great physiological
importance, playing a role in a variety of physiological processes,
such as long-term potentiation (learning and memory), the
development of synaptic plasticity, motor control, respiration,
cardiovascular regulation, and sensory perception.
[0003] Excitatory amino acid receptors are classified into two
general types. Receptors that are directly coupled to the opening
of cation channels in the cell membrane of the neurons are termed
"ionotropic". This type of receptor has been subdivided into at
least three subtypes, which are defined by the depolarizing actions
of the selective agonists N-methyl-D-aspartate (NMDA),
alpha-amino-3-hydroxy-5-methylisoxazole-4-pr- opionic acid (AMPA),
and kainic acid (KA). The second general type of receptor is the
G-protein or second messenger-linked "metabotropic" excitatory
amino acid receptor. This second type is coupled to multiple second
messenger systems that lead to enhanced phosphoinositide
hydrolysis, activation of phospholipase D, increases or decreases
in c-AMP formation, and changes in ion channel function. Schoepp
and Conn, Trends in Pharmacol. Sci., 14, 13 (1993). Both types of
receptors appear not only to mediate normal synaptic transmission
along excitatory pathways, but also participate in the modification
of synaptic connections during development and throughout life.
Schoepp, Bockaert, and Sladeczek, Trends in Pharmacol. Sci., 11,
508 (1990); McDonald and Johnson, Brain Research Reviews, 15, 41
(1990).
[0004] AMPA receptors are assembled from four protein sub-units
known as GluR1 to GluR4, while kainic acid receptors are assembled
from the sub-units GluR5 to GluR7, and KA-1 and KA-2. Wong and
Mayer, Molecular Pharmacology 44: 505-510, 1993. It is not yet
known how these sub-units are combined in the natural state.
However, the structures of certain human variants of each sub-unit
have been elucidated, and cell lines expressing individual subunit
variants have been cloned and incorporated into test systems
designed to identify compounds which bind to or interact with them,
and hence which may modulate their function. Thus, European patent
application, publication number EP-A2-0574257 discloses the human
sub-unit variants GluR1B, GluR2B, GluR3A and GluR3B. European
patent application, publication number EP-A10583917 discloses the
human sub-unit variant GluR4B.
[0005] One distinctive property of AMPA and kainic acid receptors
is their rapid deactivation and desensitization to glutamate.
Yamada and Tang, The Journal of Neuroscience, September 1993,
13(9): 3904-3915 and Kathryn M. Partin, J. Neuroscience, Nov. 1,
1996, 16(21): 6634-6647. The physiological implications of rapid
desensitization, and deactivation if any, are unknown.
[0006] It is known that the rapid desensitization and deactivation
of AMPA and/or kainic acid receptors to glutamate may be inhibited
using certain compounds. This action of these compounds is often
referred to in the alternative as "potentiation" of the receptors.
One such compound, which selectively potentiates AMPA receptor
function, is cyclothiazide. Partin et al., Neuron. Vol. 11,
1069-1082, 1993. Compounds which potentiate AMPA receptors, like
cyclothiazide, are often referred to as ampakines.
[0007] International Patent Application Publication Number WO
9625926 discloses a group of phenylthioalkylsulphonamides, S-oxides
and homologs which are said to potentiate membrane currents induced
by kainic acid and AMPA.
[0008] Ampakines have been shown to improve memory in a variety of
animal tests. Staubli et al., Proc. Natl. Acad. Sci., Vol. 91, pp
777-781, 1994, Neurobiology, and Arai et al., The Journal of
Pharmacology and Experimental Therapeutics, 278: 627-638, 1996.
[0009] It has now been found that cyclothiazide and certain amide,
carbamate and urea derivatives potentiate agonist-induced
excitability of human GluR4B receptor expressed in HEK 293 cells.
Since cyclothiazide is known to potentiate glutamate receptor
function in vivo, it is believed that this finding portends that
the amide, carbamate and urea derivatives will also potentiate
glutamate receptor function in vivo, and hence that the compounds
will exhibit ampakine-like behavior.
[0010] In addition, certain sulfonamide derivatives which
potentiate glutamate receptor function in a mammal have been
disclosed in International Patent Application Publication WO
98/33496 published Aug. 6, 1998.
[0011] The present invention provides compounds of formula I: 1
[0012] wherein
[0013] B is CONR.sup.a, NR.sup.aCO, NR.sup.aCO.sub.2 or
NR.sup.aCONR.sup.a;
[0014] R.sup.a represents hydrogen or (1-6C) alkyl,
[0015] q is zero or 1;
[0016] R.sup.1 represents a naphthyl group or a phenyl, furyl,
thienyl or pyridyl group which is unsubstituted or substituted by
one or two substituents selected independently from halogen; nitro;
cyano; hydroxyimino; (1-10C)alkyl; (2-10C)alkenyl; (2-10C)alkynyl;
(3-8C)cycloalkyl; hydroxy(3-8C)cycloalkyl; oxo(3-8C)cycloalkyl;
halo(1-10C)alkyl; (CH.sub.2).sub.yX.sup.1R.sup.9 in which y is 0 or
an integer of from 1 to 4, X.sup.1 represents O, S, NR.sup.10, CO,
COO, OCO, CONR.sup.11, NR.sup.12CO, NR.sup.12COCOO or OCONR.sup.13,
R.sup.9 represents hydrogen, (1-10C)alkyl, (3-10C)alkenyl,
(3-10C)alkynyl, pyrrolidinyl, tetrahydrofuryl, morpholino or
(3-8C)cycloalkyl and R.sup.10, R.sup.11, R.sup.12 and R.sup.13 each
independently represents hydrogen or (1-10C)alkyl, or R.sup.9 and
R.sup.10, R.sup.11, R.sup.12 or R.sup.13 together with the nitrogen
atom to which they are attached form an azetidinyl, pyrrolidinyl,
piperidinyl or morpholino group; N-(1-4C)alkylpiperazinyl;
N-phenyl(1-4C)alkylpiperazinyl; thienyl; furyl, oxazolyl;
isoxazolyl; pyrazolyl; imidazolyl; thiazolyl; pyridyl; pyridazinyl;
pyrimidinyl; dihydro-thienyl; dihydrofuryl; dihydrothiopyranyl;
dihydropyranyl; dihydrothiazolyl;
(1-4C)alkoxycarbonyldihydrothiazolyl;
(1-4C)alkoxycarbonyldimethyldihydro- thiazolyl; tetrahydro-thienyl;
tetrahydrofuryl; tetrahydrothiopyranyl; tetrahydropyranyl; indolyl;
benzofuryl; benzothienyl; benzimidazolyl; and a group of formula
R.sup.14-(L.sup.a).sub.n-X.sup.2-(L.sup.b).sub.m in which X.sup.2
represents a bond, O, NH, S, SO, SO.sub.2, CO, CH(OH), CONH, NHCO,
NHCONH, NHCOO, COCONH, OCH.sub.2CONH or CH.dbd.CH, L.sup.a and
L.sup.b each represent (1-4C)alkylene, one of n and m is 0 or 1 and
the other is 0, and R.sup.14 represents a phenyl or heteroaromatic
group which is unsubstituted or substituted by one or two of
halogen, nitro, cyano, hydroxyimino, (1-10C) alkyl, (2-10C)alkenyl,
(2-10C)alkynyl, (3-8C)-cycloalkyl,
4-(1,1-dioxotetrahydro-1,2-thiazinyl), halo(1-10C)alkyl,
cyano(2-10C)alkenyl, phenyl, and (CH.sub.2).sub.zX.sup.3R.sup.15 in
which z is 0 or an integer of from 1 to 4, X.sup.3 represents O, S,
NR.sup.16, CO, CH(OH), COO, OCO, CONR.sup.17, NR.sup.18CO,
NHSO.sub.2, NHSO.sub.2NR.sup.17, NHCONH, OCONR.sup.19 or
NR.sup.19COO, R.sup.15 represents hydrogen, (1-10C)alkyl,
phenyl(1-4C)alkyl, halo(1-10C)alkyl,
(1-4C)alkoxycarbonyl(1-4C)alkyl,
(1-4C)alkylsulfonylamino(1-4C)alkyl,
(N-(1-4C)alkoxycarbonyl)(1-4C)alkyls- ulfonylamino-(1-4C)alkyl,
(3-10C)alkenyl, (3-10C)alkynyl, (3-8C)-cycloalkyl, camphoryl or an
aromatic or heteroaromatic group which is unsubstituted or
substituted by one or two of halogen, (1-4C)alkyl, halo(1-4C)alkyl,
di(1-4C)alkylamino and (1-4C)alkoxy and R.sup.16, R.sup.17,
R.sup.18 and R.sup.19 each independently represents hydrogen or
(1-10C)alkyl, or R.sup.15 and R.sup.16, R.sup.17, R.sup.18 or
R.sup.19 together with the nitrogen atom to which they are attached
form an azetidinyl, pyrrolidinyl, piperidinyl or morpholino
group;
[0017] R.sup.2 represents hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl,
fluoro(1-6C)alkyl, chloro(1-6C)alkyl, (2-6C)alkenyl,
(1-4C)alkoxy(1-4C)alkyl, (1-4C)alkylCO.sub.2(1-4C)alkyl,
phenyl(1-6C)alkyl, heteroaromatic, phenyl which is unsubstituted or
substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group of
formula R.sup.3R.sup.4N in which R.sup.3 and R.sup.4 each
independently represents (1-4C)alkyl or, together with the nitrogen
atom to which they are attached form an azetidinyl, pyrrolidinyl,
piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or
octahydroazocinyl group; and
[0018] R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each independently
selected from the group consisting of hydrogen, (1-6C)alkyl;
aryl(1.degree. C.)alkyl; (2-6C)alkenyl; aryl(2-6C)alkenyl and aryl;
or
[0019] two of R.sup.5, R.sup.6, R.sup.7 and R.sup.8 together with
the carbon atom or carbon atoms to which they are attached form a
(3-8C) carbocyclic ring; and the remainder of R.sup.5, R.sup.6,
R.sup.7 and R.sup.8 represent hydrogen; or a pharmaceutically
acceptable salt thereof;
[0020] with the proviso that when R.sup.2 represents
R.sup.3R.sup.4N, then B is other than NR.sup.aCONR.sup.a or
CONR.sup.a.
[0021] The present invention further provides a method of
potentiating glutamate receptor function in a mammal requiring such
treatment, which comprises administering an effective amount of a
compound of formula I.
[0022] According to another aspect, the present invention provides
the use of a compound of formula I, or a pharmaceutically
acceptable salt thereof as defined hereinabove for the manufacture
of a medicament for potentiating glutamate receptor function.
[0023] In addition, the present invention provides the use of a
compound of formula I or a pharmaceutically acceptable salt thereof
for potentiating glutamate receptor function.
[0024] The invention further provides a method of potentiating
glutamate receptor function in a mammal requiring such treatment,
which comprises administering an effective amount of a compound of
formula: 2
[0025] wherein
[0026] B is CONR.sup.a, NR.sup.aCO, NR.sup.aCO.sub.2 or
NR.sup.aCONR.sup.a;
[0027] R.sup.a represents hydrogen or (1-6C) alkyl,
[0028] q is zero or 1;
[0029] R.sup.1 represents an unsubstituted or substituted aromatic
or heteroaromatic group;
[0030] R.sup.2 represents hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl,
fluoro(1-6C)alkyl, chloro(1-6C)alkyl, (2-6C)alkenyl,
(1-4C)alkoxy(1-4C)alkyl, (1-4C)alkylCO.sub.2(1-4C)alkyl,
phenyl(1-4C)alkyl, heteroaromatic, phenyl which is unsubstituted or
substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group of
formula R.sup.3R.sup.4N in which R.sup.3 and R.sup.4 each
independently represents (1-4C)alkyl or, together with the nitrogen
atom to which they are attached form an azetidinyl, pyrrolidinyl,
piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or
octahydroazocinyl group; and
[0031] R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each independently
selected from the group consisting of hydrogen, (1-6C)alkyl,
aryl(1-6C)alkyl; (2-6C)alkenyl; aryl(2-6C)alkenyl and aryl; or
[0032] two of R.sup.5, R.sup.6, R.sup.7 and R.sup.8 together with
the carbon atom or carbon atoms to which they are attached form a
(3-8C) carbocyclic ring; and the remainder of R.sup.5, R.sup.6,
R.sup.7 and R.sup.8 represent hydrogen; or a pharmaceutically
acceptable salt thereof;
[0033] with the proviso that when R.sup.2 represents
R.sup.3R.sup.4N, then B is other than NR.sup.aCONR.sup.a or
CONR.sup.a.
[0034] It is further understood that the following compounds of
formula I' are further included within the scope of the present
invention: 3
[0035] wherein
[0036] B represents CONR.sup.a, NR.sup.aCO, NR.sup.aCO.sub.2 or
NR.sup.aCONR.sup.a;
[0037] R.sup.a represents hydrogen or (1-6C) alkyl;
[0038] R.sup.2' represents (1-4C)alkyl;
[0039] R.sup.30 represents hydrogen, F, Cl, Br, I, CN, CF.sub.3,
NH.sub.2, NO.sub.2,CH.sub.3CONH, (1-4C)alkyl, (1-4C)alkoxy, and
phenyl; and
[0040] P is 0, 1, 2 or 3; or a pharmaceutically acceptable salt
thereof.
[0041] In addition, the following compounds of formula I" are
further included within the scope of the present invention: 4
[0042] wherein
[0043] B represents CONR.sup.a, NR.sup.aCO, NR.sup.aCO.sub.2 or
NR.sup.aCONR.sup.a;
[0044] R.sup.a represents hydrogen or (1-6C) alkyl
[0045] R.sup.2' represents (1-4C)alkyl; and
[0046] R.sup.31 represents hydrogen, F, Cl, Br, I, CN, CF.sub.3,
NH.sub.2, (1-4C)alkyl, (1-4C)alkoxy, --CH.sub.2NHSO.sub.2R.sup.2",
--(CH.sub.2CH.sub.2)NHSO.sub.2R.sup.2", and
--(CH.sub.2CH.sub.2CH.sub.2)N- HSO.sub.2R .sup.2" wherein R.sup.2"
represents (1-4C)alkyl; or a pharmaceutically acceptable salt
thereof.
[0047] In addition, the following compounds of formula I'" are
further included within the scope of the present invention: 5
[0048] wherein
[0049] B represents CONR.sup.a, NR.sup.aCO, NR.sup.aCO.sub.2 or
NR.sup.aCONR.sup.a;
[0050] R.sup.a represents hydrogen or (1-6C) alkyl;
[0051] R.sup.2' represents (1-4C)alkyl; and
[0052] R.sup.31 represents hydrogen, F, Cl, Br, I, CN, CF.sub.3,
NH.sub.2, (1-4C)alkyl, (1-4C)alkoxy, --CH.sub.2NHSO.sub.2R.sup.2",
--(CH.sub.2H.sub.2)NHSO.sub.2R.sup.2", and
--(CH.sub.2CH.sub.2CH.sub.2)NH- SO.sub.2R.sup.2" wherein R.sup.2"
represents (1-4C)alkyl;
[0053] P is 0, 1, 2 or 3; or a pharmaceutically acceptable salt
thereof.
[0054] A preferred value for B is NR.sup.aCO with NHCO being
especially preferred.
[0055] A preferred value for R.sup.a is hydrogen.
[0056] Preferred values for R.sup.2' are methyl, ethyl and
isopropyl, with isopropyl being most preferred.
[0057] Preferred values for R.sup.2" are methyl, ethyl and
isopropyl, with methyl being most preferred.
[0058] Preferred values for R.sup.30 are hydrogen, methyl, ethyl,
isopropyl, Fl, Cl, CF.sub.3, CH.sub.3CONH and CN.
[0059] Preferred values for R.sup.31 are hydrogen, Fl, Cl, CN,
methyl, ethyl, isopropyl, CF.sub.3, and
--(CH.sub.2CH.sub.2)NHSO.sub.2R.sup.2, with
--(CH.sub.2CH.sub.2)NHSO.sub.2CH.sub.3 being especially
preferred.
[0060] Preferred values for p are 0, 1 or 2.
[0061] In this specification, the term "potentiating glutamate
receptor function" refers to any increased responsiveness of
glutamate receptors, for example AMPA receptors, to glutamate or an
agonist, and includes but is not limited to inhibition of rapid
desensitization or deactivation of AMPA receptors to glutamate.
[0062] A wide variety of conditions may be treated or prevented by
the compounds of formula I and their pharmaceutically acceptable
salts through their action as potentiators of glutamate receptor
function. Such conditions include those associated with glutamate
hypofunction, such as psychiatric and neurological disorders, for
example cognitive disorders; neuro-degenerative disorders such as
Alzheimer's disease; age-related dementias; age-induced memory
impairment; movement disorders such as tardive dyskinesia,
Hungtington's chorea, myoclonus and Parkinson's disease; reversal
of drug-induced states (such as cocaine, amphetamines,
alcohol-induced states); depression; attention deficit disorder;
attention deficit hyperactivity disorder; psychosis; cognitive
deficits associated with psychosis; and drug-induced psychosis. The
compounds of formula I may be further useful for the treatment of
sexual dysfunction. The compounds of formula I may also be useful
for improving memory (both short term and long term) and learning
ability. The present invention provides the use of compounds of
formula I for the treatment of each of these conditions.
[0063] The term "treating" (or "treat") as used herein includes its
generally accepted meaning which encompasses prohibiting,
preventing, restraining, and slowing, stopping, or reversing
progression, severity, or a resultant symptom.
[0064] The present invention includes the pharmaceutically
acceptable salts of the compounds defined by formula I. A compound
of this invention can possess a sufficiently acidic, a sufficiently
basic, or both functional groups, and accordingly react with any of
a number of organic and inorganic bases, and inorganic and organic
acids, to form a pharmaceutically acceptable salt.
[0065] The term "pharmaceutically acceptable salt" as used herein,
refers to salts of the compounds of the above formula which are
substantially non-toxic to living organisms. Typical
pharmaceutically acceptable salts include those salts prepared by
reaction of the compounds of the present invention with a
pharmaceutically acceptable mineral or organic acid or an organic
or inorganic base. Such salts are known as acid addition and base
addition salts.
[0066] Acids commonly employed to form acid addition salts are
inorganic acids such as hydrochloric acid, hydrobromic acid,
hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and
organic acids such as p-toluenesulfonic, methanesulfonic acid,
oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic
acid, citric acid, benzoic acid, acetic acid, and the like.
Examples of such pharmaceutically acceptable salts are the sulfate,
pyrosulfate, bisulfate, sulfite, bisulfite, phosphate,
monohydrogenphosphate, dihydrogenphosphate, metaphosphate,
pyrophosphate, bromide, iodide, acetate, propionate, decanoate,
caprylate, acrylate, formate, hydrochloride, dihydrochloride,
isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate,
succinate, suberate, sebacate, fumarate, maleate,
butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate,
methylbenzoate, hydroxybenzoate, methoxybenzoate, phthalate,
xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate,
citrate, lactate, g-hydroxybutyrate, glycolate, tartrate,
methanesulfonate, propanesulfonate, naphthalene-1-sulfonate,
napththalene-2-sulfonate, mandelate and the like. Preferred
pharmaceutically acceptable acid addition salts are those formed
with mineral acids such as hydrochloric acid and hydrobromic acid,
and those formed with organic acids such as maleic acid and
methanesulfonic acid.
[0067] Base addition salts include those derived from inorganic
bases, such as ammonium or alkali or alkaline earth metal
hydroxides, carbonates, bicarbonates, and the like. Such bases
useful in preparing the salts of this invention thus include sodium
hydroxide, potassium hydroxide, ammonium hydroxide, potassium
carbonate, sodium carbonate, sodium bicarbonate, potassium
bicarbonate, calcium hydroxide, calcium carbonate, and the like.
The potassium and sodium salt forms are particularly preferred.
[0068] It should be recognized that the particular counterion
forming a part of any salt of this invention is usually not of a
critical nature, so long as the salt as a whole is
pharmacologically acceptable and as long as the counterion does not
contribute undesired qualities to the salt as a whole. It is
further understood that the above salts may form hydrates or exist
in a substantially anhydrous form.
[0069] As used herein, the term "stereoisomer" refers to a compound
made up of the same atoms bonded by the same bonds but having
different three-dimensional structures which are not
interchangeable. The three-dimensional structures are called
configurations. As used herein, the term "enantiomer" refers to two
stereoisomers whose molecules are nonsuperimposable mirror images
of one another. The term "chiral center" refers to a carbon atom to
which four different groups are attached. As used herein, the term
"diastereomers" refers to stereoisomers which are not enantiomers.
In addition, two diastereomers which have a different configuration
at only one chiral center are referred to herein as "epimers". The
terms "racemate", "racemic mixture" or "racemic modification" refer
to a mixture of equal parts of enantiomers.
[0070] The term "enantiomeric enrichment" as used herein refers to
the increase in the amount of one enantiomer as compared to the
other. A convenient method of expressing the enantiomeric
enrichment achieved is the concept of enantiomeric excess, or "ee",
which is found using the following equation: 1 e e = E 1 - E 2 E 1
+ E 2 .times. 100
[0071] wherein E.sup.1 is the amount of the first enantiomer and
E.sup.2 is the amount of the second enantiomer. Thus, if the
initial ratio of the two enantiomers is 50:50, such as is present
in a racemic mixture, and an enantiomeric enrichment sufficient to
produce a final ratio of 50:30 is achieved, the ee with respect to
the first enantiomer is 25%. However, if the final ratio is 90:10,
the ee with respect to the first enantiomer is 80%. An ee of
greater than 90% is preferred, an ee of greater than 95% is most
preferred and an ee of greater than 99% is most especially
preferred. Enantiomeric enrichment is readily determined by one of
ordinary skill in the art using standard techniques and procedures,
such as gas or high performance liquid chromatography with a chiral
column. Choice of the appropriate chiral column, eluent and
conditions necessary to effect separation of the enantiomeric pair
is well within the knowledge of one of ordinary skill in the art.
In addition, the enantiomers of compounds of formula I can be
resolved by one of ordinary skill in the art using standard
techniques well known in the art, such as those described by J.
Jacques, et al., "Enantiomers, Racemates, and Resolutions", John
Wiley and Sons, Inc., 1981. Examples of resolutions include
recrystallization techniques or chiral chromatography.
[0072] Some of the compounds of the present invention have one or
more chiral centers and may exist in a variety of stereoisomeric
configurations. As a consequence of these chiral centers, the
compounds of the present invention occur as racemates, mixtures of
enantiomers and as individual enantiomers, as well as diastereomers
and mixtures of diastereomers. All such racemates, enantiomers, and
diastereomers are within the scope of the present invention.
[0073] The terms "R" and "S" are used herein as commonly used in
organic chemistry to denote specific configuration of a chiral
center. The term "R" (rectus) refers to that configuration of a
chiral center with a clockwise relationship of group priorities
(highest to second lowest) when viewed along the bond toward the
lowest priority group. The term "S" (sinister) refers to that
configuration of a chiral center with a counterclockwise
relationship of group priorities (highest to second lowest) when
viewed along the bond toward the lowest priority group. The
priority of groups is based upon their atomic number (in order of
decreasing atomic number). A partial list of priorities and a
discussion of stereochemistry is contained in "Nomenclature of
Organic Compounds: Principles and Practice", (J. H. Fletcher, et
al., eds., 1974) at pages 103-120.
[0074] As used herein, the term "aromatic group" means the same as
aryl, and includes phenyl and a polycyclic aromatic carbocyclic
ring such as naphthyl.
[0075] The term "heteroaromatic group" includes an aromatic 5-6
membered ring containing from one to four heteroatoms selected from
oxygen, sulfur and nitrogen, and a bicyclic group consisting of a
5-6 membered ring containing from one to four heteroatoms selected
from oxygen, sulfur and nitrogen fused with a benzene ring or
another 5-6 membered ring containing one to four atoms selected
from oxygen, sulfur and nitrogen. Examples of heteroaromatic groups
are thienyl, furyl, oxazolyl, isoxazolyl, oxadiazoyl, pyrazolyl,
thiazolyl, thiadiazolyl, isothiazolyl, imidazolyl, triazolyl,
tetrazolyl, pyridyl, pyridazinyl, pyrimidyl, benzofuryl,
benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indolyl
and quinolyl.
[0076] The term "substituted" as used in the term "substituted
aromatic or heteroaromatic group" herein signifies that one or more
(for example one or two) substituents may be present, said
substituents being selected from atoms and groups which, when
present in the compound of formula I, do not prevent the compound
of formula I from functioning as a potentiator of glutamate
receptor function.
[0077] Examples of substituents which may be present in a
substituted aromatic or heteroaromatic group include halogen;
nitro; cyano; hydroxyimino; (1-10C) alkyl; (2-10C)alkenyl;
(2-10C)alkynyl; (3-8C)cycloalkyl; hydroxy(3-8C)cycloalkyl;
oxo(3-8C)cycloalkyl; halo(1-10C)alkyl; (CH.sub.2).sub.yX.sup.1
R.sup.9 in which y is 0 or an integer of from 1 to 4, X.sup.1
represents O, S, NR.sup.10, CO, COO, OCO, CONR.sup.11, NR.sup.12CO,
NR.sup.12COCOO, OCONR.sup.13, R.sup.9 represents hydrogen, (1-10C)
alkyl, (3-10C)alkenyl, (3-10C)alkynyl, pyrrolidinyl,
tetrahydrofuryl, morpholino or (3-8C)cycloalkyl and R.sup.10,
R.sup.11, R.sup.12 and R.sup.13 each independently represents
hydrogen or (1-1.degree. C.)alkyl, or R.sup.9 and R.sup.10,
R.sup.11, R.sup.12 or R.sup.13 together with the nitrogen atom to
which they are attached form an azetidinyl, pyrrolidinyl,
piperidinyl or morpholino group; N-(1-4C)alkylpiperazinyl;
N-phenyl(1-4C)alkylpiperazinyl; thienyl; furyl; oxazolyl;
isoxazolyl; pyrazolyl; imidazolyl; thiazolyl; pyridyl; pyridazinyl;
pyrimidinyl; dihydrothienyl; dihydrofuryl; dihydrothiopyranyl;
dihydropyranyl; dihydrothiazolyl; (1-4C)alkoxycarbonyl
dihydrothiazolyl; (1-4C)alkoxycarbonyl dimethyl-dihydrothiazolyl;
tetrahydrothienyl; tetrahydrofuryl; tetrahydrothiopyranyl;
tetrahydropyranyl; indolyl; benzofuryl; benzothienyl;
benzimidazolyl; and a group of formula
R.sup.14-(L.sup.a).sub.n--X.sup.2-(L.sup.b).sub.m in which X.sup.2
represents a bond, O, NH, S, SO, SO.sub.2, CO, CH(OH), CONH, NHCO,
NHCONH, NHCOO, COCONH, OCH.sub.2CONH, or CH.dbd.CH, L.sup.a and
L.sup.b each represent (1-4C)alkylene, one of n and m is 0 or 1 and
the other is 0, and R.sup.14 represents a phenyl or heteroaromatic
group which is unsubstituted or substituted by one or two of
halogen, nitro; cyano; (1-10C) alkyl;
[0078] (2-10C)alkenyl; (2-10C)alkynyl; (3-8C)cycloalkyl;
4-(1,1-dioxotetrahydro-1,2-thiazinyl); halo(1-10C)alkyl;
cyano(2-10C)alkenyl; phenyl; and (CH.sub.2).sub.zX.sup.3R.sup.15 in
which z is 0 or an integer of from 1 to 4, X.sup.3 represents O, S,
NR.sup.16, CO, CH(OH), COO, OCO, CONR.sup.17, NR.sup.18CO,
NHSO.sub.2, NHSO.sub.2NR.sup.17, OCONR.sup.19 or NR.sup.19COO,
R.sup.15 represents hydrogen, (1-10C)alkyl, phenyl(1-4C)alkyl,
halo(11.degree. C.)alkyl, (1-4C)alkoxycarbonyl(1-4C)alkyl,
(1-4C)alkylsulfonylamino(1-4C)alkyl,
N-(1-4C)alkoxycarbonyl)(1-4C)alkylsulfonylamino(1-4C)alkyl,
(3-10C)alkenyl, (3-10C)alkynyl, (3-8C)cycloalkyl, camphoryl, or an
aromatic or heteroaromatic group which is unsubstituted or
substituted by one or two of halogen, (1-4C)alkyl, halo(1-4C)alkyl,
di(1-4C)alkylamino and (1-4C)alkoxy, and R.sup.16, R.sup.17,
R.sup.18 and R.sup.19 each independently represents hydrogen or
(1-10C)alkyl, or R.sup.15 and R.sup.16, R.sup.17, R.sup.18 or
R.sup.19 together with the nitrogen atom to which they are attached
form an azetidinyl, pyrrolidinyl, piperidinyl or morpholino
group.
[0079] The term (1-10C)alkyl includes (1-8C)alkyl, (1-6C)alkyl and
(1-4C)alkyl. Particular values are methyl, ethyl, propyl,
isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl, octyl,
nonyl and decyl.
[0080] The term (2-10C)alkenyl includes (3-10C)alkenyl,
(1-8C)alkenyl, (1-6C)alkenyl and (1-4C)alkenyl. Particular values
are vinyl and prop-2-enyl.
[0081] The term (2-10C)alkynyl includes (3-10C)alkynyl,
(1-8C)alkynyl, (1-6C)alkynyl and (3-4C)alkynyl. A particular value
is prop-2-ynyl.
[0082] The term (1-4C)alkoxy includes methoxy, ethoxy, propoxy,
isopropoxy, butoxy, t-butoxy, and the like.
[0083] The term (3-8C)cycloalkyl, as such or in the term
(3-8C)cycloalkyloxy, includes monocyclic and polycyclic groups.
Particular values are cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl and bicyclo[2.2.2]octane. The term includes
(3-6C)cycloalkyl: cyclopropyl, cyclobutyl, cyclopentyl and
cyclohexyl.
[0084] The term hydroxy(3-8C)cycloalkyl includes
hydroxy-cyclopentyl, such as 3-hydroxycyclopentyl.
[0085] The term oxo(3-8C)cycloalkyl includes oxocyclopentyl, such
as 3-oxocyclopentyl.
[0086] The term halogen includes fluorine, chlorine, bromine and
iodine.
[0087] The term halo(1-10C)alkyl includes fluoro(1-10C)alkyl, such
as trifluoromethyl and 2,2,2-trifluoroethyl, and chloro(1-10C)alkyl
such as chloromethyl.
[0088] The term phenyl(1-6C)alkyl includes the term
--CH.sub.2phenyl.
[0089] The term cyano(2-10C)alkenyl includes 2-cyanoethenyl.
[0090] The term (2-4C)alkylene includes ethylene, propylene and
butylene. A preferred value is ethylene.
[0091] The term thienyl includes thien-2-yl and thien-3-yl.
[0092] The term furyl includes fur-2-yl and fur-3-yl.
[0093] The term oxazolyl includes oxazol-2-yl, oxazol-4-yl and
oxazol-5-yl.
[0094] The term isoxazolyl includes isoxazol-3-yl, isoxazol-4-yl
and isoxazol-5-yl.
[0095] The term oxadiazolyl includes [1,2,4]oxadiazol-3-yl and
[1,2,4]oxadiazol-5-yl.
[0096] The term pyrazolyl includes pyrazol-3-yl, pyrazol-4-yl and
pyrazol-5-yl.
[0097] The term thiazolyl includes thiazol-2-yl, thiazol-4-yl and
thiazol-5-yl.
[0098] The term thiadiazolyl includes [1,2,4]thiadiazol-3-yl, and
[1,2,4]thiadiazol-5-yl.
[0099] The term isothiazolyl includes isothiazol-3-yl,
isothiazol-4-yl and isothiazol-5-yl.
[0100] The term imidazolyl includes imidazol-2-yl, imidazolyl-4-yl
and imidazolyl-5-yl.
[0101] The term triazolyl includes [1,2,4]triazol-3-yl and
[1,2,4]triazol-5-yl.
[0102] The term tetrazolyl includes tetrazol-5-yl.
[0103] The term pyridyl includes pyrid-2-yl, pyrid-3-yl and
pyrid-4-yl.
[0104] The term pyridazinyl includes pyridazin-3-yl,
pyridazin-4-yl, pyridazin-5-yl and pyridazin-6-yl.
[0105] The term pyrimidyl includes pyrimidin-2-yl, pyrimidin-4-yl,
pyrimidin-5-yl and pyrimidin-6-yl.
[0106] The term benzofuryl includes benzofur-2-yl and
benzofur-3-yl.
[0107] The term benzothienyl includes benzothien-2-yl and
benzothien-3-yl.
[0108] The term benzimidazolyl includes benzimidazol-2-yl.
[0109] The term benzoxazolyl includes benzoxazol-2-yl.
[0110] The term benzothiazolyl includes benzothiazol-2-yl.
[0111] The term indolyl includes indol-2-yl and indol-3-yl.
[0112] The term quinolyl includes quinol-2-yl.
[0113] The term dihydrothiazolyl includes 4,5-dihydrothiazol-2-yl,
and the term (1-4C)alkoxycarbonyldihydrothiazolyl includes
4-methoxycarbonyl-4,5-dihydrothiazol-2-yl.
[0114] Preferably either one or two of R.sup.5, R.sup.6, R.sup.7
and R.sup.8 represents (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl,
aryl(2-6C)alkenyl or aryl, or two of R.sup.5, R.sup.6, R.sup.7 and
R.sup.8 together with the carbon atom or carbon atoms to which they
are attached form a (3-8C)carbocyclic ring; and the remainder of
R.sup.5, R.sup.6, R.sup.7 and R.sup.8 represent hydrogen.
[0115] Examples of a (1-6C)alkyl group represented by R.sup.5,
R.sup.6, R.sup.7 and R.sup.8 are methyl, ethyl and propyl. An
example of an aryl(1-C)alkyl group is benzyl. An example of a
(2-6C)alkenyl group is prop-2-enyl. An example of a
(3-8C)carbocyclic ring is a cyclopropyl ring.
[0116] More preferably R.sup.6 and R.sup.7 represent hydrogen.
[0117] Preferably R.sup.5 and R.sup.8 each independently represents
hydrogen or (1-4C)alkyl, or together with the carbon atom to which
they are attached form a (3-8C) carbocyclic ring.
[0118] More preferably R.sup.8 represents methyl or ethyl, or
R.sup.5 and R.sup.8 together with the carbon atom to which they are
attached form a cyclopropyl ring. When R.sup.8 represents methyl or
ethyl, R.sup.5 preferably represents hydrogen or methyl.
[0119] Especially preferred are compounds in which R.sup.8
represents methyl and R.sup.5, R.sup.6 and R.sup.7 represent
hydrogen.
[0120] Preferably R.sup.3 and R.sup.4 each represent methyl.
[0121] Examples of values for R.sup.2 are methyl, ethyl, propyl,
2-propyl, butyl, 2-methylpropyl, cyclohexyl, trifluoromethyl,
2,2,2-trifluoroethyl, chloromethyl, ethenyl, prop-2-enyl,
methoxyethyl, phenyl, 4-fluorophenyl, or dimethylamino. Preferably
R.sup.2 is ethyl, 2-propyl or dimethylamino.
[0122] Examples of values for R.sup.9 are hydrogen, methyl, ethyl,
propyl, isopropyl, t-butyl, ethenyl, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, 2-pyrrolidinyl, morpholino or
2-tetrahydrofuryl.
[0123] Examples of values for R.sup.15 are hydrogen, methyl, ethyl,
propyl, isopropyl, butyl, t-butyl, benzyl, 2,2,2-trifluoroethyl,
2-methoxycarbonylethyl, cyclohexyl, 10-camphoryl, phenyl,
2-fluorophenyl, 3-fluorophenyl, 2-trifluoromethylphenyl,
4-trifluoromethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl,
4-methoxyphenyl, 1-(5-dimethylamino)naphthyl, and 2-thienyl.
[0124] X.sup.1 preferably represents O, CO, CONH or NHCO.
[0125] z is preferably 0.
[0126] R.sup.9 is preferably (1-4C)alkyl, (2-4C)alkenyl,
(3-6C)cycloalkyl, pyrrolidinyl, morpholino or tetrahydrofuryl.
[0127] Particular values for the groups (CH.sub.2).sub.yX.sup.1
R.sup.9 and (CH.sub.2).sub.zX.sup.3R.sup.15 include (1-10C)alkoxy,
including (1-6C)alkoxy and (1-4C)alkoxy, such as methoxy, ethoxy,
propoxy, isopropoxy and isobutoxy; (3-10C)alkenyloxy, including
(3-6C)alkenyloxy, such as prop-2-enyloxy; (3-10C)alkynyloxy,
including (3-6C)alkynyloxy, such as prop-2-ynyloxy; and
(1-6C)alkanoyl, such as formyl and ethanoyl.
[0128] Examples of particular values for y are 0 and 1.
[0129] Examples of particular values for z are 0, 1, 2 and 3.
[0130] L.sup.a and L.sup.b preferably each independently represents
CH.sub.2.
[0131] X.sup.2 preferably represents a bond, O, NH, CO, CH(OH),
CONH, NHCONH or OCH.sub.2CONH.
[0132] Preferably the group (CH.sub.2).sub.yX.sup.1 R.sup.9
represents CHO; COCH.sub.3, OCH.sub.3; OCH(CH.sub.3).sub.2;
NHCOR.sup.9 in which R.sup.9 represents methyl, ethyl, isopropyl,
t-butyl, ethenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
2-pyrolidinyl or morpholino; CONHR.sup.9 in which R.sup.9
represents cyclopropyl or cyclopentyl; NHCOCOOCH3; or
2-tetrahydrofurylmethoxy.
[0133] Preferably the group (CH.sub.2).sub.zX.sup.3R.sup.15
represents NH.sub.2; CH.sub.2NH.sub.2; (CH.sub.2).sub.2NH.sub.2;
(CH.sub.2).sub.3NH.sub.2; CONH.sub.2; CONHCH.sub.3;
CON(CH.sub.3).sub.2; N(C.sub.2H.sub.5).sub.2; CH.sub.2OH;
CH(OH)CH.sub.3; CH(OH)CH.sub.2CH.sub.2; CHO; COCH.sub.3; COOH;
COOCH.sub.3; CH.sub.2NHCOOC(CH.sub.3).sub.3;
(CH.sub.2).sub.2NHCOOC(CH.sub.3).sub.3;
NHSO.sub.2CH(CH.sub.3).sub.2; a group of formula
(CH.sub.2).sub.2NHSO.sub- .2R.sup.15 in which R.sup.15 represents
CH.sub.3, CH.sub.2CH.sub.3, CH(CH.sub.3).sub.2,
(CH.sub.2).sub.2CH.sub.3, (CH.sub.3).sub.3CH.sub.3, benzyl,
CH.sub.2CF.sub.3, 2-methoxycarbonylethyl, cyclohexyl, 10-camphoryl,
phenyl, 2-fluorophenyl, 4-fluorophenyl, 2-trifluoromethylphenyl,
4-trifluoromethylphenyl, 4-methoxyphenyl,
1-(2-dimethylamino)naphthyl or 2-thienyl;
CH(OH)CH.sub.2NHSO.sub.2CH.sub.- 3;
(CH.sub.2).sub.3NHSO.sub.2CH(CH.sub.3).sub.2;
COCH.sub.2N(OCOC(CH.sub.3- ).sub.2SO.sub.2CH.sub.3;
COCH.sub.2NHSO.sub.2CH.sub.3; (CH.sub.2).sub.2NHCOR.sup.15 in which
R.sup.15 represents CH.sub.3, CH(CH.sub.3).sub.2,
CH.sub.2CH(CH.sub.3).sub.2, phenyl, 3-fluorophenyl, 4-fluorophenyl,
benzyl, 2-methoxyphenyl, 4-methoxyphenyl, 2-thienyl, CH.dbd.CH,
CH.dbd.CHCN, OCH.sub.3 or O(CH.sub.2).sub.3CH.sub.3.
[0134] Examples of particular values for
(L.sup.a).sub.n--X.sup.2-(L.sup.b- ).sub.m are a bond, O, NH, S,
SO, SO.sub.2, CO, CH.sub.2, COCH.sub.2, COCONH, CH(OH)CH.sub.2,
CONH, NHCO, NHCONH, CH.sub.2O, OCH.sub.2, OCH.sub.2CONH,
CH.sub.2NH, NHCH.sub.2 and CH.sub.2CH.sub.2.
[0135] R.sup.14 is preferably an unsubstituted or substituted
phenyl, naphthyl, furyl, thienyl, isoxazolyl, thiazolyl,
tetrazolyl, pyridyl, pyrimidyl benzothienyl or benzothiazolyl
group.
[0136] Examples of particular values for R.sup.14 are phenyl,
2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chloro-phenyl,
3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl,
4-bromophenyl, 4-iodophenyl, 2,3-difluoro-phenyl,
2,4-difluorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl,
4-cyanophenyl, 3-nitrophenyl, 4-hydroxyiminophenyl, 2-methylphenyl,
4-methylphenyl, 4-ethylphenyl, 3-propylphenyl, 4-t-butylphenyl,
2-prop-2-enylphenyl,
4-(4-(1,1-dioxotetrahydro-1,2-thiazinyl)phenyl,
2-trifluoromethylphenyl, 3-trifluoromethylphenyl,
4-trifluoromethylphenyl, 2-bromomethylphenyl,
2-fluoro-4-trifluoromethylphenyl, 4-(2-cyanoethenyl)phenyl,
4-phenyl, 2-formylphenyl, 3-formylphenyl, 4-formylphenyl,
2-acetylphenyl, 3-acetylphenyl, 4-acetylphenyl, 2-propanoylphenyl,
2-(2-methyl-propanoyl)phenyl, 2-methoxyphenyl, 3-methoxyphenyl,
4-methoxyphenyl, 4-butoxyphenyl, 2-hydroxymethylphenyl,
4-hydroxymethylphenyl, 2-(1-hydroxyethyl)phenyl,
3-(1-hydroxyethyl)phenyl- , 4-(1-hydroxyethyl)phenyl,
2-(1-hydroxypropyl)phenyl, 4-(1-hydroxypropyl)phenyl,
2-(1-hydroxy-2,2-dimethyl-propyl)phenyl, 4-trifluoromethoxyphenyl,
2-aminophenyl, 4-aminophenyl, 4-N,N-diethylaminophenyl,
4-aminomethylphenyl, 4-(2-aminoethyl)phenyl,
4-(3-aminopropyl)phenyl, 4-carboxyphenyl, 4-carbamoylphenyl,
4-N-methylcarbamoylphenyl, 4-N,N-dimethylcarbamoylphenyl,
2-isopropylaminomethylphenyl, 4-t-butoxycarbonylaminomethylphenyl,
4-(2-isopropoxy-carboxamido)ethylphenyl,
4-(2-t-butoxycarboxamido)ethyl-p- henyl,
4-isopropylsulfonylaminophenyl,
4-(2-methane-sulfonylamino)ethylphe- nyl,
4-(2-ethylsuffonylamino)ethyl-phenyl,
4-(3-isopropylsulfonylamino)pro- pylphenyl,
4-(1-(2-(2-propane)sulfonylamino)propyl)phenyl,
4-(2-propylsulfonylamino)ethylphenyl,
4-(2-isopropylsulfonylamino)ethylph- enyl,
4-(2-butylsulfonylamino)ethylphenyl,
4-(1-isopropyl-sulfonylaminomet- hyl)ethylphenyl,
4-(1-hydroxy-2-methane-sulfonylamino)ethylphenyl,
4-(2-(2,2,2-trifluoroethyl)-sulfonylaminoethyl)phenyl,
4-(2-cyclohexylsulfonylamino)-ethylphenyl,
4-(2-(2,2,2-trifluoroethyl)sul- fonylamino)-ethylphenyl,
4-(2-N,N-dimethylaminosulfonylamino)-ethylphenyl,
4-(2-phenylsulfonylaminoethyl)phenyl,
4-(2-(2-fluorophenyl)sulfonylaminoe- thyl)phenyl,
4-(2-(4-fluorophenyl)sulfonylaminoethyl)phenyl,
4-(2-(2-trifluoromethylphenyl)sulfonylaminoethyl)phenyl,
4-(2-(4-trifluoromethylphenyl)sulfonylaminoethyl)phenyl,
4-(2-(4-methoxyphenyl)sulfonylaminoethyl)phenyl,
4-(2-(1-(5-dimethylamino- )napthalenesulfonylamino)ethyl)phenyl,
4-(2-(2-thienyl)sulfonylamino)ethyl- )phenyl,
4-(2-benzamidoethyl)-phenyl, 4-(2-(4-fluorobenzamido)ethyl)phenyl-
, 4-(2-(3-methoxybenzamido)ethyl)phenyl,
4-(2-(3-fluorobenzamido)-ethyl)ph- enyl,
4-(2-(4-methoxybenzamido)ethyl)phenyl,
4-(2-(2-methoxybenzamido)ethy- l)phenyl,
4-(1-(2-(2-methoxycarbonylethanesulfonylamino)ethyl)phenyl,
4-(1-(2-(10-camphorsulfonylamino)ethyl)phenyl,
4-(1-(2-(benzylsulfonyl-am- ino)ethyl)phenyl,
4-(2-phenylacetamido)ethyl)phenyl,
4-methanesulfonylaminoethanoylphenyl,
4-(N-(t-butoxy-carbonyl)methanesulf- onylaminoethanoyl)phenyl,
4-(2-(2-thienylcarboxamido)ethyl)phenyl, thien-2-yl,
5-hydroxy-methylthien-2-yl, 5-formylthien-2-yl, thien-3-yl,
5-hydroxymethylthien-3-yl, 5-formylthien-3-yl, 2-bromothien-3-yl,
fur-2-yl, 5-nitrofur-2-yl, fur-3-yl, isoxazol-5-yl,
3-bromoisoxazol-5-yl, isoxazol-3-yl, 5-trimethylsilylisoxazol-3-yl,
5-methylisoxazol-3-yl, 5-hydroxymethylisoxazol-3-yl,
5-methyl-3-phenylisoxazol-4-yl, 5-(2-hydroxyethyl)isoxazol-3-yl,
5-acetylisoxazol-3-yl, 5-carboxyisoxazol-3-yl,
5-N-methylcarbamoylisoxazol-3-yl, 5-methoxycarbonylisoxazol-3-yl,
3-bromo[1,2,4]oxadiazol-5-yl, pyrazol-1-yl, thiazol-2-yl,
4-hydroxymethylthiazbl-2-yl, 4-methoxycarbonylthiazol-2-yl,
4-carboxythiazol-2-yl, imidazol-1-yl, 2-sulfhydryl-imidazol-1-yl,
[1,2,4]triazol-1-yl, tetrazol-5-yl, 2-methyltetrazol-5-yl,
2-ethyltetrazol-5-yl, 2-isopropyl-tetrazol-5-yl,
2-(2-propenyl)tetrazol-5-yl, 2-benzyltetrazol-5-yl, pyrid-2-yl,
5-ethoxycarbonylpyrid-2-yl, pyrid-3-yl, 6-chloropyrid-3-yl,
pyrid-4-yl, 5-trifluoro-methylpyrid-2-yl, 6-chloropyridazin-3-yl,
6-methylpyridazin-3-yl, 6-methoxypyrazin-3-yl, pyrimidin-5-yl,
benzothien-2-yl, benzothiazol-2-yl, and quinol-2-yl.
[0137] Examples of an unsubstituted or substituted aromatic or
heteroaromatic group represented by R.sup.1 are unsubstituted or
substituted phenyl, furyl, thienyl (such as 3-thienyl) and pyridyl
(such as 3-pyridyl).
[0138] More preferably, R.sup.1 represents 2-naphthyl or a group of
formula 6
[0139] in which
[0140] R.sup.20 represents halogen; nitro; cyano; hydroxyimino;
(1-10C)alkyl; (2-10C)alkenyl; (2-10C)alkynyl; (3-8C)cyclo-alkyl;
hydroxy(3-8C)cycloalkyl; oxo(3-8C)cycloalkyl; halo(1-10C)alkyl;
(CH.sub.2).sub.yX.sup.1 R.sup.9 in which y is 0 or an integer of
from 1 to 4, X.sup.1 represents O, S, NR.sup.10, CO, COO, OCO,
CONR.sup.11, NR.sup.12CO, NR.sup.12COCOO, OCONR.sup.13, R.sup.9
represents hydrogen, (1-10C) alkyl, (3-10C)alkenyl, (3-10C)alkynyl,
pyrrolidinyl, tetrahydrofuryl, morpholino or (3-8C)cycloalkyl and
R.sup.10 R.sup.11, R.sup.12 and R.sup.13 each independently
represents hydrogen or (1-10C)alkyl, or R.sup.9 and R.sup.10,
R.sup.11,R.sup.12 or R.sup.13 together with the nitrogen atom to
which they are attached form an azetidinyl, pyrrolidinyl,
piperidinyl or morpholino group; N-(1-4C)alkylpiperazinyl;
N-phenyl(1-4C)alkylpiperazinyl; thienyl; furyl; oxazolyl;
isoxazolyl; pyrazolyl; imidazolyl; thiazolyl; tetrazolyl; pyridyl;
pyridazinyl; pyrimidinyl; dihydrothienyl; dihydrofuryl;
dihydrothiopyranyl; dihydropyranyl; dihydrothiazolyl;
(1-4C)alkoxycarbonyldihydrothiazolyl;
(1-4C)alkoxycarbonyldimethyl-dihydr- othiazolyl; tetrahydrothienyl;
tetrahydrofuryl; tetrahydrothiopyranyl; tetrahydropyranyl; indolyl;
benzofuryl; benzothienyl; benzimidazolyl; benzothiazolyl; and a
group of formula R.sup.14-(L.sup.a).sub.n--X.sup.2--
(L.sup.b).sub.m in which X.sup.2 represents a bond, O, NH, S, SO,
SO.sub.2, CO, CH(OH), CONH, NHCONH, NHCOO, COCONH, OCH.sub.2CONH or
CH.dbd.CH, NHCO, L.sup.a and L.sup.b each represent (1-4C)alkylene,
one of n and m is 0 or 1 and the other is 0, and R.sup.14
represents a phenyl or hetero-aromatic group which is unsubstituted
or substituted by one or two of halogen; nitro; cyano;
(1-10C)alkyl; (2-10C)alkenyl; (2-10C)alkynyl; (3-8C)cycloalkyl;
4-(1,1-dioxotetrahydro-1,2-thiazinyl); halo(1-10C)alkyl;
cyano(2-10C)alkenyl; phenyl; (CH.sub.2).sub.zX.sup.3R.s- up.15 in
which z is 0 or an integer of from 1 to 4, X.sup.3 represents O, S,
NR.sup.16, CO, CH(OH), COO, OCO, CONR.sup.17, NR.sup.18CO,
NHSO.sub.2, NHSO.sub.2NR.sup.17, NHCONH, OCONR.sup.19 or
NR.sup.19COO, R.sup.15 represents hydrogen, (1-10C)alkyl,
phenyl(1-4C)alkyl, halo(1-10C)alkyl,
(1-4C)alkoxycarbonyl(1-4C)alkyl,
(1-4C)alkylsulfonylamino(1-4C)alkyl,
(N-(1-4C)alkoxycarbonyl)(1-4C)alkylsulfonylamino(1-4C)alkyl,
(3-10C)alkenyl, (3-10C)alkynyl, (3-8C)cycloalkyl, camphoryl or an
aromatic or heteroaromatic group which is unsubstituted or
substituted by one or two of halogen, (1-4C)alkyl, halo(1-4C)alkyl,
di(1-4C)alkylamino and (1-4C)alkoxy, and R.sup.16, R.sup.17,
R.sup.18 and R.sup.19 each independently represents hydrogen or
(1-10C)alkyl, or R.sup.15 and R.sup.16, R.sup.17, R.sup.18 or
R.sup.19 together with the nitrogen atom to which they are attached
form an azetidinyl, pyrrolidinyl, piperidinyl or morpholino group;
and
[0141] R.sup.21 represents a hydrogen atom, a halogen atom, a
(1-4C)alkyl group or a (1-4C)alkoxy group.
[0142] Examples of particular values for R.sup.20 are fluorine,
chlorine, bromine, cyano, hydroxyimino, methyl, ethyl, propyl,
2-propyl, butyl, 2-methylpropyl, 1,1-dimethylethyl, cyclopentyl,
cyclohexyl, 3-hydroxycyclopentyl, 3-oxocyclopentyl, methoxy,
ethoxy, propoxy, 2-propoxy, acetyl, acetylamino, ethylcarboxamido,
propylcarboxamido, 1-butanoylamido, t-butylcarboxamido,
acryloylamido, 2-pyrrolidinylcarboxamido, 2-tetrahydrofurylmethoxy,
morpholinocarboxamido, methyloxalylamido, cyclo-propylcarboxamido,
cyclobutylcarboxamido, cyclopentyl-carboxamido,
cyclohexylcarboxamido, cyclopropylcarbamoyl, cyclopentylcarbamoyl,
pyrrolidin-1-yl, morpholino, piperidin-1-yl, N-methylpiperazinyl,
N-benzylpiperazinyl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl,
isoxazol-3-yl, thiazol-2-yl, tetrazol-5-yl, pyrid-2-yl, pyrid-3-yl,
pyrid-4-yl, pyrimidin-5-yl, 4,5-dihydrothiazol-2-yl,
4,5-dihydro-4-methoxycarbonylthiazol-2-yl,
4,5-dihydro-methoxy-carbonyl-5,5-dimethylthiazol-2-yl,
benzothien-2-yl, benzothiazol-2-yl, phenyl, 2-fluorophenyl,
3-fluorophenyl, 2,3-difluorophenyl, 4-chlorophenyl,
3,4-dichlorophenyl, 3,5-dichlorophenyl, 3-nitrophenyl,
4-cyanophenyl, 2-methylphenyl, 4-methylphenyl,
4-(4-(1,1-dioxotetrahydro-1,2-thiazinyl)phenyl,
3-trifluoromethylphenyl, 4-trifluoro-methylphenyl,
4-(2-cyanoethenyl)phenyl, 2-formylphenyl, 3-formylphenyl,
4-formylphenyl, 3-acetylphenyl, 4-acetylphenyl, 4-carboxyphenyl,
2-methoxyphenyl, 4-methoxyphenyl, 2-hydroxymethylphenyl,
4-hydroxymethylphenyl, 3-(1-hydroxyethyl)phenyl,
4-(1-hydroxyethyl)phenyl, 4-(1-hydroxypropyl)phenyl, 2-aminophenyl,
4-aminophenyl, 4-N,N-diethylaminophenyl, 4-aminomethylphenyl,
4-(2-aminoethyl)-phenyl, 4-(3-aminopropyl)phenyl,
4-(2-acetylaminoethyl)-phenyl, 4-t-butoxycarboxylaminoethyl)phenyl,
4-(2-t-butoxycarboxylaminoethyl)phen- yl, benzylsulfonylamino,
4-isopropylsulfonylaminophenyl,
4-(2-methanesulfonylaminoethyl)phenyl,
4-(2-ethylsulfonylaminoethyl)pheny- l,
4-(2-propylsulfonylaminoethyl)phenyl,
4-(2-butylsulfonyl-aminoethyl)phe- nyl,
4-(2-isopropylsulfonylaminoethyl)phenyl,
4-(1-hydroxy-2-methanesulfon- ylaminoethyl)phenyl,
4-(2-dimethylaminosulfonylaminoethyl)phenyl,
4-(1-(2-(2-propyl)sulfonylaminopropyl)phenyl,
4-(2-(2,2,2-trifluoroethyl)- sulfonylaminoethyl)phenyl,
4-(2-cyclohexylsulfonyl-aminoethyl)phenyl,
4-(2-phenylsulfonylaminoethyl)phenyl,
4-(2-(2-fluorophenyl)sulfonylaminoe- thyl)phenyl,
4-(2-(4-fluorophenyl)sulfonylaminoethyl)phenyl,
4-(2-(2-trifluoromethylphenyl)sulfonylaminoethyl)phenyl,
4-(2-(4-trifluoromethylphenyl)sulfonylaminoethyl)phenyl,
4-(2-(4-methoxyphenyl)sulfonylaminoethyl)phenyl,
4-(2-(1-(5-dimethylamino- )napthalenesulfonylamino)ethyl)phenyl,
4-(2-(2-thienyl)sulfonylamino)ethyl- )phenyl,
4-(2-benzamidoethyl)-phenyl, 4-(2-(4-fluorobenzamido)ethyl)phenyl-
, 4-(2-(3-methoxybenzamido)ethyl)phenyl,
4-(2-(3-fluorobenzamido)-ethyl)ph- enyl,
4-(2-(4-methoxybenzamido)ethyl)phenyl,
4-(2-(2-methoxybenzamido)ethy- l)phenyl,
4-2-(2-thienyl-carboxamido)ethyl)phenyl, 4-carbamoylpheny),
4-methyl-carbamoylphenyl, 4-dimethylcarbamoylphenyl,
4-(2-(2-methylpropaneamido)ethyl)phenyl,
4-(2-(3-methyl-butaneamido)ethyl- )phenyl, benzoylmethyl,
benzamido, 2-fluorobenzamido, 3-flurobenzamido, 4-fluorobenzamido,
2,4-difluorobenzamido, 3-chlorobenzamido, 4-chlorobenzamido,
4-bromobenzamido, 4-iodobenzamido, 4-cyanobenzamido,
3-methylbenzamido, 4-methylbenzamido, 4-ethylbenzamido,
4-propylbenzamido, 4-t-butylbenzamido, 4-vinylbenzamido,
2-trifluoromethylbenzamido, 3-trifluoromethylbenzamido,
4-trifluoromethylbenzamido, 2-fluoro-4-trifluoromethylbenzamido,
2-methoxybenzamido, 3-methoxybenzamido, 4-methoxybenzamido,
4-butoxybenzamido, 4-phenylphenyl-carboxamido, 4-benzylcarboxamido,
4-phenoxymethyl-carboxamido, 2-fluorobenzylamino, benzyloxy,
2-fluorobenzyloxy, 2-hydroxy-2-phenylethyl,
2-fluorophenylcarbamoyl,
4-(1-(2-(2-methoxycarbonylethanesuifonylamino)ethyl)phenyl,
4-(1-(2-(10-camphorsulfonylamino)ethyl)phenyl,
4-(1-(2-(benzylsulfonylami- no)ethyl)phenyl,
4-(2-phenylacetamido)-ethyl)phenyl,
4-(methanesulfonylaminoethanoyl)phenyl,
4-(N-t-butoxycarbonyl)methanesulf- onylaminoethanoyl)phenyl,
2-thienylcarboxamido, 2-furylcarboxamido,
3-(5-methyl-isoxazolyl)carboxamido, 5-isoxazolylcarboxamido,
2-benzothienylcarboxamido,
4-(5-methyl-3-phenylisoxazolyl)-carboxamido, 4-pyridylcarboxamido,
2-(5-nitrofuryl)-carboxamido, 2-pyridylcarboxamido,
6-chloro-2-pyridyl-carboxamido, 2-thienylsulfonamido,
2-thienylmethylamino, 3-thienylmethylamino, 2-furylmethylamino,
3-furylmethylamino, 3-acetylureido and
2-(2-thienyl)ethylureido.
[0143] Examples of particular values for R.sup.21 are hydrogen and
chlorine. R.sup.21 is preferably ortho to R.sup.20.
[0144] Examples of particular values for R.sup.1 are 2-naphthyl,
4-bromophenyl, 4-cyanophenyl, 4-benzamidophenyl, 4-methylphenyl,
4-isopropyl-phenyl, 4-isobutylphenyl, 4-t-butylphenyl,
4-methoxyphenyl, 4-isopropoxyphenyl, 4-cyclopentylphenyl,
4-cyclohexylphenyl, 4-(2-hydroxymethylphenyl)phenyl,
4-(4-hydroxymethylphenyl)-phenyl, 4-(2-furyl)phenyl,
4-(3-furyl)phenyl, 4-(2-thienyl)-phenyl, 4-(3-thienyl)phenyl,
4-(pyrrolidin-1-yl)phenyl, 4-(piperidin-1-yl)phenyl,
3-chloro-4-piperidin-1-ylphenyl, 4-benzyloxyphenyl,
4-(2-fluorophenyl)phenyl, 4-(3-fluoro-phenyl)phenyl,
4-(2-formylphenyl)phenyl, 4-(3-formylphenyl)-phenyl,
4-(4-formylphenyl)phenyl, 4-(4-methylphenyl)phenyl and
4-(2-methoxyphenyl)phenyl.
[0145] The compounds of formula I can be prepared as described in
Schemes 1-V below. The reagents and starting materials are readily
available to one of ordinary skill in the art. All the
substituents, unless otherwise specified are previously defined.
7
[0146] In Scheme I, the compounds of formula Ia are prepared from
compounds of formula II and formula IIIa under standard amide
forming conditions well known to one of ordinary skill in the art.
For examples of standard amide forming conditions see J. March,
"Advanced Organic Chemistry: Reactions, Mechanisms, and Structure,"
2.sup.nd Edition, McGraw Hill Inc., (1977) pages 382-386, and T. W
Green, "Protective Groups in Organic Synthesis," John Wiley &
Sons, Inc. (1981) pages 249-266.
[0147] More specifically, for example, an amine of formula II is
dissolved in a suitable organic solvent, such as tetrahydrofuran or
methylene chloride and treated with an equivalent of a compound of
formula IIIa wherein "Lg" represents a suitable leaving group.
Examples of suitable leaving groups are Cl, Br, I,
(1-6C)alkyl(C.dbd.O)O--, and the like. The reaction can be
performed at a temperature of from about -5.degree. C. to about
50.degree. C., preferably at a temperature of about 0.degree. C. to
about 25.degree. C. After about 2 hours to about 12 hours, the
product, formula Ia, is isolated and purified by techniques well
known in the art, such as extraction techniques and chromatography.
For example, the reaction is diluted with a suitable organic
solvent, such as methylene chloride, rinsed with saturated sodium
bicarbonate, brine, dried over anhydrous magnesium sulfate,
filtered and concentrated under vacuum. The crude product can then
be purified by flash chromatography on silica gel with a suitable
eluent, such ethyl acetate/hexanes to provide the purified compound
of formula Ia. 8
[0148] In Scheme II, the compounds of formula Ib are prepared from
compounds of formula II and formula IIIb under standard carbamate
forming conditions well known to one of ordinary skill in the art.
For examples of standard carbamate forming conditions see J. March,
"Advanced Organic Chemistry: Reactions, Mechanisms, and Structure,"
2.sup.nd Edition, McGraw Hill Inc., (1977) pages 382-383, and T. W
Green, "Protective Groups in Organic Synthesis," John Wiley &
Sons, Inc. (1981) pages 223-248.
[0149] More specifically, for example, an amine of formula II is
dissolved in a suitable organic solvent, such as tetrahydrofuran or
methylene chloride and treated with an equivalent of a compound of
formula IIIb wherein "Lg" represents a suitable leaving group.
Examples of suitable leaving groups are Cl, Br, I, and the like.
The reaction can be performed at a temperature of from about
-10.degree. C. to about 50.degree. C., preferably at a temperature
of about 0.degree. C. to about 25.degree. C. After about 2 hours to
about 12 hours, the product, formula Ib, is isolated and purified
by techniques well known in the art, such as extraction techniques
and chromatography. For example, the reaction is diluted with a
suitable organic solvent, such as methylene chloride, rinsed with
saturated sodium bicarbonate, brine, dried over anhydrous magnesium
sulfate, filtered and concentrated under vacuum. The crude product
can then be purified by flash chromatography on silica gel with a
suitable eluent, such ethyl acetate/hexanes to provide the purified
compound of formula Ib. 9
[0150] In Scheme III, the compounds of formula Ic are prepared from
compounds of formula II and formula IIIc under standard urea
forming conditions well known to one of ordinary skill in the art.
For examples of standard urea forming conditions see J. March,
"Advanced Organic Chemistry: Reactions, Mechanisms, and Structure,"
2.sup.nd Edition, McGraw Hill Inc., (1977) page 823, and T. W
Green, "Protective Groups in Organic Synthesis," John Wiley &
Sons, Inc. (1981) pages 248-49.
[0151] More specifically, for example, a compound of formula II is
dissolved in a suitable organic solvent, such as methylene
chloride, and the solution is treated with about 1.1 equivalents of
an isocyanate of formula IIIc. The reaction can be performed at a
temperature of about -10.degree. C. to about 50.degree. C. for
about 2 hours to about 12 hours to provide the urea of formula Ic.
The urea of formula Ic can be isolated and purified by techniques
well known in the art, such as extraction techniques and
chromatography. For example, the reaction is diluted with a
suitable organic solvent, such as methylene chloride, rinsed with
water, brine, dried over anhydrous sodium sulfate, filtered and
concentrated under vacuum. The crude product can then be purified
by flash chromatography on silica gel with a suitable eluent, such
ethyl acetate/hexanes to provide the purified urea of formula Ic.
10
[0152] Ureas of formula Id can be prepared from a compound of
formula II and the compound of formula IIId under standard
conditions well known in the art. "Lg" represents a suitable
leaving group. Examples of suitable leaving groups are Cl, Br, I,
and the like. Examples of a compound of formula IIId are
N,N-dimethylcarbamoyl chloride, N,N-diethylcarbamoyl chloride,
pyrrolidine carbonyl chloride, 4-morpholine carbonyl chloride, and
the like. The reaction is performed under standard amide forming
conditions in a manner analogous to the procedure described
previously in Scheme I. 11
[0153] In Scheme V, the compound of formula Ie is prepared from the
compound of formula IV and formula V under standard amide forming
conditions in a manner analogous to the conditions described
previously in Scheme I.
[0154] The compounds of formula I in which R.sup.1 represents a
4-bromophenyl group may conveniently be converted into other
compounds of formula I in which R represents another 4-substituted
phenyl group by reaction with an appropriate boronic acid
derivative, for example, a benzeneboronic acid derivative. The
reaction is conveniently performed in the presence of a tetrakis
(triarylphosphine)palladium(0) catalyst, such as tetrakis
(triphenylphosphine)palladium(0) and a base such as potassium
carbonate. Convenient solvents for the reaction include aromatic
hydrocarbons, such as toluene. The temperature at which the
reaction is conducted is conveniently in the range of from 0 to
150.degree. C., preferably 75 to 120.degree. C. Bis aromatic
intermediates useful in the preparation of compounds of formula I
may be prepared by reacting a bromoaromatic or bromoheteroaromatic
compound with an aromatic or heteroaromatic boronic acid in an
analogous manner.
[0155] More specifically, for example, to a degassed solution of a
compound of formula I wherein R.sup.1 represents a 4-bromophenyl
group, approximately 1.5 equivalents of a benzeneboronic acid
derivative, such as 3fluorobenzeneboronic acid, and approximately
1.5 equivalents of potassium carbonate in a suitable organic
solvent, such as toluene, is added a catalytic amount of
bis(triphenyl-phosphine)palladium(II) dichloride. The mixture is
heated to about 100.degree. C. for about 16 hours, cooled to
ambient temperature and diluted with ethyl acetate. The mixture is
washed with water and the organic portion is separated. The aqueous
portion is extracted with ethyl acetate and the combined organics
are dried anhydrous magnesium sulfate, filtered and concentrated
under vacuum. Chromatography on silica gel with a suitable eluent,
such as ethyl acetate/toluene provides the desired bis aromatic
compound of formula I.
[0156] The boronic acid derivative used as a starting material may
be prepared by reacting a trialkyl borate, such as triisopropyl
borate with an appropriate organolithium compound at reduced
temperature. For example, 2-fluorobenzeneboronic acid may be
prepared by reacting 2-fluorobromobenzene with butyllithium in
tetrahydrofuran at about -78.degree. C. to afford 2-fluorophenyl
lithium, and then reacting this organolithium compound with
triisopropyl borate.
[0157] Alternatively, the compounds of formula I in which R.sup.1
represents a 4-bromophenyl group may be converted to a
4-(trimethylstannyl)phenyl or 4-(tri-n-butylstannyl)phenyl group by
treatment of the corresponding bromide with a palladium(0)
catalyst, such as tetrakis(triphenylphosphine)-palladium(0) and
hexaalkyldistannane, where the alkyl group is methyl or n-butyl, in
an aprotic solvent such as toluene in the presence of a tertiary
amine base such as triethylamine, at temperatures ranging from 80
to 140.degree. C., preferably from 90 to 111.degree. C.
[0158] The compounds of formula I in which R.sup.1 represents a
4-(tri-n-butylstannyl)phenyl group may then be reacted with an
aryl- or heteroarylbromide, such as
2-bromothiophene-5-carboxaldehyde, in the presence of a
palladium(0) catalyst, such as tetrakis(triphenylphosphine)-
palladium(0), or a palladium(II) catalyst, such as
bis(triphenylphosphine)- -palladium(II) dichloride, in an aprotic
solvent, such as dioxane, at temperatures ranging from 80 to
140.degree. C., preferably from 90 to 110.degree. C., to afford the
corresponding 4-(aryl)phenyl or 4-(heteroaryl)phenyl substituted
compound.
[0159] The compounds of formula I in which R.sup.1 represents a
4-bromophenyl group may be converted into other compounds of
formula I in which R.sup.1 represents a 4-substituted alkyl- or
cycloalkylphenyl group, such as 4-cyclopentylphenyl by treatment of
the corresponding bromide with an appropriate alkyl- or cycloalkyl
Grignard reagent, such as cyclopentyl-magnesium bromide, in the
presence of a palladium(II) catalyst, such as
[1,1-bis(diphenylphosphino)ferrocene]-dichloropalladium-
(II)(PdCl.sub.2(dppf)), in an aprotic solvent, such as diethyl
ether at temperatures ranging from -78.degree. C. to 25.degree.
C.
[0160] The compounds of formula I in which R.sup.1 represents a
4-bromophenyl group may be converted into a 4-substituted
carboxyaldehydephenyl(formylphenyl) group by reaction of the
corresponding bromide with the carbon monoxide gas which is bubbled
into the reaction under atmospheric pressure in the presence of a
palladium(II) catalyst, such as
bis(triphenyl-phosphine)palladium(II) dichloride and sodium formate
in an aprotic solvent, such as dimethylformamide at temperatures
ranging from 70 to 110.degree. C., preferably at 90.degree. C.
[0161] The compounds of formula I in which R.sup.1 represents a
4-hydroxyphenyl group may be converted into other compounds of
formula I in which R.sup.1 represents an alkoxy group by treatment
of the corresponding hydroxyphenyl group with an appropriate
alkylhalide such as benzylbromide in the presence of sodium hydride
in an aprotic solvent such as dimethylformamide at temperatures
ranging from 25 to 100.degree. C., preferably from 50 to 90.degree.
C.
[0162] The ability of compounds of formula I to potentiate
glutamate receptor-mediated response may be determined using
fluorescent calcium indicator dyes (Molecular Probes, Eugene,
Oreg., Fluo-3) and by measuring glutamate-evoked efflux of calcium
into GluR4 transfected HEK293 cells, as described in more detail
below.
[0163] In one test, 96 well plates containing confluent monolayers
of HEK cells stably expressing human GluR4B (obtained as described
in European Patent Application Publication Number EP-A1-583917) are
prepared. The tissue culture medium in the wells is then discarded,
and the wells are each washed once with 200 .mu.l of buffer
(glucose, 10 mM, sodium chloride, 138 mM, magnesium chloride, 1 mM,
potassium chloride, 5 mM, calcium chloride, 5 mM,
N-[2-hydroxyethyl]-piperazine-N-[2-ethanesulfonic acid], 10 mM, to
pH 7.1 to 7.3). The plates are then incubated for 60 minutes in the
dark with 20 .mu.M Fluo3-AM dye (obtained from Molecular Probes
Inc., Eugene, Oreg.) in buffer in each well. After the incubation,
each well is washed once with 100 .mu.l buffer, 200 .mu.l of buffer
is added and the plates are incubated for 30 minutes.
[0164] Solutions for use in the test are also prepared as follows.
30 .mu.M, 10 .mu.M, 3 .mu.M and 1 .mu.M dilutions of test compound
are prepared using buffer from a 10 mM solution of test compound in
DMSO. 100 .mu.M cyclothiazide solution is prepared by adding 3
.mu.l of 100 mM cyclothiazide to 3 ml of buffer. Control buffer
solution is prepared by adding 1.5 .mu.l DMSO to 498.5 .mu.l of
buffer.
[0165] Each test is then performed as follows. 200 .mu.l of control
buffer in each well is discarded and replaced with 45 .mu.l of
control buffer solution. A baseline fluorescent measurement is
taken using a FLUOROSKAN II fluorimeter (Obtained from Labsystems,
Needham Heights, Mass., USA, a Division of Life Sciences
International Plc). The buffer is then removed and replaced with 45
.mu.l of buffer and 45 .mu.l of test compound in buffer in
appropriate wells. A second fluorescent reading is taken after 5
minutes incubation. 15 .mu.l of 400 .mu.M glutamate solution is
then added to each well (final glutamate concentration 100 .mu.M),
and a third reading is taken. The activities of test compounds and
cyclothiazide solutions are determined by subtracting the second
from the third reading (fluorescence due to addition of glutamate
in the presence or absence of test compound or cyclothiazide) and
are expressed relative to enhance fluorescence produced by 100
.mu.M cyclothiazide.
[0166] In another test, HEK293 cells stably expressing human GluR4
(obtained as described in European Patent Application Publication
No. EP-A1-0583917) are used in the electro-physiological
characterization of AMPA receptor potentiators. The extracellular
recording solution contains (in mM): 140 NaCl, 5 KCl, 10 HEPES, 1
MgCl.sub.2, 2 CaCl.sub.2, 10 glucose, pH 7.4 with NaOH, 295 mOsm
kg-1. The intracellular recording solution contains (in mM): 140
CsCl, 1 MgCl.sub.2, 10 HEPES,
(N-[2-hydroxyethyl]piperazine-N-1-[2-ethanesulfonic acid]) 10 EGTA
(ethylene-bis(oxyethylene-nitrilo)tetraacetic acid), pH=7.2 with
CsOH, 295 mOsm kg-1. With these solutions, recording pipettes have
a resistance of 2-3 M.OMEGA.. Using the whole-ceil voltage clamp
technique (Hamill et al. (1981)Pflugers Arch., 391: 85-100), cells
are voltage-clamped at -60 mV and control current responses to 1 mM
glutamate are evoked. Responses to 1 mM glutamate are then
determined in the presence of test compound. Compounds are deemed
active in this test if, at a test concentration of 10 .mu.M, they
produce a greater than 30% increase in the value of the current
evoked by 1 mM glutamate.
[0167] In order to determine the potency of test compounds, the
concentration of the test compound, both in the bathing solution
and co-applied with glutamate, is increased in half log units until
the maximum effect was seen. Data collected in this manner are fit
to the Hill equation, yielding an EC.sub.50 value, indicative of
the potency of the test compound. Reversibility of test compound
activity is determined by assessing control glutamate 1 mM
responses. Once the control responses to the glutamate challenge
are re-established, the potentiation of these responses by 100
.mu.M cyclothiazide is determined by its inclusion in both the
bathing solution and the glutamate-containing solution. In this
manner, the efficacy of the test compound relative to that of
cyclothiazide can be determined.
[0168] According to another aspect, the present invention provides
a pharmaceutical composition, which comprises a compound of formula
I or a pharmaceutically acceptable salt thereof as defined
hereinabove and a pharmaceutically acceptable diluent or
carrier.
[0169] The pharmaceutical compositions are prepared by known
procedures using well-known and readily available ingredients. In
making the compositions of the present invention, the active
ingredient will usually be mixed with a carrier, or diluted by a
carrier, or enclosed within a carrier, and may be in the form of a
capsule, sachet, paper, or other container. When the carrier serves
as a diluent, it may be a solid, semi-solid, or liquid material
which acts as a vehicle, excipient, or medium for the active
ingredient. The compositions can be in the form of tablets, pills,
powders, lozenges, sachets, cachets, elixirs, suspensions,
emulsions, solutions, syrups, aerosols, ointments containing, for
example, up to 10% by weight of active compound, soft and hard
gelatin capsules, suppositories, sterile injectable solutions, and
sterile packaged powders.
[0170] Some examples of suitable carriers, excipients, and diluents
include lactose, dextrose, sucrose, sorbitol, mannitol, starches,
gum, acacia, calcium phosphate, alginates, tragcanth, gelatin,
calcium silicate, micro-crystalline cellulose,
polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose,
methyl and propyl hydroxybenzoates, talc, magnesium stearate, and
mineral oil. The formulations can additionally include lubricating
agents, wetting agents, emulsifying and suspending agents,
preserving agents, sweetening agents, or flavoring agents.
Compositions of the invention may be formulated so as to provide
quick, sustained, or delayed release of the active ingredient after
administration to the patient by employing procedures well known in
the art.
[0171] The compositions are preferably formulated in a unit dosage
form, each dosage containing from about 1 mg to about 500 mg, more
preferably about 5 mg to about 300 mg (for example 25 mg) of the
active ingredient. The term "unit dosage form" refers to a
physically discrete unit suitable as unitary dosages for human
subjects and other mammals, each unit containing a predetermined
quantity of active material calculated to produce the desired
therapeutic effect, in association with a suitable pharmaceutical
carrier, diluent, or excipient. The following formulation examples
are illustrative only and are not intended to limit the scope of
the invention in any way.
Formulation 1
[0172] Hard gelatin capsules are prepared using the following
ingredients:
1 Quantify (mg/capsule) Active Ingredient 250 Starch, dried 200
Magnesium Stearate 10 Total 460
[0173] The above ingredients are mixed and filled into hard gelatin
capsules in 460 mg quantities.
Formulation 2
[0174] Tablets each containing 60 mg of active ingredient are made
as follows:
2 Quantity (mg/tablet) Active Ingredient 60 Starch 45
Microcrystalline Cellulose 35 Polyvinylpyrrolidone 4 Sodium
Carboxymethyl Starch 4.5 Magnesium Stearate 0.5 Talc 1 Total
150
[0175] The active ingredient, starch, and cellulose are passed
through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution
of polyvinylpyrrolidone is mixed with the resultant powders which
are then passed through a No. 14 mesh U.S. sieve. The granules so
produced are dried at 50.degree. C. and passed through a No. 18
mesh U.S. sieve. The sodium carboxymethyl starch, magnesium
stearate, and talc, previously passed through a No. 60 mesh U.S.
sieve, are then 10 added to the granules which, after mixing, are
compressed on a tablet machine to yield tablets each weighing 150
mg.
[0176] As used herein the term "patient" refers to a mammal, such a
mouse, guinea pig, rat, dog or human. It is understood that the
preferred patient is a human.
[0177] As used herein the term "effective amount" refers to the
amount or dose of the compound which provides the desired effect in
the patient under diagnosis or treatment.
[0178] The particular dose of compound administered according to
this invention will of course be determined by the particular
circumstances surrounding the case, including the compound
administered, the route of administration, the particular condition
being treated, and similar considerations. The compounds can be
administered by a variety of routes including oral, rectal,
transdermal, subcutaneous, intravenous, intramuscular, or
intranasal routes. Alternatively, the compound may be administered
by continuous infusion. A typical daily dose will contain from
about 0.01 mg/kg to about 100 mg/kg of the active compound of this
invention. Preferably, daily doses will be about 0.05 mg/kg to
about 50 mg/kg, more preferably from about 0.1 mg/kg to about 25
mg/kg.
[0179] The following examples represent typical syntheses of
compounds within formula I as described generally above. These
examples are illustrative only and are not intended to limit the
invention in any way. The reagents and starting 10 materials are
readily available to one of ordinary skill in the art. As used
herein, the following terms have the meanings indicated: "eq"
refers to equivalents; "g" refers to grams; "mg" refers to
milligrams; "L" refers to liters; "mL" refers to milliliters;
".mu.L" refers to microliters; "mol" refers to moles; "mmol" refers
to millimoles; "psi" refers to pounds per square inch; "min" refers
to minutes; "h" refers to hours; ".degree. C." refers to degrees
Celsius; "LC" refers to thin layer chromatography; "HPLC" refers to
high performance liquid chromatography; "R.sub.f" refers to
retention factor; "R.sub.t" refers to retention time; ".delta."
refers to part per million down-field from tetramethylsilane; "THF"
refers to tetrahydrofuran; "DMF" refers to N,N-dimethylformamide;
"DMSO" refers to methyl sulfoxide; "LDA" refers to lithium
diisopropylamide; "aq" refers to aqueous; "TFA" refers to
trifluoroacetic acid: "iPrOAc" refers to isopropyl acetate; "EtOAc"
refers to ethyl acetate; "Me" refers to a methyl group: "Et" refers
to an ethyl group: "iPr" refers to an isopropyl group; "Bu" refers
to a butyl group; and "RT" refers to room temperature.
Preparation 1
2-(4-Bromophenyl)propionitrile
[0180] A solution of 50.0 g (225.0 mmol) of
4-bromophenyl-acetonitrile and 1.8 g (12.8 mmol) of potassium
carbonate in 387 mL of dimethyl carbonate was heated to 180.degree.
C. in a sealed vessel for 16 hours. The solution was then cooled,
diluted with 200 mL of ethyl acetate and washed once with 100 mL
water, once with 100 mL of 10% aqueous sodium bisulfate and once
with 100 mL brine. The organic portion was dried (MgSO.sub.4),
filtered and concentrated in vacuo. The residue was distilled under
vacuum through a short path distillation apparatus to afford 40.3 g
(85%) of the title compound.
Preparation 2
2-(4-Bromophenyl)propylamine Hydrochloride
[0181] To a solution of 35.2 g (167.6 mmol) of material from
Preparation 1 under reflux in 35.0 mL of tetrahydrofuran was added
18.4 mL (184.3 mmol) of 1 M borane-dimethyl-sulfide slowly via a
syringe. The solution was heated under reflux for an additional 1
hour after the addition was complete. The solution was cooled to
ambient temperature and a saturated solution of hydrogen chloride
in methanol was added slowly until pH 2 was achieved. The resulting
slurry was concentrated in vacuo. The residue was dissolved in
methanol and concentrated in vacuo twice. The resulting solid was
suspended in ethyl ether, filtered, rinsed with ethyl ether and
dried in vacuo to afford 31.2 g (74%) of the title compound.
Preparation 3
2-Fluorobenzeneboronic Acid
[0182] A solution of 50 g (285.6 mmol) of 2-fluorobromobenzene in
400 mL of tetrahydrofuran was cooled to -78.degree. C. and 200 mL
(320.0 mmol) of 1.6M n-Butylithium was added via a cannula. The
mixture was stirred at -78.degree. C. for 60 minutes, then 98.9 mL
(428.4 mmol) of triisopropyl borate was added via a cannula and
stirring was continued for 60 minutes. The cooling bath was removed
and the mixture was stirred at ambient temperature for 1.5 hours,
then 150 mL of 6N hydrochloric acid was added and stirring was
continued for 1.5 hours. To the mixture was added 100 mL of brine,
and then the organic layer was separated and the aqueous layer was
extracted three times with 30 mL each of ether. The combined
organic extracts were dried (MgSO.sub.4), filtered and concentrated
in vacuo. The residue was recrystallized from water to afford 25.2
g (63%) of the title compound.
Preparation 4
2-(4-bromophenyl)-N-(t-butoxycarbonyl)propylamine
[0183] To a solution of 11.8 g (55.0 mmol) of material from
Preparation 2 in 100 mL of chloroform and 100 mL of saturated
sodium bicarbonate was added 12.0 g (55.0 mmol) of di-tert-butyl
dicarbonate. The solution was stirred at ambient temperature for 1
hour. The organic layer was separated and the aqueous layer was
extracted three times with 30 mL each of chloroform. The combined
organic extracts were dried (MgSO.sub.4), filtered and concentrated
in vacuo to afford 16.5 g (95%) of the title compound.
Preparation 5
2-(4-(2-fluorophenyl)phenyl)-N-(t-butoxycarbonyl)propylamine
[0184] To a degassed solution of 12.5 g (39.8 mmol) of material
from Preparation 4, 6.7 g (47.7 mmol) of material from Preparation
3 and 8.2 g (59.7 mmol) of potassium carbonate in 140 mL of toluene
was added 2.3 g (1.9 mmol) of tetrakis
(triphenylphosphine)palladium(0). The mixture was heated at
90.degree. C. for 18 hours.
[0185] The mixture was then cooled to ambient temperature and 300
mL of water and 150 mL of ether were added. The organic layer was
separated and the aqueous layer was extracted three times with 50
mL each of ethyl acetate. The combined organic extracts were dried
(MgSO.sub.4), filtered and concentrated in vacuo. Chromatography
(500 g of silica gel, 10% ethyl acetate/hexanes) of the residue
afforded 9.3 g (71%) of the title compound.
Preparation 6
2-(4-(2-fluorophenyl)phenyl)propylamine
[0186] A solution of 9.3 g of material from Preparation 5 in 100 mL
20% trifluoroacetic acid/dichloromethane was stirred at ambient
temperature for 2 hours. The mixture was concentrated in vacuo to
afford 11.7 g of material. The material was dissolved in 100 mL of
ether and washed twice with 50 mL of 1N sodium hydroxide The
organic layer was concentrated in vacuo to afford 5.48 g (85%) of
the title compound.
Preparation 7
2-(4-Isopropylphenyl)propionitrile
[0187] In a 250 mL flask, 4-isopropylphenylacetonitrile 8.00 g
(50.2 mmol) was dissolved in tetrahydrofuran (150 mL) under a
nitrogen atmosphere. The solution was cooled to -78.degree. C. and
lithium bis(trimethylsilyl)amide (1M in tetrahydrofuran, 52.8 mL
(52.8 mmol) added. The resulting mixture was stirred at -78.degree.
C. for 1 hour. To this reaction mixture was added iodomethane 3.29
mL (52.8 mmol). The resulting mixture was slowly allowed to warm to
ambient temperature over 16 hours then quenched with 0.2M
hydrochloric acid and extracted twice with diethyl ether. The
organic fractions were combined, dried (MgSO.sub.4) and
concentrated under vacuo. Chromatography (SiO.sub.2, 20% ethyl
acetate/hexanes) gave 6.32 g (73%) of the title compound.
[0188] Field Desorption Mass Spectrum: M=173.
[0189] Analysis for C.sub.12H.sub.15N: Theory: C, 83.19; H, 8.73;
N, 8.08. Found: C, 82.93; H, 8.57, N, 8.02.
Preparation 8
2-(4-Isopropylphenyl)propylamine hydrochloride
[0190] In a 100 mL flask, fitted with a condenser,
2-(4-isopropylphenyl) propionitrile 1.90 g (11.0 mmol) was
dissolved in tetrahydrofuran (70 mL) under a nitrogen atmosphere.
Borane-methyl sulfide complex (10.0-10.2 M in tetrahydrofuran, 1.20
mL, 12.1 mmol) was added to the solution and the mixture heated to
reflux for 3 hours. The solution was cooled to ambient temperature
and a saturated solution of hydrochloric acid in methanol added
slowly until a white precipitate formed. The solvent was removed in
vacuo and the resulting white solid triturated (.times.4) with
diethyl ether. Drying under vacuo gave 1.76 g (73%) of the title
compound.
Preparation 9
2-(4-Methoxyphenyl)propionitrile
[0191] Following the method of Preparation 7, but using
4-methoxyphenylacetonitrile 5.00 g (34.0 mmol), 6.32 g of the title
compound was obtained.
[0192] Field Desorption Mass Spectrum: M 161.
[0193] Analysis for C.sub.10H.sub.11NO: Theory: C, 74.51; H, 6.88;
N, 8.69. Found: C, 74.34; H, 6.67; N, 8.93.
Preparation 10
2-(4-Methoxyphenyl)propylamine Hydrochloride
[0194] Following the method of Preparation 8, but using the product
of Preparation 9, 2.75 g (17.1 mmol), 2.77 g (81%) of the title
compound was 15 obtained.
[0195] Analysis for C.sub.10H.sub.16ClNO: Theory: C, 59.55; H,
8.00; N, 6.94. Found: C, 59.33; H, 7.89; N, 6.71.
Preparation 11
Methyl 2-(4-t-butylphenyl)propanoate
[0196] 23.3 mL of lithium bis (trimethylsilyl) amide (1.0 M, 23
mmols) was added dropwise to 4.75 g (23 mmol) of methyl
4-tert-butylphenylacetate in 100 mL of dry THF at -78.degree. C.
while stirring under nitrogen. The mixture was stirred at this
temperature for 45 minutes, then 1.5 mL (24 mmol) methyl iodide was
added dropwise and the solution was stirred for an additional 1
hour at -78.degree. C. The mixture was poured into 200 mL of
H.sub.2O and the desired product was extracted with 500 mL diethyl
ether. The organic layer was backwashed once with 500 mL H.sub.2O,
dried over K.sub.2CO.sub.3, and concentrated under reduced pressure
to yield 5.12 g of a dark oil. The oil was purified via silica gel
chromatography eluting with a solvent gradient of hexanes to
hexanes/ethyl acetate 19:1. The fractions containing the desired
product were combined and concentrated under reduced pressure to
yield the title compound 2.65 g (53%).
[0197] Mass Spectrum: M=220.
Preparation 12
Methyl 2-(4-t-butylphenyl)butanoate
[0198] 4 g (19 mmol) of methyl 4-tert-butylphenylacetate, 19.5 mL
(1.0 M, 19 mmol) of lithium bis (trimethylsilyl) amide and 3.12 g
(20 mmol) of ethyl iodide were reacted as described in Preparation
11 to yield 5.13 g of a brown oil. Chromatography, eluting with a
gradient solvent of hexanes to hexanes/ethyl acetate 19:1 gave the
title compound 2.35 g (53%).
[0199] Mass Spectrum: M=234.
Preparation 13
Methyl 2-(4-t-butylphenyl)-2-methylpropanoate
[0200] 4.75 g (23 mmol) of methyl 4-tert-butylphenylacetate, 46.6
mL (1.0 M, 46 mmol) of lithium bis (trimethylsilyl) amide, and 6.80
g (48 mmols) of methyl iodide were reacted as described in
Preparation 11 to yield 4.73 g of a crude oil. Chromatography,
eluting with a solvent gradient of hexanes to hexanes/ethyl acetate
19:1, gave the title compound 2.0 g (37%).
[0201] Mass Spectrum: M=234.
Preparation 14
Ethyl 2-(2-naphthyl)propanoate
[0202] 5 g (23 mmol) of ethyl 2-naphthylacetate, 23.3 mL (1.0 M, 23
mmol) of lithium bis (trimethylsilyl) amide, and 1.5 mL (24 mmol)
of methyl iodide were reacted as described in Preparation 11 to
yield 5.71 g of a dark oil. Chromatography eluting with a solvent
gradient of hexanes to hexanes/ethyl acetate 19:1 gave the title
compound 2.85 g (54%).
[0203] Mass Spectrum: M=228.
Preparation 15
2-(4-t-butylphenyl)propanoic Acid
[0204] 2.60 g (12 mmol) of the product of Preparation 11 and 1.75 g
(42 mMol) of lithium hydroxide were placed into a tri-solvent
solution of tetrahydrofuran (189 mL), CH.sub.3OH (63 mL), and
H.sub.2O (63 mL) and stirred at ambient temperature for 16 hours.
The mixture was then concentrated under reduced pressure and the
resulting white solid was taken into 200 mL 1N HCl and the desired
product was extracted with 250 mL ethyl acetate. The organic layer
was concentrated under reduced pressure to give the title compound
1.21 g (49%).
[0205] Mass Spectrum: M=206.
Preparation 16
2-(4-t-butylphenyl)butanoic Acid
[0206] The title compound (2.14 g) was prepared by the method of
Preparation 15, starting from the product of Preparation 12, and
recrystallized from hexanes.
[0207] Mass Spectrum: M=220.
Preparation 17
2-(4-t-butylphenyl)-2-methylpropanoic Acid
[0208] The title compound (1.75 g) was prepared by the method of
Preparation 15 starting from the product of Preparation 13, and
recrystallized from hexanes.
[0209] Mass Spectrum: M=220.
Preparation 18
2-(2-Naphthyl)propanoic Acid
[0210] The title compound (3.81 g) was prepared by the method of
Preparation 15 starting from the product of Preparation 14, and
recrystallized from hexanes/ethyl acetate 9:1.
[0211] Mass Spectrum: M=214.
Preparation 19
2-(4-t-butylphenyl)propionamide
[0212] 900 mg (4.4 mmol) of the product of Preparation 15 was added
portionwise to oxalyl chloride (10 mL) at ambient temperature under
N.sub.2 followed by CH.sub.2Cl.sub.2 (10 mL). Initiation of the
reaction was accomplished by the addition of one drop of DMF. An
evolution of gas appeared and the reaction was stirred at ambient
temperature for 2 hours. The solution was concentrated under
reduced pressure to yield an oil. Dioxane (10 mL) was added for
solubility and while stirring at ambient temperature, 28% ammonium
hydroxide (10 mL) was added and the reaction was stirred for 16
hours. The solution was then concentrated under reduced pressure to
yield a white solid. This solid was taken into 50 mL ethyl acetate,
backwashed once with 50 mL H.sub.2O, dried over K.sub.2CO.sub.3,
and concentrated under reduced pressure to yield 770 mg of a solid.
Recrystallization from hexanes/ethyl acetate 1:1 gave the title
compound 555 mg (61%).
[0213] Mass Spectrum: M=205.
Preparation 20
2-(4-t-butylphenyl)butanamide
[0214] The title compound was prepared by the method of Preparation
19, starting from the product of Preparation 16. Purification was
achieved by silica gel chromatography (Chromatotron-2000 micron
rotor) eluting with a solvent of hexanes/ethyl acetate 1:1 to yield
471 mg (60%).
[0215] Mass Spectrum: M=219.
Preparation 21
2-(4-t-butylphenyl)-2-methylpropionamide
[0216] The title compound was prepared following the method of
Preparation 19, starting from the product of Preparation 17. The
crude product was triturated with a solution of hexanes/-ethyl
acetate 19:1 for 112 hour and filtered to yield 1.16 g of a white
solid. Subsequent recrystallization from ethyl acetate/ethanol 1:1
gave an 80% recovery as platelets.
[0217] Mass Spectrum: M 219.
Preparation 22
2-(2-Naphthyl)propionamide
[0218] The title compound was prepared following the method of
Preparation 19, starting from the product of Preparation 18.
Recrystallization from hexanes/ethyl acetate 1:1 yielded 1.65 g
(90%).
[0219] Mass Spectrum: M 199.
Preparation 23
2-(4-t-butylphenyl)propylamine
[0220] 25 mL of Borane-tetrahydrofuran complex (1.0 M, 0.025 Mol)
was added via a syringe to 1.10 g (5.4 mmol) of the product of
Preparation 19 (60 mL) at ambient temperature under N.sub.2. The
mixture was then heated at 60.degree.-65.degree. C. for 16 hours. A
saturated HCl/methanol solution (5 mL) was then added via a syringe
at ambient temperature with severe foaming and the solution was
then concentrated under reduced pressure. The resulting white solid
was taken into 100 mL 1 N NaOH and the liberated free amine was
extracted once with 200 ml diethyl ether. The organic layer was
backwashed once with 200 mL H.sub.2O, dried over K.sub.2CO.sub.3,
and concentrated under reduced pressure to yield 1.21 g of a brown
oil. Chromatography (Chromatotron-2000 micron rotor) eluting with a
gradient solvent of ethyl acetate/MeOH 9:1 to MeOH gave 856 mg
(83%).
[0221] Mass Spectrum: M=191.
Preparation 24
2-(4-t-butylphenyl)butylamine
[0222] The title compound 540 mg was prepared as an oil by the
method of Preparation 23, starting from the product of Preparation
20.
[0223] Mass Spectrum: M=205.
Preparation 25
2-(4-t-butylphenyl)-2-methylpropylamine
[0224] The title compound 428 mg (42%) was prepared following the
method of Preparation 23, starting from the product of Preparation
21, and using methanol as the chromatography solvent.
[0225] Mass Spectrum: M=205.
Preparation 26
2-(2-Naphthyl)propylamine
[0226] The title compound, 450 mg (44%) was prepared as an oil
following the method of Preparation 23, starting from the product
of Preparation 22, and using methanol as the chromatography
solvent.
[0227] Mass Spectrum: M=185.
Preparation 27
Methyl 1-(4-t-butylphenyl)cyclopropanecarboxylate
[0228] 4 g (19.4 mmol) of Methyl 4-tert-butylphenylacetate, 39 mL
(1.0 m, 2 Eq.) of lithium bis (trimethylsilyl) amide, and 3 g (2
Eq.) of 1-bromo-2-chloroethane in 100 mL dry THF were reacted as
described in Preparation 11, except that the reaction mixture was
stirred for one hour at ambient temperature before work-up. This
reaction yielded 4.21 g of a brown oil. This material was purified
via silica gel chromatography eluting with a gradient solvent of
hexanes to hexanes/EtOAc 19:1 to yield the title compound 1.57 g
(35%) as a pale yellow solid m.p. 58.degree.-60.degree. C.
Calculated for C.sub.15H.sub.20O.sub.2: Theory: C, 77.37; H, 8.81
Found: C, 77.54; H, 8.68.
Preparation 28
1-(4-t-butylphenyl)cyclopropanecarboxylic Acid
[0229] 1 g (4.3 mmol) of the product of Preparation 27 and 650 mg
(15.5 mmol) of lithium hydroxide were placed in a tri-solvent
solution of THF (66 mL), methanol (22 mL), and H.sub.2O (22 mL) and
reacted as described in Preparation 15 to yield 840 mg of a solid.
This material was purified via silica gel chromatography eluting
with hexanes/EtOAc 1:1 as a solvent to yield the title compound,
600 mg, (64%) as a white solid. m.p. dec>150.degree. C.
Calculated for C.sub.14H.sub.18O.sub.2: Theory: C, 77.03; H, 8.31
Found: C, 77.08; H, 8.02.
Preparation 29
1-(4-t-butylphenyl)cyclopropanecarboxamide
[0230] 580 mg. (2.7 mmol) of the product of Preparation 27, oxalyl
chloride (10 mL), methylene chloride (10 mL) and one drop DMF were
reacted as described in 10 Preparation 19 to yield 573 mg of the
crude acid chloride. Amide conversion was accomplished with 28%
ammonium hydroxide (10 mL) and dioxane (10 mL) as described in
Preparation 27 to yield 590 mg of a solid. Trituration in
hexanes/EtOAc. 19:1 and subsequent filtration yielded 510 mg (87%)
of the title compound as a white solid. m.p. 178-180.degree. C.
Calculated for C.sub.14H.sub.19NO: Theory: C, 77.38; H, 8.81; N,
6.45 Found: C, 77.53; H, 8.77; N, 6.39.
Preparation 30
1-(4-t-butylphenyl)cyclopropylmethylamine
[0231] 7 mL of Borane-tetrahydrofuran complex (1.0 M, 7 mmol) and
500 mg (2.3 mmol) of the product of Preparation 29 in THF (50 mL)
were reacted as described in Preparation 23 to yield 510 mg of an
oil. Purification was achieved via silica gel chromatography
eluting with a gradient solvent of EtOAc/methanol 9:1 to methanol
to yield 222 mg (47%) as a solid, m.p. 39.degree.-41.degree. C.
Calculated for C.sub.14H.sub.21N: Theory C, 82.70; H, 10.41; N,
6.89 Found: C, 81.36; H, 10.13; N, 7.24.
Preparation 31
2-(4-Bromophenyl)propylamine Hydrochloride
[0232] To a -15.degree. C. solution of 50.0 g (251.2 mmol) of
4-bromo-acetophenone and 49.0 g (251.2 mmol) of tosylmethyl
iso-cyanide in 800 mL of dry 30 dimethoxyethane was added a hot
solution of 50.7 g (452.2 mmol) of potassium tert-butoxide in 230
mL of tert-butyl alcohol dropwise at a rate to maintain the
temperature below 0.degree. C. The reaction was stirred at
-5.degree. C. for 45 min after addition was complete. The cooling
bath was removed and the reaction stirred for 2.5 h more. The
mixture was concentrated in vacuo to a volume of 200 mL and diluted
with 500 mL of water. The aqueous mixture was extracted four times
with diethyl ether, and the combined organic portions were dried
(MgSO.sub.4), filtered and concentrated in vacuo. The residue was
dissolved in 55 mL of tetrahydrofuran and heated to reflux. To the
refluxing solution was added slowly dropwise 27.6 mL (276.3 mmol)
of 10.0 M borane-dimethylsulfide complex. Refluxing was continued
for 20 min after addition was complete. The mixture was cooled to
ambient temperature and methanol saturated with hydrogen chloride
was added very slowly until pH 2 was achieved. The mixture was
concentrated in vacuo and the residue was dissolved in methanol and
concentrated in vacuo again. The solid residue was suspended in 125
mL of ethanol, filtered, rinsed with ethanol then diethyl ether.
The white solid was dried in vacuo to afford 25.4 g (40%) of the
title compound. The filtrate was concentrated in vacuo and
suspended in diethyl ether. The solid was filtered, rinsed with
diethyl ether and dried in vacuo to afford another 15.6 g (25%) of
the title compound.
Preparation 32
2-(4-Methylphenyl)propionitrile
[0233] The title compound was prepared from
4-methylphenyl-acetonitrile as described in Preparation 7.
[0234] Analysis for C.sub.10H.sub.11N:
[0235] Theory: C, 82.72; H, 7.64; N, 9.65.
[0236] Found: C, 82.75; H, 7.42; N, 9.94.
Preparation 33
2-(4-Methylphenyl)propylamine Hydrochloride
[0237] The title compound was prepared from the product of
Preparation 32 as described in Preparation 8.
[0238] Field Desorption Mass Spectrum: M=150 (M--HCl)
Preparation 34
2-(4-Benzyloxyphenyl)propionitrile
[0239] 4-Hydroxyphenylacetonitrile (15.3 g, 114.9 mmol) was
dissolved in dimethylformamide (120 mL) and to this was added
potassium carbonate (23.78 g, 172.4 mmol), benzyl bromide (20.64 g,
120.6 mmol) and potassium iodide (3.81 g, 30.0 mmol). The solution
was stirred at ambient temperature for 6 hours after which water
was added. 4-Benzyloxyphenyl-acetonitrile precipitated out of
solution. The suspension was filtered and the precipitate washed
with water (3.times.). Yield 24.8 g (97%) as yellow crystals. The
title product was prepared from 4-benzyloxyphenyl-acetonitrile as
described in Preparation 7. Yield 76%.
[0240] Field Desorption Mass Spectrum: M=237.2.
[0241] Analysis for C.sub.16H.sub.15NO:
[0242] Theory: C, 80.98; H, 6.37; N, 5.90.
[0243] Found: C, 80.93; H, 6.46; N, 6.11.
Preparation 35
2-(4-Benzyloxyphenyl)propylamine Hydrochloride
[0244] The title compound was prepared from the product of
Preparation 34 as described in Preparation 2.
[0245] Analysis for C.sub.16H.sub.20ClNO:
[0246] Theory: C, 59.55; H, 8.00; N, 6.94.
[0247] Found: C, 59.33; H, 7.89; N, 6.71.
Preparation 37
2-(4-bromophenyl)-1-nitro-1-methylethylene
[0248] A solution of 30.0 g (162 mmol) of 4-bromobenzaldehyde, 116
mL (1.6 mole) of nitroethane, and 37.5 g (486 mmol) of ammonium
acetate in 200 mL of toluene was heated under a Dean and Stark trap
for 18 hours. The mixture was then cooled to 80.degree. C., 1 mL of
concentrated sulfuric acid was added, and the 30 mixture was
stirred at 80.degree. C. for 2 hours. The mixture was then cooled
to ambient temperature and washed with 200 mL of brine. The organic
layer was separated and the aqueous layer was extracted three times
with 60 mL of diethyl ether. The combined organics were dried
(MgSO.sub.4), filtered and concentrated in vacuo. The residue was
recrystallized from methanol to afford 18.7 g (47%) of the title
compound.
Preparation 38
2-(4-bromophenyl)-1-nitro-1-methylethane
[0249] A suspension of 1.3 g (33.9 mmol) of lithium aluminum
hydride in 55 mL of tetrahydrofuran (THF) was cooled to 0.degree.
C. A solution of 4.1 g (16.9 mmol) of material from Preparation 37
in 5 mL of THF was added dropwise. 1.3 mL of 10 water, 1.3 mL of 1
M sodium hydroxide and 4.0 mL of water were added in sequence. The
mixture was filtered through Celite and rinsed with
dichloromethane. The organics were concentrated in vacuo to afford
3.0 g of the title compound (83%).
Preparation 41
2-(4-bromophenyl)-N-(t-butoxycarbonyl)ethylamine
[0250] To a room temperature solution of 10.0 g (50.0 mmol) of
4-bromophenethylamine and 11.0 g (50.0 mmol) of di-tert-butyl
dicarbonate in 100 mL of chloroform was added 100 mL of saturated
aqueous sodium bicarbonate. The mixture was stirred at room
temperature for 1.5 hours and diluted with 100 mL of water. The
organic layer was separated and the aqueous layer was extracted two
times with 100 mL each of chloroform. The combined organics were
washed once with 100 mL of 10% aqueous sodium bisulfate, dried
(NaSO.sub.4), filtered and concentrated in vacuo to afford 14.6 g
(97%).
[0251] Mass Spectrum: M+1=301.
Preparation 42
4-cyanophenylboronic Acid
[0252] A solution of 10.0 g (54.9 mmol) of 4-bromobenzonitrile in
100 mL of 30 tetrahydrofuran was cooled to -85.degree. C. whereupon
36.0 mL (57.6 mmol) of 1.6 M solution of n-butyllithium in hexanes
was added. The mixture was stirred for five minutes and 19.0 mL
(82.4 mmol) of triisopropylborate was added. The mixture was
stirred at -85.degree. C. for 30 minutes then warmed to ambient
temperature over one hour. To the mixture was added 35 mL of 5 N
hydrochloric acid and stirring was continued for 2.5 hours. The
mixture was diluted with 100 mL of saturated aqueous sodium
chloride and extracted three times with 100 mL each of ethyl ether.
The combined organics were dried (MgSO.sub.4), filtered and
concentrated in vacuo. The residue was recrystallized from water
and filtered to afford 2.0 g (25%) of the title compound.
Preparation 45
Dibromoformaldoxime
[0253] A solution of 150 g (1.6 mole) of glyoxylic acid and 142 g
(2.0 mole) of hydroxylamine hydrochloride in 1200 mL of water was
stirred for 2 days. To the mixture was added slowly 342 g (4.1
mole) of sodium bicarbonate and 1000 mL of dichloromethane. The
mixture was cooled to 0.degree. C. and a solution of 147 mL (2.8
mole) bromine in 700 mL of dichloromethane was added dropwise. The
mixture was stirred at ambient temperature for 18 hr. The organic
layer was separated and the aqueous layer was extracted three times
with 300 mL each of dichloromethane. The combined organic extracts
were dried (MgSO.sub.4), filtered and concentrated in vacuo to
afforded 93.1 g (28%) of the title compound.
Preparation 46
2-trimethylstannylthiazole
[0254] A. To a -78.degree. C. solution of 5.0 g (58.7 mmol) of
thiazole in 120 mL of tetrahydrofuran was added of 36.7 mL (58.7
mmol) of a 1.6 M solution of n-butyllithium in hexanes. The mixture
was stirred for 20 minutes whereupon 11.7 g (58.7 mmol) in 15 mL of
tetrahydrofuran was added dropwise over 15 minutes. The cooling
bath was removed and the mixture was stirred for two hours. The
mixture was diluted with 100 mL of water and extracted three times
with 100 mL ethyl ether. The combined organics were dried
(MgSO.sub.4), filtered and concentrated in vacuo. The residue was
dissolved in 50 mL of ethyl ether, filtered through silica gel and
concentrated in vacuo to afford 3.6 g (24%) of the title
compound.
Preparation 49
4-(4-Bromophenyl)-1,1-dioxotetrahydro-1,2-thiazine
[0255] A. Ethyl 4-bromophenylacetate: A solution of 25.0 g (116.3
mmol) of 4-bromophenylacetic acid, 24.1 g (174.4 mmol) of potassium
carbonate and 10.2 mL (127.9 mmol) of iodoethane in 250 mL of
acetonitrile was heated at 70.degree. C. for 16 hours. The mixture
was cooled to ambient temperature, diluted with 200 mL of ethyl
acetate and washed once with 200 mL of saturated aqueous sodium
bicarbonate. The organic layer was separated and the aqueous layer
was extracted three times with 75 mL each of ethyl acetate. The
combined organics 10 were dried (MgSO.sub.4), filtered and
concentrated in vacuo to afford 16.2 g (57%) of the title
compound.
[0256] B. Phenyl 3-carbethoxy-3-(4-bromophenyl)propyl-sulfonate: A
solution of 16.2 g (66.6 mmol) of material from Step A, 4.6 g (33.3
mmol) of potassium carbonate and 4.4 g (16.7 mmol) of 18-crown-6 in
130 mL of toluene was heated 5 to 90.degree. C. and 6.1 g (33.3
mmol) of phenyl vinylsulfonate in 35 mL of toluene was added
dropwise over one hour. The mixture was heated for 16 hours, cooled
to ambient temperature and diluted with 100 mL of ethyl acetate.
The mixture was washed once with 100 mL of half saturated brine.
The organic layer was separated and the aqueous layer was extracted
once with 50 mL of ethyl acetate. The combined organics were dried
(MgSO.sub.4), filtered and concentrated in vacuo. Chromatography
(Waters 2000, 15% ethyl acetate/hexanes) of the residue affords 4.8
g (17%) of the title compound.
[0257] Analysis calculated for C.sub.18H.sub.19O.sub.5SBr: % C,
50.59; % H, 4.48. Found: % C, 50.61; % H, 4.47.
[0258] Mass Spectrum: M+1=428.
[0259] C. Phenyl 3-carboxy-3-(4-bromophenyl)propylsulfonate: To a
solution of 4.8 g (11.3 mmol) of material from Step B in 40 mL of
methanol was added 6.8 mL of 2 N aqueous sodium hydroxide. The
mixture was stirred at ambient temperature for 5 hours and
concentrated in vacuo. The residue was dissolved in 50 mL of water
and extracted three times with 20 mL each of ethyl ether. The
aqueous layer is acidified to pH 2 with 10% aqueous sodium
bisulfate and extracted four times with 20 mL each of ethyl
acetate. The combined ethyl acetate layers were dried (MgSO.sub.4),
filtered and concentrated in vacuo to afford 4.1 g (91%) of the
title compound.
[0260] Analysis calculated for C.sub.16H.sub.15O.sub.5SBr: % C,
48.13; % H, 3.79. Found: % C, 48.17; % H, 3.53.
[0261] Mass Spectrum: M=399.
[0262] D. Phenyl 3-carboxamido-3-(4-bromophenyl)propyl-sulfonate:
To a 0.degree. C. solution of 4.1 g (10.2 mmol) of material from
Step C and 2.0 mL (14.3 mmol) of triethylamine in 23 mL of
tetrahydrofuran was added 1.9 mL (14.3 mmol) of isobutyl
chloroformate. The mixture was stirred at 0.degree. C. for 25
minutes whereupon 11.2 mL (22.4 mmol) of a 2 N solution of ammonia
in methanol was added. The cooling bath was removed and the mixture
stirred for 16 hours. The mixture was diluted with 50 mL of ethyl
acetate and washed once with 50 mL of water. The organic layer was
separated and the aqueous layer was extracted three times with 25
mL each of ethyl acetate. The combined organics were dried
(MgSO.sub.4), filtered and concentrated in vacuo. Chromatography
(250 g silica gel, 35% acetone/hexanes) of the residue affords 1.7
g (44%) of the title compound.
[0263] Mass Spectrum: M=398.
[0264] E. 4-(4-Bromophenyl)-1,1,3-trioxotetrahydro-1,2-thiazine: To
a 0.degree. C. solution of 9.0 mL (9.0 mmol) of a 1.0 M
tetrahydrofuran solution of potassium tert-butoxide in 15 mL of
tetrahydrofuran was added a solution of 1.7 g (4.5 mmol) of
material from Step D in 14 mL of tetrahydrofuran dropwise over 30
minutes. After stirring at 0.degree. C. for two hours, the cooling
bath was removed and stirring continued for 30 minutes. The mixture
was diluted with 25 mL of water and extracted two times with 10 mL
each of ethyl ether. The aqueous portion was acidified to pH 2 with
10% aqueous sodium bisulfate and extracted four times with 20 mL
each of ethyl acetate. The combined ethyl acetate layers were dried
(MgSO.sub.4), filtered and concentrated in vacuo. Chromatography
(75 g silica gel, 0.25% acetic acid/40% acetone/hexanes) of the
residue affords 0.2 g (17%) of the title compound.
[0265] Analysis calculated for C.sub.10H.sub.10NO.sub.3SBr: % C,
39.49; % H, 3.31; % N, 4.61. Found: % C, 39.74; % H, 3.23; % N,
4.42.
[0266] Mass Spectrum: M=304.
[0267] F. To a suspension of 0.13 g (0.4 mmol) of material from
Step E and 0.2 g (4.9 mmol) of sodium borohydride in 3 mL of
dioxane was added 0.4 mL (4.9 mmol) of trifluoroacetic acid slowly
via syringe. After stirring at ambient temperature for 30 minutes
the mixture was heated to reflux for 5 hours. The mixture was
cooled to ambient temperature, diluted with 3 mL of methanol and
stirred for 16 hours. The mixture was removed and stirring
continued for 30 minutes. The mixture was concentrated in vacuo,
dissolved in 10 mL of ethyl acetate and washed two times with 5 mL
each of 1 N hydrochloric acid and once with 5 mL of 20% saturated
aqueous sodium bicarbonate/brine. The organics were dried
(MgSO.sub.4), filtered and concentrated in vacuo to afford 0.1 g
(89%) of the final title compound.
[0268] Analysis calculated for C.sub.10H.sub.12NO.sub.3SBr: % C,
41.39; % H, 4.17; % N, 4.83. Found: % C, 41.10; % H, 4.34; % N,
4.76.
[0269] Mass Spectrum: M-1=289.
Preparation 50
D,L-penicillamine Methyl Ester Hydrochloride
[0270] Through a suspension of 10.0 g (67.0 mmol) of
D,L-penicillamine in 200 mL of methanol was bubbled hydrogen
chloride for 5 minutes. The mixture was 20 refluxed for 16 hours,
cooled to ambient temperature and concentrated in vacuo The residue
was suspended in ethyl ether, filtered and dried to afford 12.6 g
(94%) of the title compound.
[0271] Mass Spectrum: M=163.
Preparation 51
N-(t-butoxycarbonyl)-4-tributylstannylaniline
[0272] A. N-(t-Butoxycarbonyl)-4-bromoaniline: To a solution of 6.0
g (39.4 mmol) of 4-bromoaniline in 30 mL of tetrahydrofuran was
added 69.8 mL (69.8 mmol) of a 1.0 M solution of sodium
bis(trimethylsilyl)amide in tetrahydrofuran. To the mixture was
added 7.6 g (34.9 mmol) of di-t-butyldicarbonate in 10 mL of
tetrahydrofuran. The mixture was stirred at ambient temperature for
one hour and concentrated in vacuo. The residue was dissolved in 50
mL of ethyl acetate and washed once with 50 mL of 10% aqueous
sodium bisulfate. The organic layer was separated and the aqueous
layer was extracted two times with 25 mL each of ethyl acetate. The
combined organics were dried (MgSO.sub.4), filtered and
concentrated in vacuo. Chromatography (250 g of silica gel, 10%
ethyl acetate/hexanes) of the residue afforded 5.0 g (53%) of the
title compound. Analysis calculated for C.sub.11H.sub.14NO.sub.2Br:
% C, 48.55; % H, 5.19; % N, 5.15. Found: % C, 48.81; % H, 5.29; %
N, 4.95.
[0273] Mass Spectrum: M-1=271.
[0274] B. A degassed solution of 4.9 g (18.0 mmol) of material from
Step A, 2.6 mL (18.9 mmol) of triethylamine, 9.6 mL (18.9 mmol) of
bis(tributyltin) and 1.0 g (0.9 mmol) of
tetrakis(triphenylphosphine)pall- adium(0) in 45 mL of toluene was
heated to 100.degree. C. for 5 hours. The mixture was cooled to
ambient temperature and diluted with 40 mL of ethyl acetate. The
mixture was washed once with 50 mL of 10% aqueous sodium bisulfate,
the organics separated and the aqueous layer extracted three times
with 20 mL each of ethyl acetate. The combined organics were dried
(MgSO.sub.4), filtered and concentrated in vacuo. Chromatography
(400 g of silica gel, 5% ethyl acetate/hexanes) of the residue
afforded 1.4 g (16%) of the final title compound.
[0275] Mass Spectrum: M+1=483.
Preparation 53
N-2-(4-(3-thienyl)phenyl)propyl Amine
[0276] A. 2-(3-thienyl)phenyl-N-(t-butoxycarbonyl)propyl amine: To
a solution of 0.7 g (2.2 mmol) of material from Preparation 4, 0.3
g (2.4 mmol) thiophene-3-boronic acid and 0.46 g (3.3 mmol) of
potassium carbonate in 5 mL of dioxane and 1 mL of water was added
0.025 .mu.g (0.11 mmol) of palladium(II)acetate and 0.058 g (0.22
mmol) triphenylphosphine. The mixture was heated at 100.degree. C.
for 18 hr. The mixture was cooled to room temperature and 5 mL of
brine was added. The organic layer was separated and dried
(MgSO.sub.4), filtered and concentrated in vacuo. Chromatography.
(25 g of silica gel, 25% ethyl acetate/hexanes) of the residue
afforded 0.44 g (60%) of the title compound.
[0277] B. A solution of 0.4 g (1.3 mmol) of material from
Preparation 53A in 4 mL of dichloromethane and 1 mL of
trifluoroacetic acid was stirred at ambient temperature for 3 hr.
The mixture was concentrated in vacuo and the residue was dissolved
in 5 mL ethyl acetate and 5 mL saturated sodium bicarbonate. The
organic layer was separated and the aqueous layer extracted three
times with 5 mL of ethyl acetate. The combined organics were dried
(MgSO.sub.4), filtered and concentrated in vacuo to afford 0.21 g
(74%) of the title compound.
Preparation 54A
4-(N,N-dibenzylamino)phenylacetonitrile
[0278] A solution of 4-aminophenylacetonitrile (20 g, 151.3 mmol)
in dry DMF (150 ml) was treated with potassium carbonate (50.1 g,
363.1 mmol), benzyl bromide (54.4 g, 318 mmol), and potassium
iodide (5 g, 0.2 30.3 mmol). The reaction mixture was stirred at
room temperature for 12 h. Water (100 mL) was added to the mixture
and the organic was extracted with ether (3.times.200 mL). The
combined organic fraction was washed with brine (200 mL), dried
over sodium sulfate and concentrated. The crude product was further
purified by flash chromatography (SiO.sub.2, 20% EtOAc:Hexanes) to
give 36.2 g (76%) of the pure product. THE NMR SPECTRUM was
consistent with the proposed title structure. Field Desorption Mass
Spectrum :M.sup.+=312.
Preparation 55
2-(4-(N,N-dibenzylamino)phenyl)propionitrile
[0279] A -78.degree. C. solution of the material from Preparation
54A (22.8 g, 73 mmol) in dry THF (70 mL) was treated with lithium
bis(trimethylsilyl)amide (1M in THF, 76.6 mL, 76.6 mmol). The
resulting mixture was stirred at -78.degree. C. for 1 h. Methyl
iodide (4.8 mL, 76.6 mmol) was added to the mixture. The reaction
mixture was stirred at -78.degree. C. for 1 h and gradually was
allowed to warm to room temperature over 12 h. Hydrochloric acid
(0.2 M, 100 mL) was added to the mixture and the organic layer was
extracted with ether (3.times.200 mL). The combined organic
fraction was washed with water (3.times.200 mL), brine (200 mL),
dried over sodium sulfate and concentrated. The crude product was
further purified by flash chromatography (SiO.sub.2, 20% EtOAc:
Hexanes) to give 22.6 g (95%) of the pure product. The NMR spectrum
was consistent with the proposed title structure.
[0280] Field Desorption Mass Spectrum :M.sup.+326.
Preparation 56
2-(4-(N,N-dibenzylamino)phenyl)propylamine Hydrochloride
[0281] A 0.degree. C. solution of the material from Preparation 55
(23.6 g, 72.3 mmol) in dry THF (100 mL) was treated with borane
methylsulfide (10 M in THF, 8 mL, 80 mmol). The reaction mixture
was stirred while refluxing for 3 h. The solution was cooled down
to room temperature and was treated with a saturated solution of
hydrochloric acid in methanol until a white precipitate formed. The
solvent was removed in vacuo and the resulting white solid was
triturated with ether (4.times.100 mL). The desired hydrochloric
salt was dried under vacuo to give 28.2 g (97%) of the pure product
which was used in next step without any further purification. The
NMR spectrum was consistent with the proposed title structure.
Preparation 61
2-(4-nitrophenyl)propionitrile
[0282] A -15.degree. C. solution of 4-nitroacetophenone (16.5 g,
100 mmol) and tosylmethyl isocyanide (29.3 g, 150 mmol) in
methoxyethyl ether (400 mL) was slowly treated with a room
temperature solution of the potassium t-butoxide (28 g, 250 mmol)
in t-butanol (200 mL). The reaction mixture was stirred at
-15.degree. C. for 1 h and then allowed to warm to room temperature
over night. Water (100 mL) was added to the mixture and organic was
extracted with ether (3.times.200 mL). The combined organic
fraction was washed with water (3.times.200 mL), brine (100 mL),
dried over sodium sulfate, and concentrated in vacuo to give the
crude material which was further purified by flash chromatography
(SiO.sub.2, 30% EtOAc: Hexanes) to give 13.6 g (77%) of the title
compound. The NMR spectrum was consistent with the proposed title
structure. Field Desorption Mass Spectrum :M.sup.+=225.
Preparation 62
2-(4-nitrophenyl)propylamine
[0283] A 0.degree. C. solution of the material from Preparation 61
(11.8 g, 67 mmol) in dry THF (200 mL) was treated with borane
tetrahydrofuran (1 M in THF, 72 mL, 72 mmol). The reaction mixture
was stirred at room temperature for 16 h. A solution of THF: MeOH
(1:1, 10 mL) and sodium hydroxide (5 N, 40 mL) were added to the
reaction mixture stepwise and the mixture was refluxed for 5 h. The
reaction mixture was allowed to cool to room temperature. Organic
was extracted with dichloromethane (3.times.100 mL). The combined
organic fraction was washed with water (3.times.200 mL), brine (100
mL), dried over potassium carbonate, and concentrated in vacuo to
give the crude material which was further purified by flash
chromatography (SiO.sub.2, 5% MeOH: CH.sub.2Cl.sub.2) to give 8.5 g
(71%) of the pure product. The NMR spectrum was consistent with the
proposed title structure. Field Desorption Mass Spectrum
:M.sup.+=181.
Preparation 68
N-t-butyloxycarbonyl-4-piperazinoacetophenone
[0284] A solution of the 4-piperazinoacetophenone (10 g, 49 mmol)
in tetrahydrofuran:water (200 mL, 1:1 mixture) was treated with
potassium carbonate (8.43 g, 58 mmol) and di-t-butyl dicarbonate
(13.1 g, 53.9 mmol). The reaction mixture was stirred at room
temperature for 3 h. Water (300 mL) was added to the mixture and
the organic layer was extracted with ethyl acetate (3.times.100
mL). The combined organic fraction was washed with water
(2.times.200 mL), brine (100 mL), dried over sodium sulfate, and
concentrated in vacuo to 17.41 g of the yellowish solid. The crude
product was further purified by Prep LC 2000 eluting with 30%
EtOAc:Haxanes to give 10.9 g (73%) of the title compound as a white
solid. Field Desorption Mass Spectrum :M.sup.+=305.
Preparation 69
2-(N-t-butyloxycarbonyl-4-piperazinophenyl)propionitrile
[0285] The title compound 1.8 g (16%) was prepared as a solid
following the method of Preparation 61, starting from the product
of Preparation 68 and using tosylmethyl isocyanide. The NMR
spectrum was consistent with the proposed title structure. Field
Desorption Mass Spectrum :M.sup.+=316.
Preparation 70
2-(N-t-butyloxycarbonyl-4-piperazinophenyl)propylamine
[0286] The title compound 1.78 g (100%) was prepared as a solid
following the method of Preparation 62, starting from the product
of Preparation 69 and using borane methylsulfide. The NMR spectrum
was consistent with the proposed title structure. Field Desorption
Mass Spectrum :M.sup.+=319.
Preparation 74
3-Tributyltin-2-cyclopenten-1-one
[0287] A -20.degree. C. solution of hexabutylditin (4.6 g, 7.9
mmol) in dry THF (15 mL) was treated with nBuLi (4.9 mL, 7.9 mmol,
1.6 M solution in hexanes). The reaction mixture was stirred at
-20.degree. C. for 30 minutes and then cooled to -78.degree. C. The
mixture was treated with 3-ethoxy-2-cyclopenten-1-one (1.0 g, 7.9
mmol) and the reaction mixture stirred at -78.degree. C. for 30
minutes. A saturated, aqueous solution of ammonium chloride (2 mL)
followed by water (30 mL) and the organic extracted with hexanes
(2.times.30 mL). The combined organic layers were washed with brine
(20 mL), dried over magnesium sulfate and concentrated in vacuo.
This gave 2.7 g (93%) of the crude product which was used without
further purification. The NMR spectrum was consistent with the
title structure.
Preparation 76
1-(4-bromophenyl)-2,5-dimethylpyrrole
[0288] 4-Bromoaniline (56.0 g., 0.33 Mol.), 2,5-hexanedione (37.6
g., 0.33 Mol), and acetic acid (5 mL) were placed into Toluene (500
mL) and heated under reflux for 8 hours employing a dean stark trap
to remove the water from the reaction. The reaction was cooled to
room temperature and concentrated under reduced vacuum. The
resulting oil was taken into ethyl acetate, washed one time each
with 2N hydrochloric acid, 2N NaOH, and H.sub.2O, dried over
Na.sub.2SO.sub.4, and concentrated under reduced vacuum to yield a
brown solid. The material was purified by silica gel flash
chromatography eluting with hexanes. Concentration of the
appropriate fractions yielded 55.0 gm. of a light yellow solid.
(68%) The NMR spectrum was consistent with the proposed title
structure. Field Desorption Mass Spectrum :M.sup.+249 m.p.
71.degree.-73.degree. C.
Preparation 77
1-(4-acetylphenyl)-2,5-dimethylpyrrole
[0289] A -30.degree. C. solution of the material from Preparation
76 (25.0 g, 0.1 mol) in dry ether (500 mL) was treated with
n-butyllithium (70 mL of 1.6 M, 0.12 mol) and stirred for one hour
at -30.degree. C. N,N Dimethyl acetamide (9.7 g, 0.12 mol) was
added and the reaction continued at this temperature for 4 hours.
The reaction was then allowed to warm to room temperature and
stirred over night at this temperature. In the morning, the mixture
was diluted with ethyl acetate and the combined organic layers were
washed one time each with 2.0 N hydrochloric acid and H.sub.2O,
dried over Na.sub.2SO.sub.4, and concentrated under reduced vacuum
to yield a white solid. The material was triturated in hexanes and
filtered to yield 12.8 gm. of a white solid. m.p.
106.degree.-108.degree. C. (60%) THE NMR SPECTRUM was consistent
with the proposed title structure. Field Desorption Mass Spectrum:
M.sup.+ 214
Preparation 78
1-(4-(1-cyano)ethylphenyl)-2,5-dimethylpyrrole
[0290] The starting ketone from Preparation 77 (44.3 g, 0.21 mol),
tosylmethyl isocyanide (40.6 g, 0.21 mol), potassium-t-butoxide
(39.2 g, 0.35 mol), and t-butyl alcohol (250 mL) were reacted in
ethylene glycol dimethyl ether (500 mL) as described in Preparation
61 to yield a yellow solid. Purification was achieved by silica gel
flash chromatography eluting with hexanes/ethyl acetate 4:1 to
yield 32.3 gm. of yellow crystals. m.p. 79.degree.-80.degree. C.
(68%) Field desorption Mass Spectrum: M.sup.+ 225
Preparation 79
1-(4-(2-(2-cyano)propyl)phenyl)-2,5-dimethylpyrrole
[0291] A -78.degree. C. solution of material from Preparation 78
(7.0 g, 32 mmol) in dry tetrahydrofuran (100 mL) was treated with
lithium (bis)trimethylsilylamide (40 mL of 1.0M, 1.3 eq.). After
stirring 30 minutes at this temperature, methyl iodide (2.6 mL, 1.3
eq.) was added dropwise and the reaction was allowed to warm to
room temperature. The mixture was diluted with ether and the
combined organic layers were washed once with H.sub.2O, dried over
K.sub.2CO.sub.3, and concentrated under reduced vacuum to yield
7.61 gm. of a yellow solid. Material was purified via silica gel
chromatography eluting with a solvent of hexanes/ethyl acetate 9:1
to yield 6.30 gm. of a yellow solid. m.p. 135.degree.-137.degree.
C. (83%). Field desorption
[0292] Mass Spectrum: M.sup.++1 239
Preparation 80
1-(4-(2-(3-amino-2-methyl)propyl)phenyl-2,5-dimethylpyrrole
[0293] The nitrile from Preparation 79 (6.23 g, 26.2 mmol) in
tetrahydrofuran (250 mL) was treated with borane-THF complex (17.1
mL, 1.0 M) as described in Preparation 62 to yield 6.37 gm. of a
foam. This material was purified via silica gel chromatography
eluting with a gradient solvent of dichloromethane to
dichloromethane/methanol 9:1 to yield 4.08 gm. of a white solid.
m.p. 950-97.degree. C. (65%). The NMR spectrum was consistent with
the proposed title structure. Field Desorption Mass Spectrum:
M.sup.+ 243
Preparation 85
4-Bromophenylacetyl Chloride
[0294] A solution of 50.0 g (232 mmol) of 4-bromophenylacetic acid
in 150 mL of thionyl chloride was stirred at room temperature for
18 hr. The mixture was concentrated in vacuo to afford 54 g (100%)
of the title compound.
Preparation 86
(R)-(-)-4-Benzyl-3-(4-bromophenylacetyl)-2-oxazolidinone
[0295] A solution of 20.0 g (117 mmol) of
(R)-(+)-4-benzyl-2-oxazolidinone in 300 mL of tetrahydrofuran was
cooled to -78.degree. C. and 73.0 mL (117 mmol) of 1.6M
n-Butyllithium was added dropwise. The mixture was stirred 30 min
then was slowly added via cannula to a solution of 25 g (107 mmol)
of material from Preparation 85 in 150 mL of tetrahydrofuran at
-78.degree. C. The mixture was stirred for 1 hr and then 300 mL of
10% aqueous sodium bisulfate was added. The organic layer was
separated and the aqueous layer was extracted three times 10 with
100 mL each of ether. The combined organic extracts were dried
(MgSO.sub.4), filtered and concentrated in vacuo. Chromatography
(750 g of silica gel, 25% ethyl acetate/hexanes) of the residue
afforded 27.4 g (68%) of the title compound.
[0296] Analysis calculated for C.sub.1H.sub.16BrNO.sub.3: % C,
57.77; % H, 4.31; % N, 3.74. Found: % C, 57.62; % H, 4.21; % N,
3.74.
[0297] Field Desorption Mass Spectrum: M=374.
[0298] [.alpha.].sub.D.sup.20=-59.83 (c=1.04, CHCl.sub.3).
Preparation 87
(-)-4-R-Benzyl-3-(2R-(4-bromophenyl)propionyl)-2-oxazolidinone
[0299] A solution of 48 g (128 mmol) of material from Preparation
86 in 200 mL of tetrahydrofuran was cooled to -78.degree. C. and
141 mL (141 mmol) of 1M sodium bis(trimethyl-silyl)amide was added
dropwise. The mixture was stirred 60 min then a solution of 20 g
(141 mmol) of iodomethane in 20 mL of tetrahydrofuran was slowly
added. The mixture was stirred for 60 min at -78.degree. C. and
then allowed to warm to room temperature for 60 min. To the
reaction was added 10% aqueous sodium bisulfate and the organic
layer was separated and the aqueous layer was extracted three times
with 100 mL each of ether. The combined organic extracts were dried
(MgSO.sub.4), filtered and concentrated in vacuo. Chromatography
(500 g of silica gel, 25% ethyl acetate/hexanes) of the residue
afforded 28.7 g (58%) of the title compound.
[0300] Analysis calculated for C.sub.19H.sub.18BrNO.sub.3: % C,
58.78; % H, 4.67; % N, 3.61. Found: % C, 58.81; % H, 4.63; % N,
3.54.
[0301] Field Desorption Mass Spectrum: M=388.
[0302] [.alpha.].sub.D.sup.20=-110.4 (c=0.96, CHCl.sub.3).
Preparation 88
(R)-(+)-2-(4-bromophenyl)propanol
[0303] A solution of 28.7 g (74 mmol) of material from Preparation
87 in 250 mL of ether was cooled to 0.degree. C. and 74 mL (148
mmol) of 2M lithiumborohydride in tetrahydrofuran was added
dropwise. The mixture was stirred for 2 hr then 1N sodium hydroxide
was added and the mixture was stirred until both organic and
aqueous layers became clear. The organic layer was separated and
the aqueous layer was extracted three times with 10 mL each of
ethyl acetate. The combined organic extracts were dried
(MgSO.sub.4), filtered and concentrated in vacuo. Chromatography
(800 g of silica gel, 25% ethyl acetate/hexanes) of the residue
afforded 12.3 g (79%) of the title compound.
[0304] Analysis calculated for C.sub.9H.sub.11BrO: % C, 50.26; % H,
5.15. Found: % C, 48.96; % H, 4.91.
[0305] Field Desorption Mass Spectrum: M+1=216.
[0306] [a].sub.D.sup.20=+13.79 (c=1.06, CHCl.sub.3).
Preparation 90
(R)-2-(4-bromophenyl)propyl Azide
[0307] A solution of 15.8 g (54 mmol) of material from Preparation
89 in 180 mL of N,N-dimethylformamide and 7.0 g (108 mmol) sodium
azide was heated at 80.degree. C. for 5 hr. The mixture was cooled
and concentrated in vacuo. The residue was partitioned between 100
mL of water and 100 mL of ether. The organic layer was separated
and the aqueous layer was washed three times with 30 mL each of
ether. The combined organic extracts were dried (MgSO.sub.4),
filtered and concentrated in vacuo to afforded 12.13 g (94%) of the
title compound.
Preparation 91
(R)-(+)-2-(4-bromophenyl)propyl Amine Hydrochloride
[0308] A solution of 12.2 g (50.4 mmol) of material from
Preparation 90 and 14.5 g (55.4 mmol) of triphenylphosphine in 168
mL of tetrahydrofuran and 3.6 mL of water was stirred at room
temperature for 18 hr. The mixture was diluted with 100 mL of ether
and 50 mL of brine. The organic layer was removed and dried
(MgSO.sub.4), filtered and concentrated in vacuo. The residue was
dissolved in 100 mL of ether and to this was added 200 mL of
hydrochloric acid saturated ether. Filtration of the resulting
solid afforded 11.9 g (94%) of the title compound.
[0309] Analysis calculated for C.sub.9H.sub.13BrClN: % C, 43.14; %
H, 5.23; % N, 5.59. Found: % C, 43.44; % H, 5.23; % N, 5.56.
[0310] Mass Spectrum: [M-HCl]=214.
[0311] [.alpha.].sub.D.sup.20=+24.06 (c=1.00, H.sub.2O).
Preparation 92
(R)-2-(4-bromophenyl)-N-(t-butoxycarbonyl)propyl Amine
[0312] To a solution of 5.0 g (20.0 mmol) of material from
Preparation 91 in 30 mL of chloroform and 30 mL of saturated sodium
bicarbonate was added 4.3 g (20.0 mmol) of di-tert-butyl
dicarbonate. The solution was stirred at room temperature for 18
hr. The organic layer was separated and the aqueous layer was
extracted three times with 10 mL each of chloroform. The combined
organic extracts were dried (MgSO.sub.4), filtered and concentrated
in vacuo to afford 6.2 g (100%) of the title compound.
Preparation 93
(S)-(+)-4Benzyl-3-(4-bromophenylacetyl)-2-oxazolidinone
[0313] Following the procedure of Preparation 86 and using
(S)-(-)-4-benzyl-2-oxazolidinone instead of
(R)-(+)-4-benzyl-2-oxazolidin- one afforded 25.3 g (63%) of the
title compound.
[0314] Analysis calculated for C.sub.18H.sub.16BrNO.sub.3: % C,
57.77; % H, 4.31; % N, 3.74. Found: % C, 57.69; % H, 4.18; % N,
3.82.
[0315] Field Desorption Mass Spectrum: M=374.
[0316] [.alpha.].sub.D.sup.20=+59.35 (c=1.04, CHCl.sub.3).
Preparation 94
(+)-4S-Benzyl-3-(2S-(4-bromophenyl)propionyl)-2-oxazolidinone
[0317] Following the procedure of Preparation 87 and using material
from Preparation 93 instead of material from Preparation 86
afforded 28.9 g (51%) of the title compound.
[0318] Analysis calculated for C.sub.19H.sub.18BrNO.sub.3: % C,
58.78; % H, 4.67; % N, 3.61. Found: % C, 59.40; % H, 4.61; % N,
3.64.
[0319] Field Desorption Mass Spectrum. M=388.
[0320] [.alpha.].sub.D.sup.20=+114.8 (c=1.01, CHCl.sub.3).
Preparation 95
(S)-(-)-2-(4-bromophenyl)propanol
[0321] Following the procedure of Preparation 88 and using material
from Preparation 94 instead of material from Preparation 87
afforded 12.3 g (79%) of the title compound.
[0322] Analysis calculated for C.sub.9H.sub.11BrO: % C, 50.26; % H,
5.15. Found: % C, 50.38; % H, 5.08.
[0323] Field Desorption Mass Spectrum: M+1=216.
[0324] [.alpha.].sub.D.sup.20=-13.25 (c=1.06, CHCl.sub.3).
Preparation 97
(S)-2-(4-bromophenyl)propyl Azide
[0325] Following the procedure of Preparation 90 and using material
from Preparation 96 instead of material from Preparation 89
afforded 13.0 g (94%) of the title compound.
Preparation 98
(S)-(-)-2-(4-bromophenyl)propyl Amine Hydrochloride
[0326] Following the procedure of Preparation 91 and using material
from Preparation 97 instead of material from Preparation 90
afforded 11.6 g (86%) of 5 the title compound.
[0327] Analysis calculated for C.sub.9H.sub.13BrClN: % C, 43.14; %
H, 5.23; % N, 5.59. Found: % C, 43.36; % H, 5.39; % N, 5.64.
[0328] Mass Spectrum: [M-HCl]=214.
[0329] [.alpha.].sub.D.sup.2=-25.3 (c=1.02, H.sub.2O).
Preparation 99
(S)-2-(4-bromophenyl)-N-(t-butoxycarbonyl)propyl Amine
[0330] Following the procedure of Preparation 92 and using material
from Preparation 98 instead of material from Preparation 91
afforded 5.9 g (94%) of the title compound.
Preparation 100
(R)-2-(4-(3-thienyl)phenyl)-N-(t-butoxycarbonyl)propyl Amine
[0331] To a solution of 2.0 g (6.4 mmol) of material from
Preparation 92, 0.9 g (7.0 mmol) of thiophene-3-boronic acid and
1.3 g (9.6 mmol) of potassium carbonate in 20 mL of dioxane and 5
mL of water was added 0.4 g (0.32 mmol) of tetrakis
(triphenylphosphine)palladium(0). The mixture was heated at
100.degree. C. for 18 hr. The mixture was cooled to room
temperature and 20 mL of water and 20 mL of ether was added. The
organic layer was separated and the aqueous layer was extracted
three times with 10 mL each of ether. The combined organic extracts
were dried (MgSO.sub.4), filtered and concentrated in vacuo.
Chromatography (150 g of silica gel, 15% ethyl acetate/hexanes) of
the residue afforded 1.4 g (70%) of the title compound.
Preparation 101
(S)-2-(4-(3-thienyl)phenyl)-N-(t-butoxycarbonyl)propyl Amine
[0332] Following the procedure of Preparation 100 and using
material from Preparation 99 instead of material form Preparation
92 afforded 5.9 g (94%) of the title compound.
Preparation 102
2R-(4-(3-thienyl)phenyl)propyl Amine
[0333] A solution of 1.4 g of material from Preparation 100 in 15
mL 25% trifluoroacetic acid/dichloromethane was stirred at room
temperature for 3 hr. The mixture was concentrated in vacuo and the
residue was dissolved in 20 mL of 1N sodium hydroxide and 20 mL of
ethyl acetate. The organic layer was separated and the aqueous
layer was extracted four times with 10 mL each of ethyl acetate.
The combined organic extracts were dried (MgSO.sub.4), filtered and
concentrated in vacuo to afford 0.85 g (89%) of the title
compound.
Preparation 103.
2S-(4-(3-thienyl)phenyl)propyl Amine
[0334] Following the procedure of Preparation 102 and using
material from Preparation 101 instead of material from Preparation
100 afforded 0.9 g (94%) of the title compound.
Preparation 104
2-(4'-(2-fluorobiphenyl))ethylamine
[0335] A. (2-(4-bromophenyl)-N-(t-butoxycarbonyl)ethylamine: To a
solution of 10.0 g (50.0 mmol) of 4-bromophenethylamine in 100 mL
of chloroform and 100 mL of saturated sodium bicarbonate was added
11.0 g (50.0 mmol) of di-tert-butyl dicarbonate. The solution was
stirred at ambient temperature for 1 hour. The organic layer was
separated and the aqueous layer was extracted three times with 30
mL each of chloroform The combined organic extracts were dried
(MgSO.sub.4), filtered and concentrated in vacuo to afford 15 g
(100%) of the title compound.
[0336] B. 2-(4-(2-fluorophenyl)phenyl)-N-(t-butoxycarbonyl)-phenyl
ethylamine. To a degassed solution of 7.9 g (26.2 mmol) of material
from Step A, 5.5 g (39.3 mmol) of material from Preparation 3 and
5.4 g (39.3 mmol) of potassium carbonate in 90 mL of toluene was
added 1.5 g (1.3 mmol) of
tetrakis-(triphenylphosphine)palladium(0). The mixture was heated
at 90.degree. C. for 3 hours. The mixture was cooled to ambient
temperature and 90 mL of water was added. The organic layer was
separated and the aqueous layer was extracted three times with 30
mL each of ethyl acetate. The combined organic extracts were dried
(MgSO.sub.4), filtered and concentrated in vacuo. Chromatography
(400 g of silica gel, 15% ethyl acetate/hexanes) of the residue
afforded 7.1 g of material that was triturated in hexanes to afford
3.5 g (42%) of the title compound.
[0337] C. 2-(4'-(2-fluorobiphenyl))ethylamine: A solution of 3.5 g
of material from Step B in 40 mL 20% trifluoroacetic
acid/dichloromethane was stirred at ambient temperature for 1 hour.
The mixture was concentrated in vacuo to afford 3.9 g (100%) of the
title compound.
Preparation 105
Preparation of (R)-2-Phenyl-1-propylamine Malate Salt
[0338] First Crop: To a mechanically stirred solution of
2-phenyl-1-propylamine amine (50.0 g, 0.370 mol, can be prepared
following the procedure disclosed by A. W. Weston, A. W. Ruddy and
C. M. Suter, J. Am. Chem. Soc. 1943, 65, 674.) in 90%
ethanol/H.sub.2O (denatured with 0.5% toluene) (450 mL) was added
L-malic acid (24.8 g, 0.185 mol) portionwise at room temperature
with a 90% ethanol/H.sub.2O rinse (50 mL) to give a clear solution
after a mild exotherm. This solution was allowed to cool and a
white precipitate appeared after 30 min. The precipitation was
allowed to proceed with slow stirring overnight. The resulting
slurry was suction filtered (buchner funnel) and rinsed with 100%
ethanol (denatured with 0.5% toluene) (2.times.100 mL) to afford,
after air-drying, 30 g of 2-phenyl-1-propylamine malate salt as a
white solid. Chiral chromatographic analysis of the
isopropylsulfonamide derivative of the free base indicated 84%
ee.
[0339] Recrystallization: This 2-phenyl-1-propylamine malate salt
(30 g) was suspended in 90% ethanol/H.sub.2O (300 mL) and heated to
78.degree. C. with slow stirring to afford a clear colorless
solution. The solution was allowed to cool slowly to room
temperature overnight. Precipitation commenced at 60-65.degree. C.
The solids were filtered and rinsed at room temperature with 100%
ethanol (2.times.50 mL) to give 24.3 grams (32%) of white
crystalline solid. Chiral chromatographic analysis of the
isopropylsulfonamide derivative of the free base indicated 96.5%
ee.
[0340] Preparation of (R)-2-phenyl-1-propylamine. 12
[0341] To a stirred suspension of (R)-2-phenyl-1-propylamine malate
salt (24.3 g, 0.0601 mol, prepared directly above) in
CH.sub.2Cl.sub.2 (200 mL) was added 1.0 N NaOH dropwise at room
temperature. The organic phase was isolated, extracted with brine
(1.times.125 mL), dried (Na.sub.2SO.sub.4), filtered and
concentrated under reduced pressure to give 19 g (theory: 16.3 g)
of (R)-2-phenyl-1-propylamine as a clear, colorless oil.
EXAMPLE 1
[0342] Preparation of
2-(4-(3-thienyl)phenyl)-N-(methyloxycarbonyl)propyl Amine. 13
[0343] Preparation of 2-(4-(3-thienyl)phenyl)propyl Amine
Trifluoroacetate. 14
[0344] A. (R)-2-(4-bromophenyl)-N-(t-butoxycarbonyl)propyl amine
(12 g, 38.2 mmol, see preparation 92) was dissolved in 100 mL of
dioxane:water (4:1). This solution was treated with potassium
carbonate (7.9 g, 57.3 mmol), tetrakis(triphenylphosphine)palladium
(1.9 g, 1.91 mmol) and thiophene-3-boronic acid (5.4, 42 mmol). The
reaction mixture was stirred at 100.degree. C. for 12 hours. The
reaction mixture was partitioned between diethyl ether and water.
The organic was washed with brine, dried over sodium sulfate and
concentrated in vacua. Chromatography (SiO.sub.2, 10-20% ethyl
acetate/hexanes) gave the pure product. The resulting product was
dissolved in 50 mL of dichloromethane: TFA (1:1). The mixture was
stirred for 4 hours. The solvent was removed to give 8.01 g (66%)
of the trifluoroacetate salt of the resulting amine.
[0345] B. A 0.degree. C. solution of 2-(4-(3-thienyl)phenyl)propyl
amine trifluoroacetate (200 mg, 0.6 mmol, prepared above) in 3 mL
of dichloromethane was treated with triethylamine (263 .mu.L, 1.9
mmol) and methyl chloroformate (58.5 .mu.L, 0.76 mmol). The
reaction mixture was stirred at room temperature for 3 hours. The
crude mixture was partitioned between 30 mL of dichloromethane and
water (1:1). The organic layer was extracted with dichloromethane
and subsequently was washed with water, brine, dried over sodium
sulfate and concentrated in vacua. Chromatography (SiO.sub.2,
20-30% ethyl acetate/hexanes) afforded 236 mg (86%) of the pure
final title compound as a white solid.
[0346] Field Desorption Mass Spectrum: 275.1
[0347] Analysis for C.sub.15H.sub.17NO.sub.2S: Theory: C, 65.43; H,
6.22; N, 5.09. Found C, 65.61; H, 6.29; N, 5.39.
EXAMPLE 2
[0348] Preparation of 2-(4-(3-thienyl
)phenyl)-N-(i-propyloxycarbonyl)prop- yl Amine. 15
[0349] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyl amine trifluoroacetate (prepared in
example 1) and i-propyl chloroformate in a manner analogous to the
procedure described in Example 1.
[0350] Field Desorption Mass Spectrum: 304.3
[0351] Analysis for C.sub.17H.sub.21NO.sub.2S: Theory: C, 67.30; H,
6.98; N, 4.62. Found C, 67.32; H, 6.92; N, 4.86.
EXAMPLE 3
[0352] Preparation of
2-(4-(3-thienyl)phenyl)-N-(t-butyloxycarbonyl)propyl Amine. 16
[0353] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyl amine trifluoroacetate (prepared in
example 1) and t-butyl chloroformate in a manner analogous to the
procedure described in Example 1.
[0354] Field Desorption Mass Spectrum: 317.2
[0355] Analysis for C.sub.18H.sub.23NO.sub.2S: Theory: C, 68.11; H,
7.30; N, 4.41. Found C, 68.15; H, 7.39; N, 4.69.
EXAMPLE 4
[0356] Preparation of
2-(4-(3-thienyl)phenyl)-N-(cyclopentyloxycarbonyl)pr-
opyl-2-propylamine. 17
[0357] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyl amine trifluoroacetate (prepared in
example 1) and cyclopentyl chloroformate in a manner analogous to
the procedure described in Example 1.
[0358] Field Desorption Mass Spectrum: 330.2
[0359] Analysis for C.sub.19H.sub.23NO.sub.2S: Theory: C, 69.27; H,
7.04; N, 4.25. Found C, 69.23; H, 7.07; N, 4.50.
EXAMPLE 5
[0360] Preparation of
2-(4-(3-thienyl)phenyl)-N-(phenyloxycarbonyl)propyl Amine. 18
[0361] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyl amine trifluoroacetate (prepared in
example 1) and phenyl chloroformate in a manner analogous to the
procedure described in Example 1.
[0362] Field Desorption Mass Spectrum: 338.2
[0363] Analysis for C.sub.20H.sub.19NO.sub.2S: Theory: C, 71.19; H,
5.68; N, 4.15. Found C, 71.34; H, 5.81; N, 4.39.
EXAMPLE 6
[0364] Preparation of
2-(4-(3-thienyl)phenyl)-N-(benzyloxycarbonyl)propyl Amine. 19
[0365] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyl amine trifluoroacetate (prepared in
example 1) and benzyl chloroformate in a manner analogous to the
procedure described in Example 1.
[0366] Field Desorption Mass Spectrum: 352.4
[0367] Analysis for C.sub.21H.sub.21NO.sub.2S: Theory: C, 71.76; H,
6.02; N, 3.99. Found C, 71.80; H, 6.02; N, 4.24.
EXAMPLE 7
[0368] Preparation of N-(2-(4-(3-thienyl)phenyl)propyl)-N'-methyl
Urea. 20
[0369] A 0.degree. C. solution of 2-(4-(3-thienyl)phenyl)propyl
amine trifluoroacetate (200 mg, 0.6 mmol, prepared in example 1) in
3 mL of dichloromethane was treated with triethylamine (263 .mu.L,
1.9 mmol) and methyl isocyanate (53 .mu.L, 0.9 mmol). The reaction
mixture was stirred at room temperature for 3 hours. The crude
mixture was partitioned between 30 mL of dichloromethane and water
(1:1). The organic was extracted with dichloromethane and
subsequently was washed with water, brine, dried over sodium
sulfate and concentrated in vacuo. Chromatography (SiO.sub.2,
20-30% ethyl acetate/hexanes) afford 253 mg (92%) of the pure
product as a white solid.
[0370] Field Desorption Mass Spectrum: 275.3
[0371] Analysis for C.sub.15H.sub.18N.sub.2OS: Theory: C, 65.66; H,
6.61; N, 10.21. Found C, 65.54; H, 6.72; N, 10.10.
EXAMPLE 8
[0372] Preparation of N-(2-(4-(3-thienyl)phenyl)propyl)-N'-1-propyl
Urea. 21
[0373] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyl-- 2-propyl amine trifluoroacetate
(prepared in example 1) and i-propyl isocyanate in a manner
analogous to the procedure described in Example 7.
[0374] Field Desorption Mass Spectrum: 303.2
[0375] Analysis for C.sub.17H.sub.22N.sub.2OS: Theory: C, 67.51; H,
7.33; N, 9.23. Found C, 67.63; H, 7.25; N, 9.43.
EXAMPLE 9
[0376] Preparation of
N-(2-(4-(3-thienyl)phenyl)propyl)-N'-cyclohexyl Urea. 22
[0377] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyl-- 2-propyl amine trifluoroacetate
(prepared in example 1) and cyclohexyl isocyanate in a manner
analogous to the procedure described in Example 1.
[0378] Field Desorption Mass Spectrum: 343.1
[0379] Analysis for C.sub.20H.sub.26N.sub.2OS: Theory: C, 70.14; H,
7.65; N, 8.18. Found C, 69.49; H, 8.95; N, 10.17.
EXAMPLE 10
[0380] Preparation of N-(2-(4-(3-thienyl)phenyl)propyl)-N'-phenyl
Urea. 23
[0381] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyl-- 2-propyl amine trifluoroacetate
(prepared in example 1) and phenyl isocyanate in a manner analogous
to the procedure described in Example 1.
[0382] Field Desorption Mass Spectrum: 337.2
[0383] Analysis for C.sub.19H.sub.20N.sub.2OS: Theory: C, 71.40; H,
5.99; N, 8.33. Found C, 71.18; H, 6.20; N, 8.57.
EXAMPLE 11
[0384] Preparation of N-(2-(4-(3-thienyl)phenyl)propyl)-N'-benzyl
Urea. 24
[0385] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyl-- 2-propyl amine trifluoroacetate
(prepared in example 1) and benzyl isocyanate in a manner analogous
to the procedure described in Example 1.
[0386] Field Desorption Mass Spectrum: 351.5
[0387] Analysis for C.sub.21H.sub.22N.sub.2OS: Theory: C, 71.99; H,
6.33; N, 7.99. Found C, 72.18; H, 6.53; N, 8.30.
EXAMPLE 12
[0388] Preparation of
N-2-methylpropyl-2-(4-(3-thienyl)phenyl)propionamide- . 25
[0389] A. 2-(4-bromophenyl)propionic acid: A mixture of
2-(4-bromophenyl)propionitrile 20.0 g (95.2 mmol, see preparation
1) and 200 mL of 6 N hydrochloric acid was refluxed for 16 hours.
The cooled mixture was concentrated in vacuo. To the residue was
added 200 mL of ether and the suspension was again concentrated in
vacuo to afford 16.0 g (73%) of -(4-bromophenyl)propionic acid.
[0390] B. N-2-methylpropyl-2-(4-bromophenyl).sub.2-methylacetamide:
To a 0.degree. C. solution of 2-(4-bromophenyl)propionic acid 1.0 g
(4.4 mmol, part A above) and 0.5 g (4.8 mmol) of N-methylmorpholine
in 12 mL of dichloromethane was added 0.6 g (4.6 mmol) of
isobutylchloroformate and the mixture was stirred for 20 minutes.
To this mixture was added 0.4 g (4.8 mmol) of isobutylamine and the
mixture was allowed to warm to room temperature over 90 minutes.
The reaction mixture was washed once with 10 mL of 10% aqueous
sodium bisulfate and once with saturated aqueous sodium
bicarbonate. The organic portion was dried (Na.sub.2SO.sub.4),
filtered and concentrated in vacuo to 1.2 g (92%) of
N-2-methylpropyl-2-(4-bromoph- enyl).sub.2-methylacetamide.
[0391] Analysis calculated for C.sub.13H.sub.18NOBr: % C, 54.94; %
H, 6.38; % N, 4.93. Found: % C, 55.10; % H, 6.45; % N, 4.65.
[0392] Electrospray Mass Spectrum: M=284.
[0393] C. To a solution of
N-2-methylpropyl-2-(4-bromophenyl)2-methylaceta- mide 1.1 g (3.9
mmol, part B above), 0.7 g (5.8 mmol) of thiophene-3-boronic acid
and 0.8 g (5.8 mmol) of potassium carbonate in 12 mL of 3:1
dioxane/water was added 0.2 g (0.2 mmol) of
tetrakis(triphenylphosphine)palladium. The mixture was heated to
reflux for 16 hours, cooled and diluted with 10 mL of water. The
mixture was extracted three times with 10 mL each of
dichloromethane. The combined organics were dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo.
Chromatography (65 g of silica gel, 35% ethyl acetate/hexanes) of
the residue afforded 0.3 g (31%) of the final title compound.
[0394] Analysis calculated for C.sub.17H.sub.21NOS: % C, 71.04; %
H, 7.36; % N, 4.87. Found: % C, 70.92; % H, 7.39; % N, 4.81.
[0395] Electrospray Mass Spectrum: M+1=288.
EXAMPLE 13
[0396] Preparation of
N-methyl-N-(2-methylpropyl)-2-(4-(3-thienyl)phenyl)p- ropionamide
26
[0397] To a room temperature solution of 0.3 g (10 mmol) of
N-2-methylpropyl-2-(4-(3-thienyl)phenyl)propionamide (prepared in
example 12) in 5 mL of dimethylformamide was added 1.1 mL (1.1
mmol) of 1.0 M sodium bis(trimethylsilyl)amide in tetrahydrofuran.
The mixture was stirred for 10 minutes whereupon 0.2 g (1.1 mmol)
of iodomethane was added and the mixture stirred at room
temperature for 16 hours. The mixture was diluted with 5 mL of
water and extracted three times with 5 mL each of dichloromethane.
The combined organics were dried (Na.sub.2SO.sub.4), filtered and
concentrated in vacuo. Chromatography (10 g silica gel, 20% ethyl
acetate/hexanes) afforded 0.2 g (75%) of the title compound.
[0398] Analysis calculated for C.sub.18H.sub.23NOS: % C, 71.72; %
H, 7.69; % N, 4.65. Found: % C, 71.53; % H, 7.76; % N, 4.62.
[0399] Electrospray Mass Spectrum: M+1=302.
EXAMPLE 14
[0400] Preparation of N-2-(4-(3-thienyl)phenyl)propyl Acetamide.
27
[0401] A. Preparation of
N-2-(4-(3-thienyl)phenyl)-N-t-butoxycarbonylpropy- l amine: To a
degassed solution of 8.2 g (26.0 mmol) of material from Preparation
4, 4.0 g (31.2 mmol) of thiophene-3-boronic acid and 5.3 g (39.0
mmol) of potassium carbonate in 75 mL of dioxane and 25 mL of water
was added 1.5 g (1.3 mmol) of tetrakis
(triphenylphosphine)palladium(0). The mixture was heated at
90.degree. C. for 18 hr. The mixture was cooled to ambient
temperature and 200 mL of water and 100 mL of ether was added. The
organic layer was separated and the aqueous layer was extracted
three times with 60 mL each of ether. The combined organic extracts
were dried (MgSO.sub.4), filtered and concentrated in vacuo.
Chromatography (500 g of silica gel, 10% ethyl acetate/hexanes) of
the residue afforded 7.8 g (94%) of
N-2-(4-(3-thienyl)phenyl)-N-t-butoxycarbonylpropyl amine.
[0402] B. Preparation of 2-(4-(3-thienyl)phenyl)propylamine: A
solution of 2.3 g (7.2 mmol) of material from part A in 20 mL of
dichloromethane and 5 mL of trifluoroacetic acid was stirred at
room temperature for three hours. The mixture was concentrated in
vacuo and the residue was dissolved in 20 mL of ethyl acetate. This
solution was washed once with saturated aqueous sodium bicarbonate.
The organic portion was separated and the aqueous portion was
extracted four times with 10 mL each of ethyl acetate. The combined
organics were dried anhydrous magnesium sulfate, filtered and
concentrated in vacuo to afford 1.5 g (100%) of
2-(4-(3-thienyl)phenyl)propylamine.
[0403] C. To a solution of 1.0 mL (0.088 mmol) of a 0.088 M
solution of 2-(4-(3-thienyl)phenyl)propylamine in tetrahydrofuran
was added 37 mg (0.132 mmol) of piperidinylmethyl polystyrene. To
the mixture was added 10.4 mg (0.132 mmol) of acetyl chloride and
the mixture was shaken for 6 hours. To this mixture was added 0.15
g (0.3 mmol) of aminomethyl polystyrene and the vessel was shaken
for 12 hours. The reaction mixture was filtered through a cotton
plug and concentrated to afford the title compound. The NMR
spectrum was consistent with the proposed title structure.
[0404] Electrospray Mass Spectrum: M+1=260.
EXAMPLE 15
[0405] Preparation of N-2-(4-(3-thienyl)phenyl)propyl
2-methylpropionamide. 28
[0406] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and
isobutyryl chloride in a manner analogous to the procedure
described in example 14. The NMR spectrum was consistent with the
proposed title structure.
[0407] Electrospray Mass Spectrum: M+1=288.
EXAMPLE 16
[0408] Preparation of N-2-(4-(3-thienyl)phenyl)propyl
3-methylbutyramide. 29
[0409] The title compound from 2-(4-(3-thienyl)phenyl)propylamine
(see example 14) and isovaleryl chloride in a manner analogous to
the procedure described in example 14. The NMR spectrum was
consistent with the proposed title structure.
[0410] Electrospray Mass Spectrum: M+1=302.
EXAMPLE 17
[0411] Preparation of N-2-(4-(3-thienyl)phenyl)propyl
4-methylvaleramide. 30
[0412] The title compound was prepared
2-(4-(3-thienyl)phenyl)propylamine (see example 14) and isovaleryl
chloride in a manner analogous to the procedure described in
example 14. The NMR spectrum was consistent with the proposed title
structure.
[0413] Electrospray Mass Spectrum M+1=316.
EXAMPLE 18
[0414] Preparation of N-2-(4-(3-thienyl)phenyl)propyl
Cyclopropylamide. 31
[0415] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and
cyclopropanecarbonyl chloride in a manner analogous to the
procedure described in example 14. The NMR spectrum was consistent
with the proposed title structure.
[0416] Electrospray Mass Spectrum: M+1=286.
EXAMPLE 19
[0417] Preparation of N-2-(4-(3-thienyl)phenyl)propyl
Cyclobutylamide. 32
[0418] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and
cyclobutanecarbonyl chloride in a manner analogous to the procedure
described in example 14. The NMR spectrum was consistent with the
proposed title structure.
[0419] Electrospray Mass Spectrum: M+1=300.
EXAMPLE 20
[0420] Preparation of N-2-(4-(3-thienyl)phenyl)propyl
Cyclopentylamide. 33
[0421] The title compound was prepared
2-(4-(3-thienyl)phenyl)propylamine (see example 14) and
cyclopentanecarbonyl chloride in a manner analogous to the
procedure described in example 14. The NMR spectrum was consistent
with the proposed title structure.
[0422] Electrospray Mass Spectrum: M+1=314.
EXAMPLE 21
[0423] Preparation of N-2-(4-(3-thienyl)phenyl)propyl
Cyclohexylamide. 34
[0424] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and
cyclohexanecarbonyl chloride in a manner analogous to the procedure
described in example 14. The NMR spectrum was consistent with the
proposed title structure.
[0425] Electrospray Mass Spectrum: M+1=328.
EXAMPLE 22
[0426] Preparation of N-2-(4-(3-thienyl)phenyl)propyl propionamide.
35
[0427] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and propionyl
chloride in a manner analogous to the procedure described in
example 14. The NMR spectrum was consistent with the proposed title
structure.
[0428] Electrospray Mass Spectrum: M+1=274.
EXAMPLE 23
[0429] Preparation of N-2-(4-(3-thienyl)phenyl)propyl 2-furylamide.
36
[0430] The title compound was prepared
2-(4-(3-thienyl)phenyl)propylamine (see example 14) and 2-furoyl
chloride in a manner analogous to the procedure described in
example 14. The NMR spectrum was consistent with the proposed title
structure.
[0431] Electrospray Mass Spectrum: M+1=312.
EXAMPLE 24
[0432] Preparation of N-2-(4-(3-thienyl)phenyl)propyl
2-thienylamide. 37
[0433] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and
2-thiophenecarbonyl chloride in a manner analogous to the procedure
described in example 14. The NMR spectrum was consistent with the
proposed title structure.
[0434] Electrospray Mass Spectrum: M+1=328.
EXAMPLE 25
[0435] Preparation of N-2-(4-(3-thienyl)phenyl)propyl
5-oxazoylamide. 38
[0436] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and
oxazole-5-carbonyl chloride in a manner analogous to the procedure
described in example 14. The NMR spectrum was consistent with the
proposed title structure.
[0437] Electrospray Mass Spectrum: M+1=313.
EXAMPLE 26
[0438] Preparation of N-2-(4-(3-thienyl)phenyl)propyl Nicotinamide.
39
[0439] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and
nicotinoyl chloride in a manner analogous to the procedure
described in example 14. The NMR spectrum was consistent with the
proposed title structure.
[0440] Electrospray Mass Spectrum M+1=323.
EXAMPLE 27
[0441] Preparation of N-2-(4-(3-thienyl)phenyl)propyl Picolinamide.
40
[0442] The title compound was prepared
2-(4-(3-thienyl)phenyl)propylamine (see example 14) and picolinoyl
chloride in a manner analogous to the procedure described in
example 14. The NMR spectrum was consistent with the proposed title
structure.
[0443] Electrospray Mass Spectrum M+1=323.
EXAMPLE 28
[0444] Preparation of N-2-(4-(3-thienyl)phenyl)propyl
Isonicotinamide. 41
[0445] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and
isonicotinoyl chloride in a manner analogous to the procedure
described in example 14. The NMR spectrum was consistent with the
proposed title structure.
[0446] Electrospray Mass Spectrum: M+1=323.
EXAMPLE 29
[0447] Preparation of N-2-(4-(3-thienyl)phenyl)propyl
Ethylcarbamate. 42
[0448] The title compound was prepared
2-(4-(3-thienyl)phenyl)propylamine (see example 14) and ethyl
chloroformate in a manner analogous to the procedure described in
example 14. The NMR spectrum was consistent with the proposed title
structure.
[0449] Electrospray Mass Spectrum: M+1=290.
EXAMPLE 30
[0450] Preparation of N-2-(4-(3-thienyl)phenyl)propyl
2-methylpropylcarbamate. 43
[0451] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and
2-methylpropyl chloroformate in a manner analogous to the procedure
described in example 14. The NMR spectrum was consistent with the
proposed title structure.
[0452] Electrospray Mass Spectrum: M+1=318.
EXAMPLE 31
[0453] Preparation of N,N-dimethyl-N'-2-(4-(3-thienyl)phenyl)propyl
Urea. 44
[0454] The title compound was prepared
2-(4-(3-thienyl)phenyl)propylamine (see example 14) and
N,N-dimethylcarbamoyl chloride in a manner analogous to the
procedure described in example 14. The NMR spectrum was consistent
with the proposed title structure.
[0455] Electrospray Mass Spectrum: M+1=289.
EXAMPLE 32
[0456] Preparation of N,N-diethyl-N'-2-(4-(3-thienyl)phenyl)propyl
Urea. 45
[0457] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and
N,N-diethylcarbamoyl chloride in a manner analogous to the
procedure described in example 14. The NMR spectrum was consistent
with the proposed title structure.
[0458] Electrospray Mass Spectrum: M+1=317.
EXAMPLE 33
[0459] Preparation of
N-2-(4-(3-thienyl)phenyl)propyl-1-pyrrolidinecarboxa- mide. 46
[0460] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and
pyrrolidine carbonyl chloride in a manner analogous to the
procedure described in example 14. The NMR spectrum was consistent
with the proposed title structure.
[0461] Electrospray Mass Spectrum: M+1=315.
EXAMPLE 34
[0462] Preparation of
N-2-(4-(3-thienyl)phenyl)propyl-4-morpholinecarboxam- ide. 47
[0463] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and
4-morpholine carbonyl chloride in a manner analogous to the
procedure described in example 14. The NMR spectrum was consistent
with the proposed title structure.
[0464] Electrospray Mass Spectrum: M+1=331.
EXAMPLE 35
[0465] Preparation of N-2-(4-(3-thienyl)phenyl)propyl Methyl
Malonamide 48
[0466] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and methyl
malonyl chloride in a manner analogous to the procedure described
in example 14. THE NMR SPECTRUM was consistent with the proposed
title structure.
[0467] Electrospray Mass Spectrum: M+1=318.
EXAMPLE 36
[0468] Preparation of N-2-(4-(3-thienyl)phenyl)propyl Methyl
Succinamide 49
[0469] The title compound was prepared from
2-(4-(3-thienyl)phenyl)propyla- mine (see example 14) and methyl
succinyl chloride in a manner analogous to the procedure described
in example 14. The NMR spectrum was consistent with the proposed
title structure.
[0470] Electrospray Mass Spectrum: M+1=332.
EXAMPLE 37
[0471] Preparation of N-2-(4-bromophenyl)propyl-2-propanamide.
50
[0472] 2-(4-bromophenyl)propylamine (5.0 g, 19.98 mmol) was
suspended in dry CH.sub.2Cl.sub.2 (150 mL) and triethylamine (6.1
mL, 43.96 mmol) was added dropwise via addition funnel. The
reaction was stirred at room temperature under N.sub.2 for 15 min.
and then isobutyryl chloride (2.3 mL, 23.98 mmol) was added
dropwise. The reaction was stirred at room temperature overnight.
150 mL of a 1 M sol. of HCl was added. The organic layer was
separated and washed with saturated NaHCO.sub.3, saturated NaCl,
dried (MgSO.sub.4), filtered and concentrated to give 5.2 g (91%)
of title compound as a white crystalline solid that was
sufficiently pure to be used without further purification.
EXAMPLE 38
[0473] Preparation of
N-2-[4-(4-cyanophenyl)phenyl]propyl-2-propanamide 51
[0474] N-2-(4-bromophenyl)propyl-2-propanamide (1.0 g, 3.52 mmol)
was combined with potassium acetate (1.04 g, 10.56 mmol) and
bis(pinacolato)diboron (0.98 g, 3.87 mmol) in a three-neck round
bottom flash under an atmosphere of N.sub.2.
Bis(diphenylphosphino)-ferrocene]di- chloropalladium(II) complex
with dichloromethane (1:1) (0.087 g, 0.11 mmol) was added followed
by 20 mL of anhydrous DMF and the reaction was heated at 80.degree.
C. for 3 hours then cooled to room temperature. 4bromophenyl
nitrile (1.3 g, 7.04 mmol) was added followed by additional
PdCl.sub.2(dppf) (0.087 g, 0.11 mmol). 8.8 mL of a 2M solution of
Na.sub.2CO.sub.3 (17.60 mmol) was added and the reaction was heated
at 80.degree. C. overnight. After cooling to room temperature 1 M
HCl solution was added and the reaction mixture was extracted with
CH.sub.2Cl.sub.2. The organic layer was dried (MgSO.sub.4),
filtered and concentrated to a brown oil. The crude material was
purified by chromatography (30% ethyl acetate/70% hexanes to give
0.58 g (54%) of the title compound as a white crystalline
solid.
[0475] LRMS(ES.sup.+): 307.2 (M+1)
[0476] Anal. Calc'd for C.sub.20H.sub.22N.sub.2O+0.25H.sub.2O: C,
77.26; H, 7.29; N, 9.01; Found C 77.84, H 7.24, N 8.92.
EXAMPLE 39
[0477] Preparation of
N-2-[4-(4-(2-hydroxy)ethylphenyl)phenyl]propyl-2-pro- panamide.
52
[0478] N-2-(4-bromophenyl)propyl-2-propanamide (2.0 g, 7.04 mmol)
was combined with potassium acetate (5.4 g, 21.12 mmol) and
bis(pinacolato)diboron (0.98 g, 3.87 mmol) in a three-neck round
bottom flash under an atmosphere of N.sub.2.
Bis(diphenylphosphirio)-ferrocene]d- ichloropalladium(II) complex
with dichloromethane (1:1) (0.172 g, 0.21 mmol) was added followed
by 50 mL of anhydrous DMF and the reaction was heated at 80.degree.
C. for 3 hours then cooled to room temperature. 4-bromophenyl
ethanol (2.8 g, 14.08 mmol) was added followed by additional
PdCl.sub.2(dppf) (0.172 g, 0.21 mmol). 17.6 mL of a 2M solution of
Na.sub.2CO.sub.3 (35.20 mmol) was added and the reaction was heated
at 80.degree. C. overnight. After cooling to room temperature the
reaction mixture was filtered through Celite. The filtrate was
diluted with ethyl acetate and washed with saturated NaCl, dried
(MgSO.sub.4), filtered, and concentrated to a brown oil. The crude
material was purified by chromatography (1:1 (v/v) ethyl
acetate/hexanes to give 1.80 g (80%) of the title compound as a
light yellow solid.
[0479] LRMS(ES.sup.+): 326.4 (M+1)
[0480] Anal. Calc'd for C.sub.20H.sub.22N.sub.2O+0.5H.sub.2O: C,
75.41; H, 8.44; N, 3.96; Found C 75.14, H 8.41, N 4.19.
EXAMPLE 40
[0481] Preparation of
N-2-[4-(4-carboxymethylphenyl)phenyl]propyl-2-propan- amide. 53
[0482] The title compound prepared above in example 39 (0.10 g,
0.31 mmol) was dissolved in anhydrous N,N-dimethylformamide (10 mL)
and pyridinium dichromate (PDC, 1.2 g, 3.1 mmol) was added in small
portions. The reaction was stirred at room temperature for 24 hours
then partitioned between methylene chloride and 1 M HCl. The
organic layer was separated and extracted with saturated
NaHCO.sub.3. The aqueous layer was separated and acidified to pH 2
with 1 M HCl and extracted with methylene chloride. The organic
layer was dried (MgSO.sub.4), filtered and concentrated to a yellow
solid which was recrystallized from cyclohexane/methylene chloride
to provide the title compound as a fine white solid.
[0483] LRMS(FD.sup.+): 339 (M.sup.+)
EXAMPLE 41
[0484] Preparation of N-2-(4-bromophenyl)propyl-N-tert-butyl
Carbamate. 54
[0485] 2-(4-bromophenyl)propylamine (6.0 g, 23.98 mmol) was
suspended in dry CH.sub.2Cl.sub.2 (80 mL) and triethylamine (8.4
mL, 59.95 mmol) was added dropwise via addition funnel. The
reaction was cooled to 0.degree. C. and stirred under N.sub.2 for
15 min. and then di-tert-butyl dicarbonate (5.8 mL, 26.38 mmol) was
added in a single portion. The reaction was stirred at room
temperature overnight. 50 mL of a 1 M sol. of HCl was added and the
reaction mixture was extracted with diethyl ether. The organic
layer was separated and washed with saturated NaHCO.sub.3,
saturated NaCl, dried (MgSO.sub.4), filtered, and concentrated to
give 7.0 g (93%) of the title compound as a white crystalline solid
that was sufficiently pure to be used without further
purification.
[0486] Anal. Calc'd for C.sub.14H.sub.20NO.sub.2Br: C, 53.51; H,
6.42; N, 4.46, Found C 53.27, H 6.34, N 4.37.
EXAMPLE 42
[0487] Preparation of
N-2-(4-(4-cyanophenyl)phenyl)propyl-N-tert-butyl Carbamate. 55
[0488] N-2-(4-bromophenyl)propyl-N-tert-butyl carbamate (2.5 g,
7.96 mmol) was combined with 4-cyanophenylboronic acid (1.4 g, 9.55
mmol) and Pd(PPh.sub.3).sub.4 (0.37 g, 0.32 mmol) in dry
1,4-dioxane (40 mL) under N.sub.2 at room temperature. 12 mL of a 2
M solution of Na.sub.2CO.sub.3 were added and the reaction was
heated at 60.degree. C. overnight then cooled to room temperature
and poured into diethyl ether. The mixture was extracted with 1 M
HCl, saturated NaHCO.sub.3, and saturated NaCl, dried (MgSO.sub.4),
filtered, and concentrated to a yellow oil that was purified by
chromatography (20% ethyl acetate/80% hexanes) to give 2.4 g (89%)
of title compound as a light yellow solid.
[0489] Anal. Calc'd for C.sub.21H.sub.24N.sub.2O.sub.2+0.5H.sub.2O:
C, 73.01; H, 7.30; N, 8.11; Found C 73.11, H 7.10, N 8.06.
EXAMPLE 43
[0490] Preparation of N-2-(4-(4-cyanophenyl)phenyl)propylamine HCl.
56
[0491] The title compound prepared above in Example 42 (2.0 g, 5.95
mmol) was combined with anisole (0.064 mL, 0.59 mmol) in dry
CH.sub.2Cl.sub.2 (30 mL) while stirring under N.sub.2.
Trifluoroacetic acid (4.6 mL, 59.50 mmol) was added dropwise and
the reaction was stirred at room temperature overnight. The solvent
was evaporated and the residue was partitioned between ethyl
acetate and 4 M NaOH. The organic layer was separated and dried
(MgSO.sub.4), filtered, and concentrated to a yellow oil. The oil
was dissolved in diethyl ether and HCL gas was bubbled through the
solution until a white precipitate formed. The precipitate was
collected by filtration and washed with diethyl ether. 1.1 g (69%)
of the title compound were isolated.
[0492] LRMS (ES.sup.+): 237.0 (M+1)
[0493] LRMS (ES.sup.-): 236.2 (M-1)
EXAMPLE 44
[0494] Preparation of
N-2-(4-(4-cyanophenyl)phenyl)propyl-N-isopropyl Carbamate. 57
[0495] The title compound prepared in Example 43 was suspended in
dry CH.sub.2Cl.sub.2 (2.0 mL) and triethylamine (0.13 mL, 0.93
mmol) was added followed by the addition of isopropyl chloroformate
(0.56 mL, 0.56 mmol). The reaction was stirred at room temperature
overnight. The solvent was evaporated and the crude residue was
purified by chromatography (30% ethyl acetate/70% hexanes) to give
101 mg (85%) of the title compound.
[0496] LRMS (ES.sup.+): 323.4 (M+1)
[0497] LRMS (ES.sup.-): 381.3 (M+59)
[0498] Anal. Calc'd for C.sub.20H.sub.22N.sub.2O.sub.2+0.5H.sub.2O:
C, 72.48; H, 6.99; N, 8.45; Found C 72.71, H 6.67, N 8.27.
EXAMPLE 45
[0499] Preparation of N-2-(4-(4-cyanophenyl)phenyl)propyl-N-ethyl
Carbamate. 58
[0500] The title compound was prepared as described in Example 44
from the product of Example 43 and ethyl chloroformate.
Chromatography (20% ethyl acetate/80% hexanes) gave the title
compound in 87% yield.
[0501] LRMS (ES.sup.+): 309.2 (M+1)
[0502] LRMS (ES.sup.-): 367.1 (M+59)
[0503] Anal. Calc'd for C.sub.19H.sub.20N.sub.2O.sub.2. C, 74.00;
H, 6.54; N, 9.08, Found C 73.86, H 6.54, N 8.92.
EXAMPLE 46
[0504] Preparation of
N-2-(4-(4-cyanophenyl)phenyl)propyl-N-isobutyl Carbamate. 59
[0505] The title compound was prepared as described in Example 44
from the product of Example 43 and isobutyl chloroformate.
Chromatography (30% ethyl acetate/70% hexanes) gave the title
compound in 87% yield.
[0506] LRMS (ES.sup.+): 337.3 (M+1)
[0507] LRMS (ES.sup.-): 395.1 (M+59)
EXAMPLE 47
[0508] Preparation of N-2-(4-bromophenyl)propyl-N,N-dimethylurea.
60
[0509] 2-(4-bromophenyl)propylamine (5.0 g, 19.95 mmol) was
suspended in dry CH.sub.2Cl.sub.2 (100 mL) and triethylamine (6.1
mL, 43.89 mmol) was added dropwise via addition funnel. The
reaction was stirred at room temperature under N.sub.2 for 15 min.
and then N,N-dimethylcarbamoyl chloride (2.2 mL, 23.94 mmol) was
added dropwise. The reaction was stirred at room temperature
overnight. 100 mL of a 1 M sol. of HCl was added and the reaction
mixture was extracted with diethyl ether. The organic layer was
separated and washed with saturated NaHCO.sub.3, H.sub.2O,
saturated NaCl, dried (MgSO.sub.4), filtered, and concentrated to
give a white solid that recrystallized from diethyl ether/hexanes
to give 5.2 g (91%) of the title compound as a white crystalline
solid.
[0510] Anal. Calc'd for C.sub.12H.sub.17N.sub.2OBr: C, 50.54; H,
6.01; N, 9.82; Found C 50.83, H 6.06, N 9.65.
EXAMPLE 48
[0511] Preparation of N-2-(4-bromophenyl)propyl-N,N-diethylurea.
61
[0512] The title compound was prepared from
2-(4-bromophenyl)propylamine and N,N-diethylcarbamoyl chloride as
described in Example 47. 2.4 g (96%) of the title compound was
isolated as a clear oil.
[0513] LRMS (ES.sup.+): 312.9, 314 (M+2)
EXAMPLE 49
[0514] Preparation of
N-2-(4-(4-cyanophenyl)phenyl)propyl-N,N-dimethyl Urea. 62
[0515] The title compound prepared in Example 47 (1.0 g, 3.51 mmol)
was combined with 4-cyanophenylboronic acid (0.62 g, 4.21 mmol) and
Pd(PPh.sub.3).sub.4 (0.16 g, 0.14 mmol) in dry 1,4-dioxane under
N.sub.2 at room temperature. 6 mL of a 2 M solution of
Na.sub.2CO.sub.3 were added and the reaction was heated at
60.degree. C. for 8 h. then cooled to room temperature and poured
into diethyl ether. The mixture was extracted with H.sub.2O and
saturated NaCl, dried (MgSO.sub.4, filtered, and concentrated to a
brown oil that was purified by chromatography (1:1 (v/v) ethyl
acetate/hexanes) to give 0.63 g (58%) of a tan solid.
[0516] LRMS (ES.sup.+): 308.0 (M+1)
[0517] LRMS (ES.sup.-): 366.0 (M+59)
EXAMPLE 50
[0518] Preparation of
N-2-(4-(4-cyanophenyl)phenyl)propyl-N,N-diethyl Urea. 63
[0519] The title compound was prepared in a manner analogous to
that described in Example 49 from the reaction of
N-2-(4-bromophenyl)propyl-N,- N-diethylurea prepared in Example 48
and 4-cyanophenylboronic acid.
[0520] LRMS (ES.sup.+): 336.0 (M+1)
EXAMPLE 51
[0521] Preparation of Intermediate N-2-(4-bromophenyl)ethyl
Methanesulfonamide.
[0522] To a 0.degree. C. solution of of 4-bromophenethylamine (10.0
g, 50.0 mmol) and triethylamine (7.7 mL, 55.0 mmol) in 150 mL of
dichloromethane was added dropwise methanesulfonyl chloride (4.3 mL
55.0 mmol) in 20 mL of dichloromethane. After two hours, the
reaction mixture was washed once with 100 mL of 10% aqueous sodium
bisulfate. The organic portion was separated and the aqueous
portion was extracted three times with 50 mL each of
dichloromethane. The combined organics were dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo to afford
14.0 g (100%) of the intermediate title compound.
[0523] Preparation of Intermediate
N-2-(4-tri-n-butylstannylphenyl)ethyl Methanesulfonamide.
[0524] The intermediate title compound (10.0 g) was prepared in a
manner analogous to Preparation 40 described in International
Patent Application Publication WO 98/33496 published Aug. 6, 1998,
which is incorporated herein by reference, starting from
N-2-(4-bromophenyl)ethyl methanesulfonamide, prepared directly
above.
[0525] Preparation of Intermediate
N-t-butoxycarbonyl-N-(2-(4-phenyl)propy-
l-2-methanesulfonamide.
[0526] To a solution of 3.2 g (10.2 mmol) of
2-(4-bromophenyl)-N-(t-butoxy- carbonyl)propylamine (See
Preparation 4 above) and N-2-(4-tri-n-5 butylstannylphenyl)ethyl
methanesulfonamide (5.0 g, 10.2 mmol) in 30 mL of toluene was added
palladium acetate (0.11 g (0.51 mmol) and triphenylphosphine (0.27
g, 1.02 mmol). The mixture was heated to 100.degree. C. for 16
hours, cooled to room temperature and diluted with 30 mL of ethyl
acetate. The mixture was filtered through celite and concentrated
in vacuo. Chromatography (250 g of silica gel, 20% ethyl
acetate/hexanes) afforded 1.7 g (39%) of the intermediate title
compound.
[0527] Preparation of Intermediate
N-(2-(4-Phenyl)propyl-2-methanesulfonam- ide.
[0528] To a solution of of
N-t-butoxycarbonyl-N-(2-(4-phenyl)propyl-2-meth- anesulfonamide
(1.7 g, 3.9 mmol in 16 mL of dichloromethane was added 4 mL of
trifluoroacetic acid. The reaction mixture was stirred at room
temperature for two hours and concentrated in vacuo. The residue
was dissolved in 20 mL of dichloromethane and washed one time with
15 mL of 1 N sodium hydroxide. The organic portion was separated
and the aqueous portion was extracted three times with 10 mL each
of dichloromethane. The combined organics were dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo to afford
1.3 g (97%) of the intermediate title compound.
[0529] Preparation of
N-2-(4-(4-(2-methanesulfonamidoethyl)phenyl)phenyl)p- ropyl
2-methylpropionamide. 64
[0530] To a room temperature solution of
N-(2-(4-Phenyl)propyl-2-methanesu- lfonamide (0.15 g, 0.45 mmol)
and triethylamine (0.06 mL, 0.45 mmol) in 2 mL of dichloromethane
was added dropwise isobutyryl chloride (47 uL, 45 mmol) and the
reaction mixture was stirred for 16 hours. The reaction mixture was
washed once with 2 mL of 10% aqueous sodium bisulfate. The organic
portion was separated and the aqueous portion was extracted three
times with 2 mL each of dichloromethane. The combined organics were
dried (Na.sub.2SO.sub.4), filtered and concentrated in vacuo. The
residue was recrystallized from chlorobutane/ethyl acetate,
filtered and dried in vacuo at 60.degree. C. to afford 0.04 g (22%)
of the title compound.
[0531] Mass Spectrum: M+1=403.
[0532] The following Table I specifically illustrates additional
preferred substituents for R.sup.1 Table I.
3 R.sup.1 65 66 67 68 69 70 71 72 73
[0533] The following Table II illustrates additional preferred
compounds of the present invention wherein R.sup.30 and R.sup.31
are defined as hereinabove for formulas I' and I". The following
compounds can be prepared by one of ordinary skill in the art in a
manner analogous to the techniques and procedures described
hereinabove.
4TABLE II 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92
93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110
111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127
128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144
145 146 147
* * * * *